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ABSTRACT OF THE DISSERTATION 
 
Cloud-based Analysis and Integration of Proteomics and Metabolomics Datasets 
by 
Jeong Ho (Howard) Choi 
Doctor of Philosophy in Bioinformatics 
University of California, Los Angeles, 2019 
Professor Peipei Ping, Chair 
 
 
Our capabilities to define cardiovascular health and disease using highly multivariate “omics” 
datasets have substantially increased in recent years. Advances in acquisition technologies as 
well as bioinformatics methods have paved the way for ultimately resolving every biomolecule 
comprising various human “omes”. Understanding how different “omes” change and interact 
with one another temporally will ultimately unveil multi-omic molecular signatures that inform 
pathologic mechanisms, indicate disease phenotypes, and identify new therapeutic targets. 
Herein we describe a thesis project that creates novel, contemporary data science methods and 
workflows to extract temporal molecular signatures of disease from multi-omics analyses, and 
develops integrated omics knowledgebases for the cardiovascular community at-large.  
 
Chapter 1 provides an overview of cardiac physiology and pathophysiology involved in cardiac 
remodeling and heart failure (HF). A description of the systematic characterization of cardiac 
proteomes and metabolomes is included, including methodologies for multi-omics phenotyping. 
Finally, an overview of bioinformatics methods for driver molecule discovery is provided, 
discussing strategies for characterizing temporal patterns and conducting functional enrichment. 
 iii 
Chapter 2 describes computational approaches to discern the oxidative posttranslational 
modification (O-PTM) proteome, an important factor in cardiac remodeling. We developed a 
novel platform involving a customized, quantitative biotin switch pipeline and advanced analytic 
workflow to profile O-PTMs in an isoproterenol (ISO)-induced cardiac remodeling mouse model. 
We identified 1,655 proteins containing 3,324 oxidized sites, and unveiled temporal progression 
of O-PTM in disease. Chapter 3 discusses computational approaches for identifying temporal 
metabolomics fingerprints in HF treatment. Pathologic remodeling from a healthy to diseased 
heart involves a series of alterations over time. Mechanical circulatory support devices (MCSD) 
are a promising strategy for unloading the heart and reversing this process. We sought to 
identify molecular drivers of pathologic remodeling and reverse remodeling in the plasma 
metabolome; however, machine learning (ML)-empowered technological platforms required for 
these analyses are lacking. Thus, we established a Multiple Reaction Monitoring (MRM)-based 
MS quantitative platform and ML-based computational workflow to discern metabolomics 
fingerprints. We quantified 610 plasma metabolites and identified those exhibiting high 
correlation to cardiac phenotype, demonstrating a novel platform for biomarker discovery. 
Finally, Chapter 4 integrates all aforementioned innovations into one unified, cloud-based 
computational knowledgebase, MetProt, equipped to analyze, annotate, and integrate 
metabolomics and proteomics information. This pipeline fully characterizes the plasma 
metabolome in HF, unveils the interplay of proteomes and metabolomes, and derives new 
knowledge in cardiovascular medicine. Innovations include engineered features for addressing 
large-scale clinical datasets as well as algorithms to connect various types of molecules (e.g., 
proteins and metabolites). Chapter 4 is subdivided into 3 projects: Project 1 describes a 
computational pipeline to characterize the plasma metabolome using datasets from the ISO 
mouse model of HF and human HF; Project 2 develops bioinformatics strategies to integrate 
proteome and metabolome datasets from six genetically distinct mouse strains; and Project 3 
establishes the cloud-based MetProt to disseminate the above computational pipelines for the 
 iv 
cardiovascular community at-large. Taken together, these innovations offer new approaches 
and workflows for integrated omics investigations that enable novel discovery and ultimately 
advance precision cardiovascular science and medicine.  
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CHAPTER 1: INTRODUCTION AND OVERVIEW. 
  
 
 
2 
1.I. The Landscape of the Human Heart and Disease. 
 
1.I.A. Cardiac Structure and Physiology. 
The heart is a muscular organ that pumps blood to the body via the vessels of the circulatory 
system (Venes 2009). The circulatory system delivers the blood to all tissues in order to provide 
the body with oxygen and nutrients, and carries away metabolic wastes such as nitrogen 
compounds or sulphates for excretion (Hall and Guyton 2011). In humans and other mammals 
(e.g., mouse), the heart consists of four chambers including left and right atria and left and right 
ventricles, as well as four valves including two atrioventricular valves between atria and 
ventricles and two semilunar valves at the exit of each ventricle that prevent backflow (Starr, 
Evers, and Starr 2009; Kaplan 2008). The right atrium and right ventricle, commonly referred to 
as the right heart, collects deoxygenated blood from superior and inferior venae cavae and 
pumps into the pulmonary circulation in order to oxygenate the blood via the lungs. The left 
atrium and the left ventricle, referred to as the left heart, receives oxygenated blood via 
pulmonary veins and pumps into the systemic circulation. The heart is primarily made up with 
two types of cells: cardiomyocytes (~99%) which are contractile cells that enable the heart to 
pump, and cardiac pacemaker cells (~1%) that spontaneously depolarize and rapidly spread the 
impulse from cell to cell to trigger the autorhythmic contraction. Cardiomyocytes have a high 
mitochondrial density, which occupy at least 30% of cell volume (Piquereau et al. 2013), 
enabling them to produce sufficient amounts of adenosine triphosphate (ATP) to fuel 
contraction. This high density of the power plant of the cell combined with its rhythmic electrical 
impulse enables the heart to beat approximately to 72 beats per minute (bpm) at rest in 
humans, and more than 31 million times per year or 2 billion beats over an average lifetime. 
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1.I.B. Cardiac Remodeling and Heart Failure. 
Cardiac remodeling, also referred to as ventricular remodeling, is defined as an alteration in the 
structure (dimensions, mass, shape) of the heart in response to hemodynamic load and/or 
cardiac injury in parallel with neurohormonal activation (Cohn, Ferrari, and Sharpe 2000). 
Remodeling can be either adaptive or maladaptive, with maladaptive cardiac remodeling leading 
to heart failure (HF) (Dorn, Robbins, and Sugden 2003). HF is a condition in which the heart is 
unable to pump a sufficient amount of blood to meet the body’s demand. HF is a convergent 
end result of many etiologies of heart disease, including cardiomyopathies. HF is a common, 
costly, and potentially fatal disease responsible for >300,000 deaths a year in the US, with 5.8 
million Americans currently afflicted (Mancini and Colombo 2015; Roger 2013; Braunwald 2015; 
Goldberg et al. 2007). A major reason why this common disease is so intractable is its complex, 
multifactorial nature where disease outcome is often the combinatorial effect of multiple genetic 
and environmental causes.  
 
1.I.C. Biomarkers of Heart Failure Progression. 
B-type natriuretic peptide (BNP) and its biologically inert, amino-terminal pro-peptide 
counterpart (NT-proBNP) are the gold standard biomarkers in determining the diagnosis and 
prognosis of HF (Hanna K. Gaggin and Januzzi 2013). An array of additional biomarkers has 
emerged and can be arranged into the following categories: 1) myocardial stress/injury (e.g., 
myocyte stretch markers: MR-proANP; myocardial injury markers: troponin T, troponin I, myosin 
light-chain I, heart-type fatty-acid protein, CKMB; oxidative stress markers: myeloperoxidase, 
uric acid, oxidized low-density lipoproteins, urinary biopyrrins, urinary and plasma isoprostanes, 
plasma malodialdehyde), 2) neurohormonal activation (e.g., renin angiotensin system markers: 
renin, angiotensin II, aldosterone; sympathetic nervous system: norepinephrine, chromogranin 
A, MR-proADM; arginine vasopressin system: arginine vasopressin, copeptin; endothelins: ET-
1, big proET-1), 3) remodeling (e.g., inflammation: C-reactive protein, TNF-α, soluble TNF 
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receptors, Fas, interleukins [I, 6 and 18], osteoprotegerin, adiponectin; hypertrophy/fibrosis: 
matrix metalloproteinases, collagen propeptides, galectin-3, soluble ST2; apoptosis: GDF-15; 
misc: MicroRNA, quiescin Q6, VEGFR-1) and 4) comorbidities (e.g., renal biomarkers: 
creatinine, BUN, eGFR, cystatin C, β-trace protein; renal injury markers: NGAL, KIM-1, NAG, 
liver-type fatty acid binding protein, IL-18; hematologic biomarkers: hemoglobin, RDW, iron 
deficiency [ferritin, transferrin sat], albumin) (Hanna Kim Gaggin et al. 2017).  
 
The majority of key biomarkers mentioned above are comprised of proteins, post-translationally 
modified proteins, and metabolites. Notably, oxidative stress-related molecules comprise a 
significant population of myocardial stress/injury markers, suggesting a prominent role for 
oxidative stress in cardiac remodeling and heart failure. Although biomarkers such as BNP and 
troponin T are helpful in the diagnosis and management of irreversible myocardial injury, we 
currently have no satisfactory diagnostic markers of many cardiovascular complications that 
possibly leads to heart failure such as reversible myocardial ischemia, i.e. either stable or 
unstable angina (Gerszten, Asnani, and Carr 2011; Morrow et al. 2003). Despite increasing 
demand for cardiovascular biomarkers, few new markers have been FDA approved for the 
diagnosis of cardiovascular diseases (Morrow et al. 2003). Mass spectrometry (MS)-based 
proteomics and metabolomic technologies are capable of identifying hundreds to thousands of 
proteins, metabolites and oxidative stress-related molecules in cells, tissues and biofluids. Thus, 
a systematic approach integrating multi-omics analysis (i.e., proteomics, O-PTM proteomics, 
and metabolomics) would provide deep phenotyping to reveal new biomarkers, prioritize 
biomarker validation, and monitor biomarker panels for heart failure progression and drug 
response. 
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1.II. Systematic Characterization of the Cardiac Proteome and Metabolome. 
 
1.II.A. Systematic Profiling of The Cardiac Proteome 
As molecules that perform most mechanical and biochemical functions in the heart, proteins 
provide critical information to systems biology studies that aim to uncover the mechanisms of 
disease susceptibility and cardiac plasticity. Technologies now exist that can easily identify and 
quantify large numbers of proteins in a single experiment (Lotz et al. 2014; Mann 2006). These 
studies have advanced our understanding of the components constructing protein interaction 
networks (Orchard et al. 2014), the role of post-translational modifications in modulating cellular 
signals (Streng et al. 2013), the dynamics of individual protein half-life in response to 
perturbation (Lam et al. 2014), and the totality of proteins contributing to a given cellular process 
or organelle (Kim et al. 2014). One of the principal lessons from the proteomics revolution is that 
gene expression is no surrogate for protein function, e.g., following ISO stimulation, protein 
abundance changes independently of mRNA (Lam et al. 2014). 
 
1.II.B. Profiling of the Cardiac Metabolomic Landscape. 
The persistent contraction of cardiomyocytes demands tremendous amounts of energy; thus, 
maintaining metabolic homeostasis is essential for heart function. Accumulating evidence 
suggests that perturbation of cardiac metabolism plays an important role in the pathological 
progression of HF (Neubauer 2007). Comprehensive quantification of metabolite abundance in 
blood plasma, also known as plasma metabolomics profiling, provides mechanistic insights into 
the molecular alterations underlying HF (Cheng et al. 2015). The large-scale quantification of 
circulating metabolites also identifies metabolic changes for clinical classification, which may 
assess the outcomes of HF patients before and after optimal medical therapy and surgical 
interventions (Lloyd-Jones 2010). These metabolomic approaches can be established as 
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important avenues for biomarker and drug target development, as well as the validation of the 
efficacy of patient treatments. 
 
1.II.C. Multi-omics Phenotyping of HF. 
Along with advances in high-throughput technologies, recent studies have integrated gene 
expression profiling with proteomics, and have facilitated our understanding of the 
pathophysiology and the molecular mechanisms of HF (Hou et al. 2015; Dos Remedios et al. 
2003). However, there are no systematic approaches for the integration of large proteomic 
datasets with metabolome datasets due to a glaring lack of bioinformatics strategies that can 
connect proteins to metabolites and elucidate their relationships. 
 
1.III. Overview of Bioinformatic Methods for Driver Molecule Identification and 
Integration. 
The availability of proteomics and metabolomics data analysis tools is currently limited 
compared to genomics analysis tools. For example, the Aztec resource discovery index 
(http://aztec.bio/) lists 778 proteomics tools, and 147 metabolomics tools while it lists thousands 
of genomics tools. To our knowledge, there is no application or computational pipeline that 
comprehensively analyzes, annotates, and integrates large-scale proteomic and metabolomic 
datasets. This limitation significantly hinders our capability to identify patterns of biomolecules 
relevant to HF. 
 
1.III.A. Computational Approaches to Identify Driver Molecules. 
Differential Expression Analysis: Differential Expression Analysis (DEA) is a univariate method 
widely used in omics studies for targeting molecules that are statistically significantly altered 
(i.e., up-regulated or down-regulated) after a medical treatment or physical exercise (Xia et al. 
2015, 2012, 2009; Xia and Wishart 2011b). This method mainly employs two criteria: the fold-
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change of the molecule abundance in two sample groups and the adjusted p-value from 
statistical hypothesis testing followed by multiple testing correction. Recent studies have shown 
that if the sample size is sufficient (i.e., n > 12), the univariate test such as t test followed by 
multiple testing correction can outperform the multivariate methods (e.g., linear support vector 
machine-recursive features elimination or principal component discriminant analysis) in terms of 
not missing the true positives (Christin et al. 2013). Alternatively to the t test, a non-parametric 
test such as Wilcoxon signed-rank test can be applied if it is difficult to test the normality of the 
dataset (Figure 1.1.). Following the statistical hypothesis test, multiple testing correction to the 
p-values can be applied using the Benjamini-Hochberg method to reduce the false positives 
rate. Subsequently, the identified molecules can be validated by classification/clustering 
methods, such as Principal Component Analysis (PCA) or Unsupervised Hierarchical 
Clustering. PCA is a multivariate method for dimensional reduction of large datasets with many 
variables or observations. This facilitates visualization, clustering, pattern recognition, and 
identification of the key variables that vary most significantly across a population. PCA can aid 
investigators in understanding complex, higher-dimensional datasets by projecting them into a 
2- or 3-dimensional space, where they can be more easily visualized without sacrificing fidelity 
(Xia et al. 2015, 2012, 2009; Xia and Wishart 2011b, [a] 2011). Moreover, Unsupervised 
Hierarchical Clustering is a widely used data analysis method to build a binary tree from data by 
merging similar groups of points based on the calculated distances across samples or 
molecules. Usually, the distances are displayed as dendrograms (Xia et al. 2015, 2012, 2009). 
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Figure 1.1. Hierachical Structure of Hypothesis Tests. Hypothetical testing related to statistical 
differences are classified into two categories: parametric and nonparametric tests, depending on prior 
knowledge about the population parameter. For each category, statistical approaches suitable for one 
sample or two samples tests are as illustrated in the hierarchical graph. For two sample test, statistical 
methods are further divided into independent and paired samples depend on the structure of the data. 
Among 11 statistical methods, t test and z test are applied in both one sample and two-sample tests of 
the parametric test, whereas Chi-square and Kolmogorov-Smirnov are applied in both subcategories of 
the non-parametric test. In addition, Runs and Binomial are specific for one sample non-parametric test; 
Mann-Whitney and Median are specific for independent two-sample non-parametric test; Sign, Wilcoxon, 
and McNemar are specific for paired two-sample non-parametric test. This hypothesis test hierarchy 
serves as the guiding principle for the implementation of statistical approaches throughout this thesis. 
 
Machine Learning-based Feature Extraction: Machine Learning (ML)-based feature selection 
algorithm aims to identify key molecules discriminating one condition from the other. The filtered 
and scaled data from a mouse model is divided into non-overlapping training and test datasets. 
A two-stage feature selection and validation workflow are created to extract signature 
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metabolites. On the training set, randomized least absolute shrinkage and selection operator 
(LASSO)-based stability selection is applied in the  first stage to screen for metabolites of 
interest and support vector machine (SVM)-based recursive feature elimination (RFE) is applied 
in the second stage to identify a subset of accurate metabolites. Subsequently, the identified 
metabolites are validated on the test sets using predictive models and then local interpretable 
model-agnostic explanations (LIME) (Ribeiro, Singh, and Guestrin 2016) is applied to 
understand the predictions made by ML models. Finally, a Bayesian networks-based graphical 
model is created to discover causal relationships between identified metabolites and phenotypic 
response. 
 
Mixed Model-based Association Study: Linear Mixed Model (LMM) with Sample Relatedness 
Correction analyzes time-series omics data generated from heterogeneous samples to identify 
driver molecules that are highly associated with phenotypic characteristics. LMM correlates two 
variables and incorporates the samples’ relatedness, represented by omics expression or 
demographic factors, to improve statistical accuracy. We have applied LMM with Sample 
Relatedness Correction in our preliminary metabolomics study to find fingerprints of pathological 
stages following induction of HF using chronic infusion of the beta-adrenergic agonist, 
isoproterenol (ISO)  HF treatment (H. M. Kang et al. 2008; Kirby et al. 2010). 
 
1.III.B. Bioinformatic Stretage to Characterize Dynamic Patterns of Molecules 
Cubic Spline-based Temporal Clustering: Cubic spline-based temporal clustering is a technique 
where first computes a low-degree polynomial pieces that fit smoothly on data, and then 
clusters the similar spline curves using clustering methods such as K-mean clustering. We used 
this technique in our studies to analyze metabolite concentrations for six genetically 
heterogeneous strains of mich that exhibit varying phenotypes including different susceptibilities 
to cardiac dysfunction. We subjected these to chronic ISO treatment over 14 days. Both CTRL 
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and ISO groups were selected for cubic spline-based temporal clustering. Missing concentration 
values were replaced with the average occupancy of the available timepoints for every strain. 
The log2-transformed ratio of concentration values of ISO to CTRL was calculated per site per 
strain. After scaling and centering these ratios, cubic splines were fitted to them across the 
timepoints in R. The degree of smoothing was automatically determined by leave-one-out cross-
validation applied to each site per strain. The predicted spline values were used for K-mean 
clustering (kmean in R), following identification of the cluster numbers (mclust package in R).  
                    
1.III.C. Functional Enrichment Analysis and Annotation 
Pathway Enrichment Analysis: Significantly altered metabolites in our studies may be searched 
against several metabolomics databases, including Chemical Entities of Biological Interest 
(ChEBI, UK) (Hastings et al. 2013), Human Metabolome Database (HMDB, Canada) (Wishart et 
al. 2013, 2009, 2007), and LIPID Metabolites And Pathways Strategy (LIPID MAPS) (Fahy et al. 
2009, 2007) to cross-reference identifiers that are commonly used by pathway enrichment 
search engines and databases. The pathways enriched with identified metabolites may be 
further annotated with resources including MetaboLights (Haug et al. 2013) and Reactome 
(EMBL-EBI, UK) (Fabregat et al. 2016; Milacic et al. 2012). 
 
Cloud-based Computational Knowledgebase: To extract biological meaning from multi-omics 
datasets, researchers rely heavily on computational resources that analyze and annotate the 
molecules of interest with known information. Currently, access to tools/annotations is not 
straightforward because they reside in fragmented and incomplete repositories. To address this 
challenge, we created a novel distributed query system and cloud-based infrastructure, MetProt, 
that is capable of providing unified access to protein and metabolite datasets, allowing users to 
submit a single query to access multiple resources including Reactome (Fabregat et al. 2016; 
Milacic et al. 2012), UniProt (UniProt Consortium 2015), MetaboLights (Haug et al. 2013), 
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BioGPS (Wu et al. 2016; Wu, Macleod, and Su 2013), Gene Wiki (Tsueng et al. 2016), and 
COPaKB (N. C. Zong et al. 2013; H. Li et al. 2013). We also engineered customized application 
programming interfaces (APIs) to provide direct access for information in MetProt. These 
resources are described below. 
 
COPaKB: COPaKB (N. C. Zong et al. 2013; H. Li et al. 2013; N. Zong et al. 2014) 
(http://heartproteome.org) is an omics analysis platform with 2 key components: (1) a peptide 
spectral search engine; and (2) spectral library modules for knowledge annotation.  
 
Reactome: The Reactome (Milacic et al. 2012; Croft et al. 2014) (http://reactome.org) platform is 
a suite of network analysis tools for performing topology analysis and over-representation 
analysis of gene/protein networks. It comprises a manually curated database of human 
pathways with views of protein and metabolite structures overlaid with expression data. We 
interfaced with Reactome to identify key pathways of interest in our omics data. 
 
MetaboLights: MetaboLights (http://ebi.ac.uk/metabolights/) is a public database dedicated to 
the submission and sharing of metabolomics data, mass spectra, annotated biological roles, 
and other derived information (Haug et al. 2013). Based on spectral similarities and chemical 
structures, we employed its search services to analyze and interpret metabolite data we 
collected from our studies.  
 
BioGPS/Gene Wiki: BioGPS (http://biogps.org) is an interface for omics research (Wu et al. 
2016). It provides a user-customizable portal with aggregated information on protein annotations 
and target list analysis. Gene Wiki translates molecular information into structured knowledge; 
relevant pages representing molecular transducers will be aggregated and recruited into 
MetProt. 
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1.IV. Overview and Rationale. 
Heart failure (HF), which afflicts an estimated 6.5 million Americans and has incurred $6.5 billion 
in medical costs that are projected to grow within the next 20 years, remains a significant 
challenge to diagnosis and treat due to its heterogeneous clinical manifestations and 
multifactorial risk drivers (Benjamin et al. 2018; Dunbar et al. 2018). Maladaptive cardiac 
remodeling and heart failure (HF) are common stages of many heart diseases and pose major 
public health problems in the United States (McMurray 2010). To date, advanced HF patients 
are clinically treated as a homogenous group with similar standard therapies (WRITING 
COMMITTEE MEMBERS et al. 2013). However, HF is a multifactorial disease and results not 
only from cardiac overload or injury, but also from a complex interplay among genetic, 
neurohormonal, inflammatory, and biochemical alterations, requiring more sophisticated means 
to stratify patient groups for divergent therapies (S. J. Shah et al. 2015; Taylor et al. 2004). Over 
the past years, racial disparities in HF are well documented (East et al. 2004; Mensah et al. 
2005) along with common comorbidities such as hypertension, obesity, kidney disease, and 
diabetes, which before the age of 40 can predict the severity and outcome of HF (Husaini et al. 
2011).  
 
Research efforts have been spurred to understand its underlying molecular mechanisms for 
developing targeted therapeutic strategies (A. M. Shah et al. 2014). Towards this goal, the 
advancement of analytical technologies has drastically increased the depth, quality and volume 
of data generated by both proteomics and metabolomics experiments. Both proteins and 
metabolites are essential building blocks of cellular processes that collaboratively formulate 
biological pathways. In addition, oxidative stress is becoming increasingly recognized as a key 
signaling event in the progression of heart failure (Maulik and Kumar 2012). In response to 
oxidative stress, O-PTMs of proteins have been shown to alter the 3-dimensional structure and 
therefore functional activities of proteins in various biological pathways contributing to 
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hypertrophy development (Qin et al. 2014; Birk et al. 2015; Bak and Weerapana 2015). 
However, many large datasets of either proteins, protein O-PTM, or metabolites are often 
fragmented and rarely integrated, hindering the understanding of mechanistic details of heart 
failure progression and the extraction of statistically significant and biologically relevant 
molecular signatures.  
 
Here, we will deep phenotype heart failure progression via newly developed machine learning 
and statistical workflows and platforms for collective analyses of the landscape of oxidative 
stress-modified proteomics, metabolomics, and protein-metabolite networks. In Chapter 2, we 
performed a multi-faceted proteomics study, combined with a state-of-the-art computational 
pipeline, to elucidate key O-PTMs of molecular signatures and pathways in cardiac remodeling 
and heart failure progression. In Chapter 3, we established a Multiple Reaction Monitoring 
(MRM)-based MS quantitative platform and a corresponding computational workflow to unravel 
the metabolomics fingerprints of healthy humans, HF patients, and a mouse model. Accordingly, 
we quantified the plasma levels of 610 metabolites, and identified metabolites highly correlated 
to phenotypic changes. Our study highlights an established computational workflow that, in 
conjunction with a benchmark dataset, will facilitate future biomarker discovery. In chapter 4, we 
built a cloud-based platform, MetProt, for quantifying, triaging and analyzing omics datasets, 
and in doing so elucidating novel connections between proteins and metabolites, annotating 
molecular functions, and providing biomedical insights. 
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CHAPTER 2: COMPUTATIONAL APPROACHES TO DISSECT THE 
CYSTEINE O-PTM PROTEOME DURING CARDIAC HYPERTROPHY 
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2.I. Abstract. 
Cysteine oxidative modification of cellular proteins is crucial for many aspects of cardiac 
hypertrophy development. However, integrated dissection of multiple types of cysteine oxidative 
post-translational modifications (O-PTM) of proteomes in cardiac hypertrophy is currently 
missing. Here we developed a novel discovery platform encompassing a customized biotin 
switch-based quantitative proteomics pipeline and an advanced analytic workflow to 
comprehensively profile the landscape of cysteine O-PTM in an ISO-induced cardiac 
hypertrophy mouse model. Specifically, we identified a total of 1,655 proteins containing 3,324 
oxidized cysteine sites by at least one of the following three modifications: reversible cysteine 
O-PTM, cysteine sulfinylation (CysSO2H), and cysteine sulfonylation (CysSO3H). Analyzing the 
hypertrophy signatures that are reproducibly discovered from this computational workflow 
unveiled 4 biological processes with increased cysteine O-PTM. Among them, protein 
phosphorylation, creatine metabolism, and response to elevated Ca2+ pathways exhibited an 
elevation of cysteine O-PTM in early stages whereas glucose metabolism enzymes were 
increasingly modified in later stages, illustrating a temporal regulatory map in cardiac 
hypertrophy. Our cysteine O-PTM platform depicts a dynamic and integrated landscape of the 
cysteine oxidative proteome, through the extracted molecular signatures, and provides critical 
mechanistic insights in cardiac hypertrophy. Data are available via ProteomeXchange with 
identifier PXD010336. 
 
2.II. Introduction. 
Cardiac hypertrophy is an adaptive response of the heart to pressure overload and a risk factor 
for heart failure and sudden cardiac death (Shimizu and Minamino 2016; Maulik and Kumar 
2012; Souders et al. 2012). The complex and dynamic pathophysiological mechanisms 
surrounding cardiac hypertrophy have been the focus of many investigations seeking 
therapeutic strategies. Reactive oxygen and nitrogen species (RO/NS) have been recognized 
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as second messengers that mediate important biological processes during the development of 
cardiac hypertrophy (Maulik and Kumar 2012; Murray and Van Eyk 2012). As a major target of 
RO/NS, protein cysteine residues can act as molecular switches and undergo various types of 
O-PTM (Lim et al. 2003), which can alter protein 3D structure and activity in cellular signaling, 
adaptive and maladaptive cardiac responses (Murray and Van Eyk 2012; Pastore and Piemonte 
2013; Sag, Santos, and Shah 2014). Major cysteine O-PTM types observed in cardiac muscle 
include reversible (S-nitrosylation, S-glutathionylation, sulfenic acid, inter- and intramolecular 
disulfide bonds and S-sulfhydration) and irreversible sulfinic acid (CysSO2H) or sulfonic acid 
(CysSO3H) modifications (Murray and Van Eyk 2012; Alcock, Perkins, and Chalker 2018; 
Forrester and Stamler 2007).  
 
As dysregulation of cysteine O-PTM is directly associated with disease pathology (Bechtel and 
Weerapana 2017; Murray and Van Eyk 2012), identification and characterization of cysteine O-
PTM could yield a wider range of biomarkers and therapeutic targets for diseases characterized 
by oxidative stress. Due to the complexity of the cysteine oxidative proteome, elucidation of 
these molecular signatures during hypertrophy progression is currently lacking. Biotin switch 
assays and numerous iterations of this technique provide validated toolkits to customize the 
proteomic discovery platform and maximize the detection and quantification of the labile 
reversible cysteine O-PTM (Murray and Van Eyk 2012; Jaffrey and Snyder 2001). For example, 
work by Jennifer van Eyk’s laboratory has advanced methodologies to specifically detect S-
nitrosylation and measure individual protein thiol-reactivity, thereby discriminating artifacts and 
ambiguity surrounding site assignment of oxidation (Murray et al. 2013, 2012). Meanwhile, 
spline-based computational analysis enables extraction of temporal patterns (T.-Y. Liu et al. 
2017; Bhasi, Forrest, and Ramanathan 2005).  
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Here, we present the first proteome-wide study of major cysteine modification types in cardiac 
hypertrophy, including reversible O-PTM, CysSO2H, and CysSO3H. We devised a biotin switch-
based cysteine O-PTM discovery platform specific for multi-time point quantitative proteomic 
analysis at different disease stages of hypertrophic progression. To limit non-biologically 
oxidized peptides, we selected a maleimide-based reagent for enrichment labeling and 
combined dimethyl labeling for quantification. Comparing to IAM based labeling, maleimide 
provides higher specificity and reactivity with free thiols (Kramer et al. 2015; Reisz et al. 2013). 
In addition, dimethyl-based quantitative labeling is highly-efficient and cost-effective in studies 
with large sample size. We implemented the cubic spline-based computational workflow to 
capture the cysteine O-PTM clusters with distinct temporal profiles and high association with a 
hypertrophic phenotypic temporal profile. We define proteins in these clusters as molecular 
signatures. The novelty lies in this being the first study to link global oxidative proteomic 
signatures to distinct time points of hypertrophic progression, thus showcasing multi-factor, 
temporal fingerprints rather than a singular protein or snapshot at one specific time point.  
 
2.III. Methods and Materials. 
 
2.III.A. Experimental Animal Models. 
Male C57BL/6J mice, 9–12 weeks of age (Jackson Laboratories), were housed in a 12-hour 
light/12-hour dark cycle with controlled temperature, humidity, and access to standard chow and 
water ad libitum. Mice were surgically implanted with a subcutaneous micro-osmotic pump 
(ALZET) delivering 15mg/kg/day isoproterenol (ISO) (Sigma) or saline vehicle (Lau et al. 2018, 
2016). In this treatment protocol, mice develop a gradual cardiac hypertrophy phenotype 
characterized by significantly increased ejection fraction and HW/BW (Lau et al. 2016; Drews et 
al. 2010). Independent groups of 3 mice from each treatment condition were euthanized for 
sample collection at 1, 3, 5, 7, 10, and 14 days post-implantation. Four technical replicates were 
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performed for each treatment condition. All animal procedures were performed in accordance 
with the Guide for the Care and Use of Laboratory Animals by the National Research Council 
and approved by the Animal Research Committee at UCLA. 
 
2.III.B. Biotin Switch-based Sample Processing 
Protein extraction. Left ventricles were collected from mouse hearts and placed in 1mL NP-40 
lysis buffer (50mM Tris–HCl, pH 8, 137mM NaCl, 10% glycerol, 1% NP-40, 2mM EDTA) 
containing 100mM N-ethylmaleimide (NEM) and Halt™ Protease Inhibitor Cocktail (100X) 
(ThermoFisher Scientific). Tissue was homogenized using a glass hand homogenizer and 
mixed by rotation for 2hr at 4°C before centrifugation at 13,800g for 20 min at 4°C. The protein 
concentration of the supernatant was measured using the DC™ protein assay (Bio-Rad).  
 
Biotin switch-based labeling of reversible cysteine O-PTM. Aliquots containing 2mg protein were 
prepared, then precipitated by 10% trichloroacetic acid (TCA) and centrifuged at 20,000g for 
15min at 4°C. One wash with ice-cold 5% TCA and two washes with 95% ethanol were 
performed to get rid of small molecules. Pellets were re-suspended and alkylated in 1mL of 
urea-containing cysteine modification buffer (CMBU) (0.1M HEPES-NaOH, pH7.4, 1% SDS, 
10mM diethylenetriaminepentaacetic acid [DTPA], 6M urea) with 0.1M NEM. After 30min 
rotation at room temperature, the samples were reduced by 0.12M dithiothreitol (DTT) and 
rotated for another 60min. To quantify the total abundance of cysteine sites and to preserve 
cysteine sulfinylation (CysSO2H) and sulfonylation (CysSO3H), 10% of the lysate was reserved 
as an unlabeled portion and underwent acetone precipitation followed by digestion. For the 
remaining 90%, proteins were separated from small molecules by centrifugation with 10% TCA, 
followed by one wash with 5% TCA and two washes with 95% ethanol. Pellets were suspended 
in 300µL CMBU with 0.1mM maleimide-biotin (Mal-Biotin) (Sigma-Aldrich). After a 30min 
rotation at room temperature, unreacted NEM was quenched with 10mM DTT for an additional 
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30min. Small molecules and proteins were separated by TCA and ethanol washes as described 
above (J. Wang and Sevier 2016; J. Wang et al. 2014).  
 
Digestion and dimethyl labeling. Pellets from both labeled and unlabeled portions were 
solubilized in 0.1M triethylammonium bicarbonate buffer (TAEB) with 0.1% Rapigest (Waters) 
and heated at 60°C for 45min. Solubilized proteins were alkylated with 9mM iodoacetamide 
(IAM) incubation in the dark at room temperature for 30min. The alkylated lysate underwent 
trypsin digestion overnight (16hr) at 37°C with a 1:100 ratio of trypsin to protein. A final 
concentration of 0.16% (vol/vol) CH2O or C2H2O (Sigma-Aldrich) and 24mM sodium 
cyanoborohydride (NaBH3CN) (Sigma-Aldrich) were added to the designated samples with light 
or medium labeling, respectively. Reciprocal labeling was performed on two out of four technical 
replicates to minimize the technical bias from dimethyl labeling. After a 1 h incubation at room 
temperature, 0.16% (vol/vol) ammonium solution was added and mixed for 15 min to quench 
the reaction (García-Santamarina et al. 2014; Gu and Robinson 2016; Boersema et al. 2009). 
 
Mal-biotin enrichment. Mal-Biotin and dimethyl labeled peptides were diluted in 1.2mL PBS with 
200µL pre-washed High-Capacity NeutrAvidin slurry (Thermo Scientific). After overnight 
incubation, the sample was centrifuged, washed twice with 1mL PBS, once with 50mM 
ammonium bicarbonate w/ 20% methanol, and eluted with 50% Pierce™ acetonitrile (ACN) w/ 
0.4% trifluoroacetic acid (TFA) (Chung et al. 2015). 
 
C18 column cleanup. All samples were subjected to 30min incubation at 37°C with 1% TFA and 
centrifugation (13,000g for 15min) to remove remaining Rapigest. Samples were cleaned with 
PierceTM C18 Spin Columns (Thermo Scientific) to remove any interfering substances prior to 
LC-MS/MS analysis. 
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2.III.C. LC-MS/MS Analysis. 
LC-MS/MS was performed on digested peptides as previously described (Lau et al. 2018, 
2016). To reduce sample complexity and increase protein coverage, we fractionated peptide 
samples using high-pH/low–pH two-dimensional reversed-phase chromatography prior to 
MS/MS. Fifty micrograms of peptides were injected into a Phenomenex C18 column (Jupiter 
Proteo C12, 4-µm particle, 90-Å pore, 100mm×1mm dimension) using a Finnigan Surveyor LC 
system (Thermo Scientific) for the first-dimension (high-pH) separation. We established a 
gradient between solvent A (20mM ammonium formate, pH 10) and solvent B (20mM 
ammonium formate, 90% acetonitrile, pH10) at a 50µL·min−1 flow-rate with the following timing 
and solvent proportions: 0–5% solvent B in solvent A from 0–2min; 5–35% solvent B in solvent A 
from 3–32min; and, finally, 80% solvent B in solvent A from 32–37min. Six fractions of peptides 
were collected from 16–40min, lyophilized, and re-dissolved in 20µL 0.5% formic acid with 2% 
acetonitrile. Each high-pH fraction was injected (10μL) to an EasySpray C18 column (PepMap, 
3-μm particle, 100-Å pore; 75μm×150mm dimension; Thermo Scientific) using an auto-sampler 
on a single Easy-nLC 1000 nano-UPLC system (Thermo Scientific) for second-dimension (low-
pH) reversed-phase chromatography analysis. We established a gradient between solvent A 
(0.1% formic acid, 2% acetonitrile) and solvent B (0.1% formic acid, 80% acetonitrile) at a flow 
rate of 300nL·min−1 with the following timing and solvent proportions: 0–40% solvent B from 0–
110 min; 40–80% B from 110–117min; and 80% B from 117–120min. Column pressure was 
maintained below 150bar. High-resolution LC-MS/MS was performed on a single LTQ Orbitrap 
Elite instrument (Thermo Scientific) through a Thermo EasySpray interface. MS signals were 
acquired in Fourier-Transform/Ion-Trap (FT/IT) mode: each FT MS1 survey scan was analyzed 
at 400 to 2000 m/z mass range and 60,000 resolving power in profile mode, followed by rapid IT 
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MS2 scans on the top 15 ions with monoisotopic peak selection and 3000 intensity threshold. 
MS2 precursor isolation width was set to 2 m/z, normalized collision energy was 35, and charge 
state 1 and unassigned charge state were excluded. MS1 and MS2 target ion accumulation 
targets were 104 and 106, respectively. MS1 lock mass (m/z 425.120025) and dynamic 
exclusion (90s) were used. Throughout the LC-MS/MS experiment, column temperature was 
held at a constant 50°C. 
 
2.III.D. Quantification of Cysteine O-PTM Abundance 
The acquired raw mass spectra were processed with MaxQuant software (Cox and Mann 2008) 
version 1.5.6.0 as described (García-Santamarina et al. 2014). Peptide identification was 
performed using the Andromeda search engine (Cox et al. 2011), against a reverse-decoyed 
protein sequence database (UniProt Reference Proteome, reviewed, accessed June-12–2016). 
This Mus musculus proteome (taxonomy ID: 10090) database contains 33588 canonical 
sequences and does not include isoform information. Common contaminants were included in 
the database search. First and main searches were performed with precursor mass tolerances 
of 20ppm and 4.5ppm. Product ion tolerance was set to 0.5Da. Specificity for trypsin cleavage 
was required, allowing up to two missed cleavage sites (van der Reest et al. 2018). 
Dimethylated peptide labels were identified using the “multiplicity” query, including “DimethLys0” 
and “DimethN-term0” as light labels as well as “DimethLys4” and “DimethN4” as medium labels 
with a maximum four modified sites for each identified peptide. Variable modification types for 
enriched samples include Mal-biotin labeled cysteine (451.1889 Da), NEM-labeled cysteine 
(125.0477 Da), IAM-labeled cysteine (57.0215 Da), and methionine sulfoxidation (15.9949 Da) 
were queried with a maximum five modified sites for each identified peptide. Variable 
modification types for unlabeled whole tissue lysate samples include NEM-labeled cysteine 
(125.0477 Da), IAM-labeled cysteine (57.0215 Da), methionine sulfoxidation (15.9949 Da), 
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CysSO2H (31.9898 Da), and CysSO3H (47.9847 Da) were queried with a maximum five 
modified sites for each identified peptide. Tryptic, semi-tryptic, and non-tryptic peptides within a 
20ppm parent mass window surrounding the candidate precursor mass were searched. Peptide 
ions from up to 3 isotopic peaks with fragment mass tolerance of 600ppm were allowed. Protein 
inference required ≤5% peptide spectra matching (PSM), posterior error probability (PEP), and 
≤1% global level protein false discovery rate (FDR) (Q-value ≤1%), as well as a minimum of 2 
ratio counts. Peptides with a cysteine count lower than one were excluded, along with reverse 
and potential contaminant flagged peptides. Modified peptide identifications with an Andromeda 
search score greater than 40, a delta score greater than 6, and a localization probability >0.8 
were allowed (Bogdanow, Zauber, and Selbach 2016). All searches for a given data set were 
based on one set of Andromeda peak list files (apl-files). Each of the cysteine modifications (i.e. 
Mal-biotin, NEM, IAM, CysSO2H, and CysSO3H) was generated as a separate output file with 
identified cysteine sites, their extracted ion chromatogram (XIC) values, and normalized ratios of 
ISO vs. Vehicle conditions calculated from the differential dimethyl labeled peptides. To ensure 
data quality, technical replicates with significant change (p-value <0.05) in overall normalized 
ratio distribution among all four replicates were excluded. The total abundance of one cysteine 
site is quantified as the sum of XIC values from both modified and unmodified forms of that 
particular cysteine. Detailed information on number of spectra for identification and 
quantification, as well as number of unique peptide identified per experimental group are listed 
in Table 2.1. Furthermore, number of unique peptides, percent sequence coverage, heavy over 
light (H/L) ratio of mean peak area (± percent ratio H/L variability). The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium (Deutsch et al. 
2017) via the PRIDE (Vizcaíno et al. 2016) partner repository with the dataset identifier 
PXD010336.  
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Experimental Group # Spectra for Identification # Spectra for Quantification # Unique Peptide Identified 
Total cysteine_Day1_Rep1 545427 9521 4935 
Total cysteine_Day1_Rep2 435853 19484 8035 
Total cysteine_Day1_Rep3 613730 18328 7422 
Total cysteine_Day1_Rep4 494484 18236 7156 
Total cysteine_Day3_Rep1 493264 13098 6039 
Total cysteine_Day3_Rep2 478093 19376 8885 
Total cysteine_Day3_Rep3 572188 19778 8007 
Total cysteine_Day3_Rep4 496781 19996 7752 
Total cysteine_Day5_Rep1 513134 6201 3293 
Total cysteine_Day5_Rep2 327835 10759 5743 
Total cysteine_Day5_Rep3 626678 20711 8109 
Total cysteine_Day5_Rep4 521663 16660 7057 
Total cysteine_Day7_Rep1 533963 16200 6780 
Total cysteine_Day7_Rep2 597921 15568 7120 
Total cysteine_Day7_Rep3 609493 24065 10116 
Total cysteine_Day7_Rep4 505500 20557 8011 
Total cysteine_Day10_Rep1 614085 18505 6755 
Total cysteine_Day10_Rep2 456761 21063 8392 
Total cysteine_Day10_Rep3 602423 18246 7832 
Total cysteine_Day10_Rep4 503221 18106 7063 
Total cysteine_Day14_Rep1 586878 11614 5019 
Total cysteine_Day14_Rep2 554245 18840 8224 
Total cysteine_Day14_Rep3 604953 20311 8381 
Total cysteine_Day14_Rep4 472933 17988 7126 
Reversible cysteine O-PTM_Day1_Rep1 227533 5012 2048 
Reversible cysteine O-PTM_Day1_Rep2 314860 5868 2080 
Reversible cysteine O-PTM_Day1_Rep3 357770 4044 1688 
Reversible cysteine O-PTM_Day1_Rep4 274523 2887 1397 
Reversible cysteine O-PTM_Day3_Rep1 262151 4290 1891 
Reversible cysteine O-PTM_Day3_Rep2 326416 6133 2061 
Reversible cysteine O-PTM_Day3_Rep3 284474 3457 1579 
Reversible cysteine O-PTM_Day3_Rep4 252848 3052 1730 
Reversible cysteine O-PTM_Day5_Rep1 213077 5751 2401 
Reversible cysteine O-PTM_Day5_Rep2 337457 6302 2123 
Reversible cysteine O-PTM_Day5_Rep3 296146 3761 1690 
Reversible cysteine O-PTM_Day5_Rep4 315913 4370 1862 
Reversible cysteine O-PTM_Day7_Rep1 312953 7326 2797 
Reversible cysteine O-PTM_Day7_Rep2 238772 3392 1568 
Reversible cysteine O-PTM_Day7_Rep3 278035 2659 1346 
Reversible cysteine O-PTM_Day7_Rep4 235911 1831 1280 
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Experimental Group # Spectra for Identification # Spectra for Quantification # Unique Peptide Identified 
Reversible cysteine O-PTM_Day10_Rep1 177615 3464 1588 
Reversible cysteine O-PTM_Day10_Rep2 336361 5053 1733 
Reversible cysteine O-PTM_Day10_Rep3 273030 2453 1332 
Reversible cysteine O-PTM_Day10_Rep4 252848 3052 1730 
Reversible cysteine O-PTM_Day14_Rep1 179144 3327 1584 
Reversible cysteine O-PTM_Day14_Rep2 339793 6088 2007 
Reversible cysteine O-PTM_Day14_Rep3 261463 2254 1136 
Reversible cysteine O-PTM_Day14_Rep4 238437 3850 2067 
 
Table 2.1. Summary information of raw file contents and statistics for all experimental groups. 
 
2.III.E. Data Analysis. 
Cubic spline-based temporal clustering. Mal-biotin labeled cysteine sites or total cysteine sites 
with abundance values represented in at least 4 out of 6 time points in both ISO and Vehicle 
groups were selected for cubic spline-based temporal clustering. The averaged ratio of 
abundance in ISO to Vehicle across replicates was calculated per site. Missing abundance 
values for a modification site were imputed using average abundance of remaining time-points. 
After scaling and centering, cubic splines were fitted to ratios across the time points in the R 
statistical programming language (v3.4.3). The predicted abundance ratios from cubic spline 
were used for K-mean clustering (kmean package in R) following identification of the cluster 
numbers (mclust package in R). All the codes used for the analyses were deposited to the 
Github public repository (https://github.com/UCLA-BD2K/Cubic-Spline-based-Temporal-
Analysis-Workflow). The statistical significance of abundance change in ISO and Vehicle 
conditions was evaluated by a paired two-sided t-test. Pearson correlation was performed to 
analyze the association between phenotype and abundance of Mal-biotin labeled cysteines.  
 
Functional annotations. Cellular pathway information was retrieved from Reactome (release 
v63, 2017_12) (https://reactome.org/) (Fabregat et al. 2018). To exclude single entity function 
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and non-specific/generalized pathway terms (e.g. metabolism), enriched pathways are required 
to house a minimum 2 found entities and a maximum of 200 total entities. Significantly enriched 
pathways are defined by FDR <0.05 calculated from Fisher’s exact test with FDR multiple test 
correction. NeXtProt (release 2018-02) was implemented to annotate the biological processes 
and disease association of key proteins identified in the analysis (Gaudet et al. 2017). 
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Figure 2.1. Quantitative cysteine O-PTM proteomics workflow. Left ventricular tissue samples 
originated from C57BL/6J were subjected to ISO (Hypertrophy) conditions or saline vehicle (Normal) for 
1, 3, 5, 7, 10, and 14 days, with n = 3 mice per group. Extracted proteins underwent biotin switch for 
reversible cysteine O-PTM labeling. First, free cysteines in the cell lysate were alkylated with NEM to 
prevent nonspecific labeling of reversible cysteine O-PTM. Subsequently, reversibly oxidized cysteine 
were reduced with DTT. At this point, 10% of the lysate was separated out for the quantification of total 
cysteine site abundance and  DTT-irreversible cysteine O-PTMs (i.e., CysSO2H and CysSO3H) (right 
side of flowchart). The remaining 90% (left side of flowchart) was treated with Mal-Biotin, which labels 
newly-reduced, free cysteine residues. Following trypsin digestion and IAM alkylation of newly exposed 
free cysteines, lysates from Normal and Hypertrophy groups were differentially labeled with medium/light 
dimethyl in two of the four technical replicates, whereas the other two received reciprocol labeling. The 
dimethyl-labeled peptides were quenched by ammonium and equally mixed. The Mal-Biotin labeled 
portion was enriched by avidin agarose and the abundance of reversible cysteine O-PTM was quantified 
by LC-MS/MS. Following differential dimethyl labeling, the unlabeled 10% (right side) underwent LC-
MS/MS to quantify the abundance of total cysteines and DTT-irreversible cysteine O-PTM. The 
identification of modified peptides is based on their mass changes by corresponding modifications, i.e., 
+451.1889 Da for reversible cysteine O-PTM, +31.9898 Da for CysSO2H, and +47.9847 Da for 
CysSO3H. Quantification of modifications is based on XIC values. Integrative analysis was performed to 
characterize the impact of ISO-induced cardiac hypertrophy on the cysteine O-PTM profile. Abbreviations: 
oxidative post-translational modification (O-PTM); isoproterenol (ISO); N-ethylmaleimide (NEM); 
dithiothreitol (DTT); cystein sulfinylation (CysSO2H); cystein sulfonylation (CysSO3H); maleimide biotin 
(Mal-Biotin); extracted ion chromatogram (XIC); iodoacetamide (IAM). 
 
2.IV. Results. 
 
2.IV.A. Overview. 
We developed a cysteine O-PTM discovery platform by integrating a biotin switch-based 
quantitative proteomics approach with advanced computational analysis, and we applied the 
novel platform on an ISO-induced cardiac hypertrophic mouse model. First, we defined the 
abundance distribution of three types of cysteine O-PTM, including reversible CysSO2H, and 
CysSO3H during the progression of hypertrophy. Secondly, we applied statistical analysis to 
identify key proteins with significantly increased or decreased cysteine O-PTM abundance, 
followed by cubic spline-based K-mean clustering to dissect the temporal profiles of cysteine O-
PTM together with their total cysteine abundance. Thirdly, temporal signatures along with their 
enriched hypertrophic pathways were identified. And finally, we established the association 
between cysteine O-PTM profiles and hypertrophic phenotypes, keying in on cysteine sites that 
were significantly correlated with the phenotype dynamics. Integrated analysis of key sites 
extracted from our computational approaches was performed to comprehensively identify 
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molecular signatures and provide mechanistic insights during the development of cardiac 
hypertrophy. 
 
2.IV.B. Impact of ISO-induced hypertrophy on cysteine O-PTM. 
Using our cysteine O-PTM discovery pipeline on mouse LV tissue from ISO and Vehicle groups 
(Figure 2.1.), we identified a total of 2,505 proteins containing 6,818 cysteine sites; with 1,655 
proteins containing 3,324 sites modified by at least one of three cysteine O-PTM types. 
Specifically, 1,095 proteins containing 2,162 sites, 484 proteins containing 671 sites, and 447 
proteins containing 613 sites were modified by reversible modification, CysSO2H, and 
CysSO3H, respectively. According to Uniprot, among the reversibly modified proteins and 
cysteine sites only 167 proteins containing 470 sites and 8 proteins containing 9 sites are known 
sites of disulfide-bonds and nitrosylation, respectively, revealing that the majority of identified 
cysteine sites are novel. Figure 2.2.A illustrates the overall change in abundance distribution of 
reversible cysteine O-PTM over the progression of hypertrophy, with the average abundance of 
reversible cysteine O-PTM sites across 4 technical replicates plotted for each time point. All 
histograms exhibit a J-shaped curve, demonstrating the higher frequency of modified cysteine 
sites concentrated in the low abundance XIC range. Notably, the distribution of O-PTM 
abundance in ISO demonstrates a sizeable reduction in the lower abundance range, indicating 
a global enrichment of O-PTM occurring as early as Day 3. Figure 2.2.B shows a Venn diagram 
to depict the number of proteins associated with each individual type of cysteine modification. 
To summarize, 1,057 sites within 377 proteins are unique to an enriched reversible O-PTM 
proteome, demonstrating the advantage of using enrichment to concentrate less abundant but 
highly oxidized proteins. The overlapping cysteine sites among three modification types are 
limited (5 sites), suggesting that this arrangement of cysteine O-PTM is highly site-specific. 
Comparatively, the numbers of proteins co-modified with all three modification types on 
separate residues are significantly higher, suggesting that diverse cysteine O-PTM patterns 
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occur on the same protein albeit in a site-specific manner. Overall, these data indicate that the 
oxidative regulation of proteins requires complex orchestration of myriad oxidative chemistries in 
a site-specific manner. 
Accession Cysteine 
Fold 
Change 
P Value Signature 
Oxidation 
Type 
Entry 
Name 
Gene 
Name 
Protein Name 
Molecular 
Weight 
A2ASQ1 
A2ASQ1
_C441 
0.842 0.026 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AGRIN_
MOUSE 
Agrn 
Agrin 
Agrin [Cleaved into: Agrin N-terminal 
110 kDa subunit; Agrin C-terminal 
110 kDa subunit; Agrin C-terminal 90 
kDa fragment (C90); Agrin C-terminal 
22 kDa fragment (C22)] 
207,539 
A2AX52 
A2AX52_
C211 
0.759 0.028 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
CO6A4_
MOUSE 
Col6a4 
Dvwa 
Collagen alpha-4(VI) chain 250,798 
B2RXS4 
B2RXS4
_C617 
0.914 0.04 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
PLXB2_
MOUSE 
Plxnb2 Plexin-B2 206,230 
O08528 
O08528_
C368 
0.715 0.029 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
HXK2_M
OUSE 
Hk2 
Hexokinase-2 (EC 2.7.1.1) 
(Hexokinase type II) (HK II) 
102,535 
O08796 
O08796_
C145 
0.876 0 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
EF2K_M
OUSE 
Eef2k 
Eukaryotic elongation factor 2 kinase 
(eEF-2 kinase) (eEF-2K) (EC 
2.7.11.20) (Calcium/calmodulin-
dependent eukaryotic elongation 
factor 2 kinase) 
81,739 
O35459 
O35459_
C91 
0.921 0.011 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ECH1_M
OUSE 
Ech1 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial (EC 5.3.3.-) 
36,118 
O35855 
O35855_
C148 
0.805 0.004 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
BCAT2_
MOUSE 
Bcat2 
Bcatm 
Eca40 
Branched-chain-amino-acid 
aminotransferase, mitochondrial 
(BCAT(m)) (EC 2.6.1.42) 
44,127 
O55143 
O55143_
C349 
0.924 0.031 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AT2A2_
MOUSE 
Atp2a2 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 (SERCA2) (SR 
Ca(2+)-ATPase 2) (EC 3.6.3.8)  
114,858 
O55143 
O55143_
C344 
0.833 0.016 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AT2A2_
MOUSE 
Atp2a2 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 (SERCA2) (SR 
Ca(2+)-ATPase 2) (EC 3.6.3.8)  
114,858 
P00397 
P00397_
C498 
0.932 0.046 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
COX1_M
OUSE 
Mtco1 
COI 
mt-
Co1 
Cytochrome c oxidase subunit 1 (EC 
1.9.3.1) (Cytochrome c oxidase 
polypeptide I) 
56,910 
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Accession Cysteine 
Fold 
Change 
P Value Signature 
Oxidation 
Type 
Entry 
Name 
Gene 
Name 
Protein Name 
Molecular 
Weight 
P02469 
P02469_
C190 
0.894 0.043 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
LAMB1_
MOUSE 
Lamb1 
Lamb-
1 
Lamb1
-1 
Laminin subunit beta-1 (Laminin B1 
chain) (Laminin-1 subunit beta) 
(Laminin-10 subunit beta) (Laminin-
12 subunit beta) (Laminin-2 subunit 
beta) (Laminin-6 subunit beta) 
(Laminin-8 subunit beta) 
197,090 
P10493 
P10493_
C616 
0.869 0.037 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
NID1_M
OUSE 
Nid1 
Ent 
Nidogen-1 (NID-1) (Entactin) 136,538 
P14094 
P14094_
C214 
0.915 0.049 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AT1B1_
MOUSE 
Atp1b1 
Atp4b 
Sodium/potassium-transporting 
ATPase subunit beta-1 
(Sodium/potassium-dependent 
ATPase subunit beta-1) 
35,195 
P18242 
P18242_
C327 
0.848 0.018 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
CATD_M
OUSE 
Ctsd Cathepsin D (EC 3.4.23.5) 44,954 
P23242 
P23242_
C198 
0.895 0.004 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
CXA1_M
OUSE 
Gja1 
Cxn-
43 
Gap junction alpha-1 protein 
(Connexin-43) (Cx43) (Gap junction 
43 kDa heart protein) 
43,004 
P32261 
P32261_
C54 
0.939 0.043 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ANT3_M
OUSE 
Serpin
c1 At3 
Antithrombin-III (ATIII) (Serpin C1) 52,004 
P41216 
P41216_
C298 
0.868 0.006 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ACSL1_
MOUSE 
Acsl1 
Acsl2 
Facl2 
Long-chain-fatty-acid--CoA ligase 1 
(EC 6.2.1.3) (Long-chain acyl-CoA 
synthetase 1) (LACS 1) 
77,951 
P41216 
P41216_
C510 
0.81 0 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ACSL1_
MOUSE 
Acsl1 
Acsl2 
Facl2 
Long-chain-fatty-acid--CoA ligase 1 
(EC 6.2.1.3) (Long-chain acyl-CoA 
synthetase 1) (LACS 1) 
77,951 
P41216 
P41216_
C626 
0.874 0.015 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ACSL1_
MOUSE 
Acsl1 
Acsl2 
Facl2 
Long-chain-fatty-acid--CoA ligase 1 
(EC 6.2.1.3) (Long-chain acyl-CoA 
synthetase 1) (LACS 1) 
77,951 
P58281 
P58281_
C856 
0.772 0.022 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
OPA1_M
OUSE 
Opa1 
Dynamin-like 120 kDa protein, 
mitochondrial (EC 3.6.5.5) (Large 
GTP-binding protein) (LargeG) (Optic 
atrophy protein 1 homolog) [Cleaved 
into: Dynamin-like 120 kDa protein, 
form S1] 
111,339 
P58281 
P58281_
C786 
0.91 0.012 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
OPA1_M
OUSE 
Opa1 
Dynamin-like 120 kDa protein, 
mitochondrial (EC 3.6.5.5) (Large 
GTP-binding protein) (LargeG) (Optic 
atrophy protein 1 homolog) [Cleaved 
into: Dynamin-like 120 kDa protein, 
form S1] 
111,339 
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Accession Cysteine 
Fold 
Change 
P Value Signature 
Oxidation 
Type 
Entry 
Name 
Gene 
Name 
Protein Name 
Molecular 
Weight 
P97370 
P97370_
C249 
0.816 0.024 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AT1B3_
MOUSE 
Atp1b3 
Sodium/potassium-transporting 
ATPase subunit beta-3 
(Sodium/potassium-dependent 
ATPase subunit beta-3) (ATPB-3) 
(CD antigen CD298) 
31,776 
P97443 
P97443_
C125 
0.886 0.024 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
SMYD1_
MOUSE 
Smyd1 
Bop 
Histone-lysine N-methyltransferase 
Smyd1 (EC 2.1.1.43) (CD8b-
opposite) (SET and MYND domain-
containing protein 1) (Zinc finger 
protein BOP) (m-BOP) 
56,496 
Q02566 
Q02566_
C949 
0.856 0.012 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
MYH6_M
OUSE 
Myh6 
Myhca 
Myosin-6 (Myosin heavy chain 6) 
(Myosin heavy chain, cardiac muscle 
alpha isoform) (MyHC-alpha) 
223,565 
Q04592 
Q04592_
C1360 
0.94 0.01 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
PCSK5_
MOUSE 
Pcsk5 
Proprotein convertase subtilisin/kexin 
type 5 (EC 3.4.21.-) (Proprotein 
convertase 5) (PC5) (Proprotein 
convertase 6) (PC6) (Subtilisin-like 
proprotein convertase 6) (SPC6) 
(Subtilisin/kexin-like protease PC5) 
209,257 
Q60675 
Q60675_
C1447 
0.676 0 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
LAMA2_
MOUSE 
Lama2 
Laminin subunit alpha-2 (Laminin M 
chain) (Laminin-12 subunit alpha) 
(Laminin-2 subunit alpha) (Laminin-4 
subunit alpha) (Merosin heavy chain) 
343,815 
Q60936 
Q60936_
C403 
0.894 0.02 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
COQ8A_
MOUSE 
Coq8a 
Adck3 
Cabc1 
Atypical kinase COQ8A, 
mitochondrial (EC 2.7.-.-) 
(Chaperone activity of bc1 complex-
like) (Chaperone-ABC1-like) 
(Coenzyme Q protein 8A) (aarF 
domain-containing protein kinase 3) 
71,743 
Q61292 
Q61292_
C505 
0.894 0.027 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
LAMB2_
MOUSE 
Lamb2 
Lams 
Laminin subunit beta-2 (Laminin-11 
subunit beta) (Laminin-14 subunit 
beta) (Laminin-15 subunit beta) 
(Laminin-3 subunit beta) (Laminin-4 
subunit beta) (Laminin-7 subunit 
beta) (Laminin-9 subunit beta) (S-
laminin subunit beta) (S-LAM beta) 
196,579 
Q61738 
Q61738_
C103 
0.556 0.023 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ITA7_MO
USE 
Itga7 
Integrin alpha-7 [Cleaved into: 
Integrin alpha-7 heavy chain; Integrin 
alpha-7 light chain] 
129,329 
Q7TQ48 
Q7TQ48
_C899 
0.671 0.002 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
SRCA_M
OUSE 
Srl Sar Sarcalumenin 99,184 
Q80TZ3 
Q80TZ3_
C372 
0.769 0 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
AUXI_M
OUSE 
Dnajc6 
Kiaa04
73 
Putative tyrosine-protein 
phosphatase auxilin (EC 3.1.3.48) 
(DnaJ homolog subfamily C member 
6) 
102,299 
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Accession Cysteine 
Fold 
Change 
P Value Signature 
Oxidation 
Type 
Entry 
Name 
Gene 
Name 
Protein Name 
Molecular 
Weight 
Q8BGK2 
Q8BGK2
_C206 
0.674 0.027 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
ARHL1_
MOUSE 
Adprhl
1 Arh2 
[Protein ADP-ribosylarginine] 
hydrolase-like protein 1 (EC 3.2.-.-) 
(ADP-ribosylhydrolase 2) 
39,885 
Q8CC88 
Q8CC88
_C415 
0.868 0.019 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
VWA8_M
OUSE 
Vwa8 
Kiaa05
64 
von Willebrand factor A domain-
containing protein 8 
213,421 
Q8CFX1 
Q8CFX1
_C621 
0.765 0.025 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
G6PE_M
OUSE 
H6pd 
GDH/6PGL endoplasmic bifunctional 
protein [Includes: Glucose 1-
dehydrogenase (EC 1.1.1.47) 
(Glucose-6-phosphate 
dehydrogenase) (EC 1.1.1.363); 6-
phosphogluconolactonase (6PGL) 
(EC 3.1.1.31)] 
88,928 
Q8K182 
Q8K182_
C140 
0.812 0 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
CO8A_M
OUSE 
C8a 
Complement component C8 alpha 
chain (Complement component 8 
subunit alpha) 
66,080 
Q8K182 
Q8K182_
C194 
0.749 0.001 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
CO8A_M
OUSE 
C8a 
Complement component C8 alpha 
chain (Complement component 8 
subunit alpha) 
66,080 
Q8K2B3 
Q8K2B3
_C536 
0.88 0.002 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
SDHA_M
OUSE 
Sdha 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial (EC 1.3.5.1) 
(Flavoprotein subunit of complex II) 
(Fp) 
72,585 
Q91VD9 
Q91VD9
_C367 
0.935 0.016 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
NDUS1_
MOUSE 
Ndufs1 
NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial (EC 
1.6.5.3) (EC 1.6.99.3) (Complex I-
75kD) (CI-75kD) 
79,777 
Q91VD9 
Q91VD9
_C727 
0.924 0.004 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
NDUS1_
MOUSE 
Ndufs1 
NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial (EC 
1.6.5.3) (EC 1.6.99.3) (Complex I-
75kD) (CI-75kD) 
79,777 
Q91WD5 
Q91WD5
_C347 
0.928 0.022 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
NDUS2_
MOUSE 
Ndufs2 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
(EC 1.6.5.3) (EC 1.6.99.3) (Complex 
I-49kD) (CI-49kD) (NADH-ubiquinone 
oxidoreductase 49 kDa subunit) 
52,626 
Q99J39 
Q99J39_
C359 
0.786 0.037 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
DCMC_
MOUSE 
Mlycd 
Malonyl-CoA decarboxylase, 
mitochondrial (MCD) (EC 4.1.1.9) 
54,736 
Q99JY8 
Q99JY8_
C68 
0.913 0.012 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
PLPP3_
MOUSE 
Plpp3 
Lpp3 
Ppap2
b 
Phospholipid phosphatase 3 (EC 
3.1.3.4) (Lipid phosphate 
phosphohydrolase 3) (PAP2-beta) 
(Phosphatidate phosphohydrolase 
type 2b)  
35,216 
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Accession Cysteine 
Fold 
Change 
P Value Signature 
Oxidation 
Type 
Entry 
Name 
Gene 
Name 
Protein Name 
Molecular 
Weight 
Q9CQN1 
Q9CQN1
_C503 
0.806 0.016 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
TRAP1_
MOUSE 
Trap1 
Hsp75 
Heat shock protein 75 kDa, 
mitochondrial (HSP 75) (TNFR-
associated protein 1) (Tumor 
necrosis factor type 1 receptor-
associated protein) (TRAP-1) 
80,209 
Q9CRB9 
Q9CRB9
_C193 
0.79 0.007 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
MIC19_
MOUSE 
Chchd
3 
Mic19 
MICOS complex subunit Mic19 
(Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3) 
26,335 
Q9CRB9 
Q9CRB9
_C183 
0.893 0.006 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
MIC19_
MOUSE 
Chchd
3 
Mic19 
MICOS complex subunit Mic19 
(Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3) 
26,335 
Q9Z2I9 
Q9Z2I9_
C430 
0.9 0.016 
Decreased 
Reversible 
Modification 
Reversible 
cysteine O-
PTM 
SUCB1_
MOUSE 
Sucla2 
Succinate--CoA ligase [ADP-forming] 
subunit beta, mitochondrial (EC 
6.2.1.5) (ATP-specific succinyl-CoA 
synthetase subunit beta) (A-SCS) 
(Succinyl-CoA synthetase beta-A 
chain) (SCS-betaA) 
 
50,114 
 
Table 2.2. List of cysteine sites with alterations in modification abundance during cardiac hypertrophy. 
 
We mapped the distribution of O-PTM abundance, expressed as a ratio of ISO over Vehicle 
across 6 time points in violin plots for the three modification types (Figure 2.2.C). Consistent 
with 2.2.A, the ratio means of reversible O-PTM on Day 3, 5, 10, and 14 in ISO over Vehicle are 
slightly above zero, demonstrating an increase in reversible O-PTM abundance. CysSO2H 
oxidized sites exhibit no distribution change whereas CysSO3H oxidized sites have upshifts on 
Day 5 and 14. The distinct patterns of abundance distribution among the three modification 
types indicate O-PTM type-specific proteomic regulation during ISO-induced hypertrophy and 
oxidative stress. 
  
To identify sites of cysteine O-PTM that are significantly altered by ISO treatment, we applied a 
t-test on the log2-transformed fold-change of the reversible cysteine O-PTM (ISO/Vehicle) with 
at least 3 time points, where a p-value <0.05 and fold-change within the top or bottom 20th 
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percentile were deemed significant. For reversible cysteine O-PTM (Figure 2.2.D, top panel), we 
found 128 sites within 74 proteins with significantly increased abundance and 46 sites within 39 
proteins with significantly decreased abundance during ISO treatment, marking their potential to 
be signatures of cardiac hypertrophy. In addition, one and two CysSO3H oxidized sites are 
significantly increased and decreased, respectively (Figure 2.2.D, lower panel). 
 
Pathway Name 
# Entities 
Found 
# Entities 
Total 
Entities 
FDR 
Submitted Entities Found Signature 
Laminin interactions 4 35 0.001 Q60675;P10493;Q61292;P02469 Significantly Decreased 
MET activates PTK2 signaling 3 36 0.011 Q60675;Q61292;P02469 Significantly Decreased 
MET promotes cell motility 3 59 0.025 Q60675;Q61292;P02469 Significantly Decreased 
Ion homeostasis 3 61 0.025 O55143;P14094;P97370 Significantly Decreased 
The citric acid (TCA) cycle and 
respiratory electron transport 
4 156 0.026 Q91VD9;Q9Z2I9;Q91WD5;Q8K2B3 Significantly Decreased 
Ion transport by P-type ATPases 3 76 0.026 O55143;P14094;P97370 Significantly Decreased 
Citric acid cycle (TCA cycle) 2 26 0.038 Q9Z2I9;Q8K2B3 Significantly Decreased 
Basigin interactions 2 32 0.052 P14094;P97370 Significantly Decreased 
Signaling by MET 3 110 0.052 Q60675;Q61292;P02469 Significantly Decreased 
Complex I biogenesis 2 59 0.083 Q91VD9;Q91WD5 Significantly Decreased 
Post-translational protein 
phosphorylation 
3 165 0.083 P32261;Q61292;P02469 Significantly Decreased 
Pyruvate metabolism and Citric 
Acid (TCA) cycle 
2 61 0.083 Q9Z2I9;Q8K2B3 Significantly Decreased 
Cardiac conduction 3 169 0.083 O55143;P14094;P97370 Significantly Decreased 
Respiratory electron transport 2 71 0.088 Q91VD9;Q91WD5 Significantly Decreased 
Peroxisomal protein import 2 79 0.105 O35459;Q99J39 Significantly Decreased 
Respiratory electron transport, 
ATP synthesis by chemiosmotic 
coupling, and heat production by 
uncoupling proteins. 
2 95 0.111 Q91VD9;Q91WD5 Significantly Decreased 
Degradation of the extracellular 
matrix 
2 172 0.111 P10493;P18242 Significantly Decreased 
      
Gluconeogenesis 5 40 0.002 
P14152;P21550;P08249;P17751;P
05201 
Significantly Increased 
Formation of the ternary 
complex, and subsequently 
5 61 0.004 
P62242;P97351;P62908;P25444;P
62754 
Significantly Increased 
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Pathway Name 
# Entities 
Found 
# Entities 
Total 
Entities 
FDR 
Submitted Entities Found Signature 
Nonsense Mediated Decay 
(NMD) enhanced by the Exon 
Junction Complex (EJC) 
6 104 0.004 
P62242;P97351;P62908;P62717;P
25444;P62754 
Significantly Increased 
Nonsense-Mediated Decay 
(NMD) 
6 104 0.004 
P62242;P97351;P62908;P62717;P
25444;P62754 
Significantly Increased 
Ribosomal scanning and start 
codon recognition 
5 66 0.004 
P62242;P97351;P62908;P25444;P
62754 
Significantly Increased 
Cap-dependent Translation 
Initiation 
5 73 0.004 
P62242;P97351;P62908;P25444;P
62754 
Significantly Increased 
Eukaryotic Translation Initiation 5 73 0.004 
P62242;P97351;P62908;P25444;P
62754 
Significantly Increased 
Respiratory electron transport, 
ATP synthesis by chemiosmotic 
coupling, and heat production by 
uncoupling proteins. 
5 95 0.01 
Q03265;Q99LC5;P52503;Q91YT0;
Q9CQJ8 
Significantly Increased 
Protein methylation 3 21 0.01 Q01853;P10126;P25444 Significantly Increased 
The citric acid (TCA) cycle and 
respiratory electron transport 
6 156 0.012 
Q03265;Q99LC5;P08249;P52503;Q
91YT0;Q9CQJ8 
Significantly Increased 
Post-translational protein 
phosphorylation 
6 165 0.015 
Q61147;Q61554;P07724;P01027;Q
921I1;P11276 
Significantly Increased 
Glucose metabolism 5 119 0.022 
P14152;P21550;P08249;P17751;P
05201 
Significantly Increased 
Respiratory electron transport 4 71 0.023 Q99LC5;P52503;Q91YT0;Q9CQJ8 Significantly Increased 
HSF1 activation 2 8 0.026 Q01853;P10126 Significantly Increased 
Molecules associated with 
elastic fibres 
3 45 0.058 Q61554;Q8K4G1;P11276 Significantly Increased 
Elastic fibre formation 3 52 0.079 Q61554;Q8K4G1;P11276 Significantly Increased 
Creatine metabolism 2 16 0.082 Q04447;Q6P8J7 Significantly Increased 
Translation 5 185 0.095 
P62242;P97351;P62908;P25444;P
62754 
Significantly Increased 
Complex I biogenesis 3 59 0.095 P52503;Q91YT0;Q9CQJ8 Significantly Increased 
Mitochondrial biogenesis 2 27 0.189 P26443;Q03265 Significantly Increased 
Plasma lipoprotein remodeling 2 30 0.21 P07724;P20918 Significantly Increased 
Amino acid synthesis and 
interconversion (transamination) 
2 33 0.22 P26443;P05201 Significantly Increased 
Metabolism of polyamines 3 91 0.22 Q04447;Q6P8J7;Q60692 Significantly Increased 
Platelet degranulation 4 166 0.22 P07724;P20918;Q921I1;P11276 Significantly Increased 
Degradation of the extracellular 
matrix 
4 172 0.226 P02463;Q61554;P20918;P11276 Significantly Increased 
Response to elevated platelet 
cytosolic Ca2+ 
4 172 0.226 P07724;P20918;Q921I1;P11276 Significantly Increased 
Non-integrin membrane-ECM 
interactions 
2 43 0.268 P02463;P11276 Significantly Increased 
Integrin cell surface interactions 3 110 0.268 P02463;Q61554;P11276 Significantly Increased 
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Pathway Name 
# Entities 
Found 
# Entities 
Total 
Entities 
FDR 
Submitted Entities Found Signature 
Detoxification of Reactive 
Oxygen Species 
2 47 0.285 P24270;P46412 Significantly Increased 
Cross-presentation of soluble 
exogenous antigens 
(endosomes) 
2 50 0.29 Q61830;Q60692 Significantly Increased 
MET promotes cell motility 2 59 0.3 P63001;P11276 Significantly Increased 
Semaphorin interactions 2 63 0.3 P63001;O08553 Significantly Increased 
Hedgehog ligand biogenesis 2 68 0.3 Q01853;Q60692 Significantly Increased 
Plasma lipoprotein assembly, 
remodeling, and clearance 
2 71 0.3 P07724;P20918 Significantly Increased 
Iron uptake and transport 2 73 0.3 Q61147;Q921I1 Significantly Increased 
MAPK6/MAPK4 signaling 2 80 0.3 P63001;Q60692 Significantly Increased 
Signaling by PDGF 2 81 0.3 P02463;P20918 Significantly Increased 
rRNA processing in the nucleus 
and cytosol 
2 88 0.3 P25444;P62754 Significantly Increased 
rRNA processing 2 88 0.3 P25444;P62754 Significantly Increased 
Major pathway of rRNA 
processing in the nucleolus and 
cytosol 
2 88 0.3 P25444;P62754 Significantly Increased 
L1CAM interactions 2 88 0.3 P63001;O08553 Significantly Increased 
Scavenging of heme from 
plasma 
2 89 0.3 P07724;Q07456 Significantly Increased 
PCP/CE pathway 2 94 0.3 P63001;Q60692 Significantly Increased 
Glycolysis 2 98 0.3 P21550;P17751 Significantly Increased 
Binding and Uptake of Ligands 
by Scavenger Receptors 
2 108 0.3 P07724;Q07456 Significantly Increased 
Cellular response to heat stress 2 110 0.3 Q01853;P10126 Significantly Increased 
Signaling by MET 2 110 0.3 P63001;P11276 Significantly Increased 
ABC-family proteins mediated 
transport 
2 112 0.3 Q01853;Q60692 Significantly Increased 
Antigen processing-Cross 
presentation 
2 113 0.3 Q61830;Q60692 Significantly Increased 
Regulation of Complement 
cascade 
2 129 0.3 P01027;P06909 Significantly Increased 
Cargo recognition for clathrin-
mediated endocytosis 
2 134 0.3 Q921I1;Q07113 Significantly Increased 
Beta-catenin independent WNT 
signaling 
2 136 0.3 P63001;Q60692 Significantly Increased 
Complement cascade 2 140 0.3 P01027;P06909 Significantly Increased 
Signaling by Hedgehog 2 161 0.3 Q01853;Q60692 Significantly Increased 
Clathrin-mediated endocytosis 2 187 0.312 Q921I1;Q07113 Significantly Increased 
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Table 2.3. Enriched biological pathways of proteins bearing cysteine sites with significantly 
increased/decreased modification abundance. 
 
Reactome identified 17 and 55 pathways that are enriched by proteins with significantly 
increased and decreased reversible cysteine sites, respectively (Figure 2.2.D, top panel). 
Specifically, proteins with significantly decreased reversibly oxidized sites are significantly 
enriched in 3 extracellular matrix organization and signaling pathways, 2 ion homeostasis and 
transportation pathways, and 2 TCA cycle and respiratory electron transport (TCA) pathway. 
Proteins with significantly increased reversibly oxidized cysteine sites are significantly enriched 
in 7 transcriptional and translational regulation pathways, 2 protein post-translational 
modification (PTM) pathways, 2 glucose metabolism pathways, and 3 TCA cycle and respiratory 
electron transport pathways. Notably, the “TCA cycle and respiratory electron transport” 
pathway is enriched in both significantly increased and decreased sites with associated proteins 
labeled by their UniProt ID. This observation reveals a significant and diverse reversible O-PTM 
regulation of mitochondrial metabolism during ISO-induced cardiac hypertrophy. In addition, 
significantly increased cysteine modifications of proteins susceptible to methylation and 
phosphorylation indicates further hierarchical interactions among PTMs. Zinc finger factor, ZEP1 
is significantly decreased in CysSO3H (associated proteins are labeled by their UniProt ID), 
demonstrating redox regulation of transcriptional regulation during hypertrophy. Detailed 
information on featured sites, proteins, and their enriched pathways are listed in Tables 2.2 and 
2.3, respectively. 
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Figure 2.2. Impact of ISO-induced cardiac hypertrophy on the reversible cysteine O-PTM profile.  
(A) Abundance distribution of reversible cysteine O-PTM during ISO treatment. Six histograms 
exhibit the distribution of abundance of reversible cysteine O-PTM in each of the 6 time-points under both 
ISO (red) and Vehicle (blue) conditions. The absolute value of the vertical axis represents the site counts 
whereas the horizontal axis represents average abundance value (XIC) across all replicates. The black 
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arrow denotes a significant change in the abundance distribution of ISO occurring on Day5, where a 
sizeable upshift is observed in the ISO distribution of reversible cysteine O-PTM.  
 
(B) Site and protein counts of reversible cysteine O-PTM, CysSO2H, and CysSO3H during ISO-
induced hypertrophy. A Venn diagram illustrates the number of reversibly oxidized proteins (left panel) 
and cysteine sites (right panel) for each of the cysteine O-PTMs that are identified from the integrated 
discovery platform. Data show that there are considerable and complex patterns of overlap among 
proteins and sites that are susceptible to modification.  
 
(C) Distribution of cysteine O-PTM abundance during ISO treatment. Three violin plots exhibit the 
log2 transformed abundance ratio of oxidation (y-axis) in ISO vs. Vehicle over 6 time points across 14 
days (x-axis). The red horizontal line depicts the ratio value of zero, demonstrating no change. The black 
bar on the violin at each time point represents the population mean. The black arrow denotes a significant 
change in the abundance distribution of ISO occurring on Day5, where a sizeable upshift is observed in 
the ISO distribution of reversible cysteine O-PTM.  
 
(D) Statistical validation of changes in oxidative molecular signatures. A volcano plot portrays 
significantly altered molecular signatures of reversible cysteine O-PTM (top panel) and CysSO3H (bottom 
panel) during ISO treatment. Each dot represents a cysteine O-PTM site with respect to its log2-
transformed fold-change of abundance ratio in ISO/Vehicle (x-axis) and -log10-transformed p-value from t-
test (y-axis). Any sites with p-value <0.05 (horizontal line) and fold-change within the top or bottom 20th 
percentile (vertical line) are identified as significantly altered molecular signatures. Significantly increased 
and decreased modification sites are labeled in green and red, respectively. Pathway enrichment by 
Reactome identified “TCA cycle and respiratory electron chain” as the significantly enriched pathway for 
signatures with reversible O-PTM. “Transcriptional and translational regulation” is enriched in CysSO3H. 
The UniProt IDs of proteins housing decreased and increased sites of cysteine O-PTM in these two 
enriched pathways are labeled. Detailed information regarding proteins of each cluster and their enriched 
pathways are listed in the Tables 2.2 and 2.3, respectively. Abbreviations: oxidative post-translational 
modification (O-PTM); isoproterenol (ISO); cystein sulfinylation (CysSO2H); cystein sulfonylation 
(CysSO3H); extracted ion chromatogram (XIC); TCA cycle and respiratory electron transport (TCA). 
 
2.IV.C. Integrated temporal profiles of cysteine O-PTM in the hypertrophic heart proteome. 
To characterize the dynamic patterns of reversible cysteine O-PTM during the progression of 
cardiac hypertrophy, we calculated the abundance ratios of each reversible cysteine O-PTM site 
in ISO over Vehicle for 1, 3, 5, 7, 10, and 14 days and employed a cubic spline-based 
smoothing approach for data de-noising. The cubic spline-fitted data were subsequently 
classified by K-means clustering to produce a total of 8 unique dynamic patterns (Figure 2.3.A). 
The largest cluster (Cluster 6, n = 198) remains unchanged during ISO treatment. These likely 
represent structural disulfide cysteines of housekeeping proteins. Consistent with this notion, 
Reactome analysis identified extracellular matrix (ECM) organization and signaling pathways to 
be enriched in this cluster, and ECM proteins are known to be rich in structural disulfide bonds.  
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The dynamic patterns of 8 clusters were represented in the stripcharts with smoothing lines, 
demonstrating the temporal feature of each cluster (Figure 2.3.B). Different temporal patterns of 
reversible O-PTM clusters may reveal the hidden association between dynamic regulation of 
biological processes and the progression of cardiac hypertrophy. We applied determination 
coefficient analysis to extract key sites as temporal signatures that are highly correlated (R2 
>0.8) with the temporal feature of their corresponding clusters. Cluster 6, with its lack of 
significant temporal changes to cysteine sites, is excluded from temporal signatures analysis. 
Among a total of 415 sites within 250 proteins that match the criteria as temporal signatures, the 
majority (404 sites within 243 proteins) are modified by reversible cysteine O-PTM, whereas 5 
sites within 4 proteins by CysSO2H and 6 sites within 5 proteins by CysSO3H. Notably, majority 
of CysSO2H sites (3 out of 5) are distributed in Cluster 1, exhibiting a continual decrease 
whereas the majority of CysSO3H sites (5 out of 6) are enriched in Cluster 7, exhibiting a 
continual increase. Notably, CysSO2H can be enzymatically reduced to free cysteine and can 
also be further oxidized into CysSO3H, which is non-reducible (Lowther and Haynes 2011; Woo 
et al. 2005). These observations revealed distinct regulation pattern of different irreversible 
modification types during ISO-induced oxidative stress. Specifically, CysSO2H on Cys164 and 
CysSO3H on Cys167 in ATP7b (Q64446) shared the temporal pattern of continual increase 
(Cluster 7), suggesting an inactivation of ATP7b during cardiac hypertrophy. As a malfunction in 
ATP7b leads to cellular copper accumulation and cardiomyopathy in Wilson disease (Patil et al. 
2013), the mapping of ATP7b’s irreversible O-PTM temporal pattern offers mechanistic insights 
into cardiac complications of Wilson disease.  
 
In a total of 243 reversibly oxidized proteins, 62 out of 90 bore at least two sites that fall into 
more than one temporal cluster. The distinct temporal regulation of cysteine sites within the 
same protein is possibly due to the unique microenvironment of the particular cysteine sites 
(e.g. cysteine pKa, enzymatic interaction). We utilized Reactome to perform pathway 
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enrichment with temporal signature proteins that are unique to one cluster. Cluster 1 is 
characterized by a continual decrease and significantly enriched in branched-chain amino acid 
(BCAA) catabolism, fatty acid beta-oxidation (FABO), and TCA pathways; Cluster 2 by an initial 
decrease that dips on Day 7 and significantly enriched in BCAA and TCA pathways; Cluster 3 
by a sharp, increase after Day 7 and significantly enriched in BCAA, TCA, and glucose 
metabolism; Cluster 4 by a sinusoidal curve and significantly enriched in protein phosphorylation 
and complement cascade; Cluster 5 by an arched curve that peaks on Day 7 and significantly 
enriched in protein phosphorylation and creatine metabolism; Cluster 6 by no change and 
significantly enriched in extracellular matrix organization and signaling; and Cluster 7 by a 
continual increase and significantly enriched in BCAA, FABO, TCA, glucose metabolism, and 
creatine metabolism; and Cluster 8 by an initial sharp decrease before returning to baseline 
levels. Reversible cysteine O-PTM sites/proteins with significant alteration in abundance ratio 
across 14 days after ISO were widely distributed among 8 clusters, suggesting that dynamic 
temporal patterns is a state-of-the-art measurement and prediction that is independent of the 
absolute value of end-point measurements. Specifically, three 40S ribosomal proteins — S3, 
S6, and S11 — with significantly increased oxidation abundance are enriched in Cluster 1 
(continual decrease), suggesting an initial wave of sharply increased oxidation in response to 
ISO treatment that diminishes as the heart hypertrophies. Notably, the majority of glucose 
metabolism proteins (4 out of 5) with significantly increased abundance belong to Cluster 7, 
demonstrating a strong and significant increase of reversible cysteine O-PTM in glucose 
metabolism during cardiac hypertrophy. In addition, the conserved Cys17 in the ATPase domain 
of the cytosolic chaperone protein, Hspa8, was continually oxidized (Cluster 7). As the perpetual 
oxidation of the conserved cysteine in the ER chaperone, Hspa5, has been shown to enhance 
chaperone function and ER homeostasis, the perpetual oxidation of Hspa8 indicates a potential 
function in cytosolic protein homeostasis during ISO-induced cardiac hypertrophy (J. Wang and 
Sevier 2016; J. Wang et al. 2014; O’Donnell et al. 2018).  
 
 
42 
The stoichiometry is an important feature of PTM and can be calculated by comparing the 
abundance of a modified form with all forms of a site of interest. Integrating the temporal 
patterns of total cysteine abundance and reversible cysteine O-PTM further reveals the 
comprehensive regulation of cysteine O-PTM stoichiometry. We applied cubic spline based 
clustering on total cysteine abundance and subsequently co-clustered temporal patterns of 
reversible cysteine O-PTM with total cysteine abundance (Figure 2.4.). Briefly, cubic spline-
based K-mean clustering was implemented to determine the temporal clusters of the total 
cysteine proteome. Subsequently, temporal signature sites of total cysteines from each cluster 
were extracted by determination coefficient analysis with R2 >0.8 as described and combined 
with the temporal pattern of oxidized cysteine sites. Clusters with more than 3 sites were 
considered as conserved patterns and included in the subsequent analysis.   
 
Figure 2.4. shows a total of 10 co-clusters with more than 3 sites identified. These co-clusters 
consist of 3 temporal patterns from reversible and irreversible cysteine modification identified 
previously and 4 newly identified temporal patterns from total cysteine abundance. Cluster 1A is 
characterized by continual decrease in oxidation with continual increase in total abundance, 
suggesting a decrease in oxidation occupancy; Cluster 1B by continual decreased oxidation 
with no change in total abundance and enriched in fatty acid metabolism; Cluster 1C by 
continual decrease in both oxidation and total abundance and enriched in branched chain amino 
acid catabolism; Cluster 1D by continual decreased oxidation with initial decreased abundance 
that dips on Day 7 and enriched in respiratory electron transport; Cluster 7A by both continual 
increase in oxidation and total abundance and enriched in glucose metabolism, FABO, and 
lipoprotein remodeling; Cluster 7B by continual increased oxidation with no change in total 
abundance and enriched in glucose metabolism and ATP synthesis; Cluster 7C by continual 
increased oxidation with decreased total abundance and enriched in retinoic acid signaling, 
suggesting a continual increase in cysteine O-PTM occupancy in regulating retinoic acid, which 
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contributes to cardiac development; Cluster 7E by continual increase oxidation with arched 
curve that peaks on Day 7; Cluster 3A by initial decreased oxidation that dips on Day7 with 
continual increased total abundance and enriched in pyruvate metabolism and TCA cycle; 
Cluster 5B by an arched curve that peaks on Day 7 with no change in total abundance. In 
addition to sites modified by reversible O-PTM, two CysSO3H sites bore the temporal pattern of 
Cluster 7A. Notably, three major enriched pathways from Cluster1, BCAA, FABO, and TCA, 
were divided into Cluster 1B, 1C, and 1D, according to the temporal patterns of their total 
cysteine abundance, demonstrating the clustering of their temporal pattern is dependent on their 
biological function. Among clusters with altered stoichiometry during cardiac hypertrophy, 
Cluster 1B and Cluster 7B are enriched in FABO and glucose metabolism, respectively. As 
cardiac hypertrophy is featured by an increased reliance on glucose with an overall reduction in 
fatty acid metabolism (Kolwicz and Tian 2011), these observations provide a detailed molecular 
map that reveals an additional layer of regulation in mitochondrial energy metabolism via 
reversible cysteine O-PTM.  
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Figure 2.3. Temporal profiling of reversible cysteine O-PTM proteomes using cubic spline-based 
clustering. (A) The temporal mapping of the reversible cysteine O-PTM proteome. Cubic spline 
followed by K-mean clustering was applied to abundance ratio of reversible cysteine O-PTM sites in ISO 
vs. Vehicle across 6 time points (x-axis), as represented by a scale from 2-fold decrease (black) to 2-fold 
increase (white), in a heat map. Our analyses yielded 8 unique temporal patterns of change in the 
reversible cysteine O-PTM abundance ratio. The numbers of sites of each cluster are as listed to the right 
of the heatmap. (B) Cluster-specific temporal patterns of reversible cysteine O-PTM. Eight 
stripcharts exhibit the trends in the normalized abundance ratio of reversible cysteine O-PTM sites (ISO 
vs. Vehicle; y-axis) over 6 time points (x-axis). Cluster 1 of reversible cysteine O-PTM sites is 
characterized by continual decrease; Cluster 2 by an initial decrease that dips on Day 7; Cluster 3 by a 
sharp increase after Day 7; Cluster4 by a sinusoidal curve with an initial increase that shifts to decrease 
on Day 5 and back to increase on Day 10; Cluster 5 by an arched curve that peaks on Day 7; Cluster 6 by 
no change; Cluster 7 by continual increase; and Cluster 8 by an initial sharp decrease that dips on Day 5. 
Key cysteine sites and pathways are listed on the stripcharts of their corresponding clusters. 
Abbreviations: oxidative post-translational modification (O-PTM); isoproterenol (ISO); TCA cycle and 
respiratory electron transport (TCA); branched-chain amino acid (BCAA) catabolism; fatty acid beta-
oxidation (FABO). 
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Figure 2.4. Temporal profiling combining reversible cysteine O-PTM and total cysteine proteomes 
using cubic spline-based co-clustering. Cubic spline followed by K-mean clustering was applied to 
abundance ratio of total cysteine sites (ISO vs. Vehicle) in the proteome. The profiles of reversible 
cysteine O-PTM temporal signatures (Figure 2.3.: R2 >0.8) were co-plotted with the well-fitted temporal 
profiles of their total cysteine abundance (labeled as A-E; R2 >0.8). Ten co-clusters with more than three 
cysteine sites were identified and demonstrated in the stripcharts, exhibiting the trends in the normalized 
abundance ratio of reversible cysteine O-PTM and total cysteine sites (y-axis) over 6 time points (x-axis). 
As previously described, Cluster 1 of reversible cysteine O-PTM sites is characterized by continual 
decrease; Cluster 3 by a sharp increase after Day7; Cluster 5 by an arched curve that peaks on Day 7; 
Cluster 6 by no change; and Cluster 7 by continual increase. Cluster A of total cysteine sites is 
characterized by continual increase; Cluster B by no change; Cluster C by continual decrease; Cluster D 
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by initial sharp decrease that dips between Day 7-10; Cluster E by an arched curve that peaks on Day7. 
Key pathways are listed on the stripcharts of their corresponding clusters. Abbreviations: oxidative post-
translational modification (O-PTM); isoproterenol (ISO); TCA cycle and respiratory electron transport 
(TCA); branched-chain amino acid (BCAA) catabolism; fatty acid beta-oxidation (FABO). 
 
2.IV.D. Correlation between hypertrophy phenotype and cysteine O-PTM abundance. 
Temporal cluster analysis revealed the intrinsic temporal regulation of a cysteine O-PTM site, 
which may contribute to or respond to the dynamic pattern of the cardiac hypertrophy 
phenotype. The heart weight-body weight (HW/BW) ratios of the mouse strain were 
documented along with the left ventriclar sample collections to provide temporal phenotypic 
profiles. During ISO treatment, all mouse strains exhibited cardiac hypertrophy development 
starting from Day 1 post ISO-treatment (Figure 2.5.A). The averaged ratio of HW/BW across 6 
time points increased 20% in ISO over Vehicle. Interestingly, we observed an arched curve of 
hypertrophy development that peaked on Day 5 (33% higher than control) and stabilized on Day 
10 (~14% higher than control). This is consistent with previous observations of the ISO mouse 
model in the C57BL/6J40 mouse strain (Rau et al. 2015). 
Protein Cysteine Correlation P value 
Oxidation 
Type 
Signature 
Entry 
Name 
Protein Names 
Gene  
Names 
O55143 
O55143_
C875 
-0.99 0.0001 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
AT2A2_
MOUSE 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 (SERCA2) (SR Ca(2+)-
ATPase 2) (EC 3.6.3.8) (Calcium pump 2)  
Atp2a2 
O55143 
O55143_
C377 
-0.96 0.0021 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
AT2A2_
MOUSE 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 (SERCA2) (SR Ca(2+)-
ATPase 2) (EC 3.6.3.8) (Calcium pump 2) 
(Calcium-transporting ATPase 
sarcoplasmic reticulum type, slow twitch 
skeletal muscle isoform) (Endoplasmic 
reticulum class 1/2 Ca(2+) ATPase) 
Atp2a2 
P00397 
P00397_
C498 
-0.96 0.0020 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
COX1_
MOUSE 
Cytochrome c oxidase subunit 1 (EC 
1.9.3.1) (Cytochrome c oxidase polypeptide 
I) 
Mtco1 
COI mt-
Co1 
Q07417 
Q07417_
C246 
-0.97 0.0010 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
ACADS_
MOUSE 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial (SCAD) (EC 
1.3.8.1) (Butyryl-CoA dehydrogenase) 
Acads 
Q3ULD
5 
Q3ULD5
_C431 
-0.99 0.0001 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
MCCB_
MOUSE 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial (MCCase subunit 
beta) (EC 6.4.1.4) (3-methylcrotonyl-CoA 
carboxylase 2)  
Mccc2 
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Protein Cysteine Correlation P value 
Oxidation 
Type 
Signature 
Entry 
Name 
Protein Names 
Gene  
Names 
Q8BFR
5 
Q8BFR5
_C290 
-0.93 0.0065 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
EFTU_M
OUSE 
Elongation factor Tu, mitochondrial Tufm 
Q8BGH
2 
Q8BGH2
_C65 
-0.93 0.0079 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
SAM50_
MOUSE 
Sorting and assembly machinery 
component 50 homolog 
Samm5
0 
Q8K182 
Q8K182
_C140 
-0.92 0.0085 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
CO8A_
MOUSE 
Complement component C8 alpha chain 
(Complement component 8 subunit alpha) 
C8a 
Q8K2B
3 
Q8K2B3
_C238 
-0.99 0.0002 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
SDHA_
MOUSE 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial (EC 
1.3.5.1) (Flavoprotein subunit of complex II) 
(Fp) 
Sdha 
Q9D8B
4 
Q9D8B4
_C115 
-0.98 0.0006 
Reversible 
cysteine O-
PTM 
Negative 
Correlation 
NDUAB_
MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 11 (Complex I-B14.7) 
(CI-B14.7) (NADH-ubiquinone 
oxidoreductase subunit B14.7) 
Ndufa1
1 
Q5SSE
9 
Q5SSE9
_C4865 
-0.93 0.0070 SO2H 
Negative 
Correlation 
ABCAD_
MOUSE 
ATP-binding cassette sub-family A member 
13 
Abca13 
A2ASQ
1 
A2ASQ1
_C441 
0.97 0.0012 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
AGRIN_
MOUSE 
Agrin [Cleaved into: Agrin N-terminal 110 
kDa subunit; Agrin C-terminal 110 kDa 
subunit; Agrin C-terminal 90 kDa fragment 
(C90); Agrin C-terminal 22 kDa fragment 
(C22)] 
Agrn 
Agrin 
P01027 
P01027_
C727 
0.95 0.0032 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
CO3_M
OUSE 
Complement C3 (HSE-MSF) [Cleaved into: 
Complement C3 beta chain; C3-beta-c 
(C3bc); Complement C3 alpha chain; C3a 
anaphylatoxin; Acylation stimulating protein 
(ASP) (C3adesArg); Complement C3b 
alpha' chain; Complement C3c alpha' chain 
fragment 1; Complement C3dg fragment; 
Complement C3g fragment; Complement 
C3d fragment; Complement C3f fragment; 
Complement C3c alpha' chain fragment 2] 
C3 
P07724 
P07724_
C302 
0.94 0.0051 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
ALBU_M
OUSE 
Serum albumin 
Alb Alb-
1 Alb1 
P07724 
P07724_
C485 
0.99 0.0001 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
ALBU_M
OUSE 
Serum albumin 
Alb Alb-
1 Alb1 
P14211 
P14211_
C137 
0.93 0.0066 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
CALR_M
OUSE 
Calreticulin (CRP55) (Calregulin) 
(Endoplasmic reticulum resident protein 60) 
(ERp60) (HACBP) 
Calr 
P19221 
P19221_
C264 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
THRB_M
OUSE 
Prothrombin (EC 3.4.21.5) (Coagulation 
factor II) [Cleaved into: Activation peptide 
fragment 1; Activation peptide fragment 2; 
Thrombin light chain; Thrombin heavy 
chain] 
F2 Cf2 
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Protein Cysteine Correlation P value 
Oxidation 
Type 
Signature 
Entry 
Name 
Protein Names 
Gene  
Names 
P62908 
P62908_
C119 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
RS3_M
OUSE 
40S ribosomal protein S3 (EC 4.2.99.18) Rps3 
P68040 
P68040_
C249 
0.97 0.0010 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
RACK1_
MOUSE 
Receptor of activated protein C kinase 1 
(12-3) (Guanine nucleotide-binding protein 
subunit beta-2-like 1) (Receptor for 
activated C kinase) (Receptor of activated 
protein kinase C 1) (p205) [Cleaved into: 
Receptor of activated protein C kinase 1, 
N-terminally processed (Guanine 
nucleotide-binding protein subunit beta-2-
like 1, N-terminally processed)] 
Rack1 
Gnb2-
rs1 
Gnb2l1 
Q01853 
Q01853_
C572 
0.93 0.0080 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
TERA_M
OUSE 
Transitional endoplasmic reticulum ATPase 
(TER ATPase) (EC 3.6.4.6)  
Vcp 
Q07113 
Q07113_
C886 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
MPRI_M
OUSE 
Cation-independent mannose-6-phosphate 
receptor (CI Man-6-P receptor) (CI-MPR) 
(M6PR) (300 kDa mannose 6-phosphate 
receptor) (MPR 300) (Insulin-like growth 
factor 2 receptor)  
Igf2r 
Q3ULD
5 
Q3ULD5
_C392 
0.94 0.0047 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
MCCB_
MOUSE 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial (MCCase subunit 
beta) (EC 6.4.1.4) (3-methylcrotonyl-CoA 
carboxylase 2)  
Mccc2 
Q60936 
Q60936_
C265 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
COQ8A_
MOUSE 
Atypical kinase COQ8A, mitochondrial (EC 
2.7.-.-) (Chaperone activity of bc1 complex-
like) (Chaperone-ABC1-like) (Coenzyme Q 
protein 8A) (aarF domain-containing 
protein kinase 3) 
Coq8a 
Adck3 
Cabc1 
Q61543 
Q61543_
C320 
0.95 0.0040 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
GSLG1_
MOUSE 
Golgi apparatus protein 1 (E-selectin ligand 
1) (ESL-1) (Selel) (Golgi sialoglycoprotein 
MG-160) 
Glg1 
Esl1 
Mg160 
Selel 
Q61554 
Q61554_
C2413 
0.92 0.0091 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
FBN1_M
OUSE 
Fibrillin-1 [Cleaved into: Asprosin] 
Fbn1 
Fbn-1 
Q8VDN
2 
Q8VDN2
_C249 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
AT1A1_
MOUSE 
Sodium/potassium-transporting ATPase 
subunit alpha-1 (Na(+)/K(+) ATPase alpha-
1 subunit) (EC 3.6.3.9) (Sodium pump 
subunit alpha-1) 
Atp1a1 
Q8VE9
6 
Q8VE96
_C254 
0.99 0.0003 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
S35F6_
MOUSE 
Solute carrier family 35 member F6 (ANT2-
binding protein) (ANT2BP) (Transport and 
Golgi organization 9 homolog) 
Slc35f6 
Q9DBH
5 
Q9DBH5
_C204 
0.95 0.0034 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
LMAN2_
MOUSE 
Vesicular integral-membrane protein VIP36 
(Lectin mannose-binding 2) (Vesicular 
integral-membrane protein 36) (VIP36) 
Lman2 
Q9ESW
4 
Q9ESW
4_C72 
1.00 0.0000 
Reversible 
cysteine O-
PTM 
Positive 
Correlation 
AGK_M
OUSE 
Acylglycerol kinase, mitochondrial (EC 
2.7.1.107) (EC 2.7.1.94) (Multiple substrate 
lipid kinase) (MuLK) (Multi-substrate lipid 
kinase) 
Agk 
Mulk 
Table 2.4. List of cysteine sites significantly correlated with the hypertrophy phenotype. 
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To directly map the association between temporal changes in cysteine O-PTM and that of the 
hypertrophy phenotype, we performed cubic spline-based Pearson correlation. We selected 29 
cysteine O-PTM sites with a p-value <0.01 as key oxidation sites that significantly associated 
with cardiac hypertrophy. Among them, 18 cysteine sites within 17 proteins and 11 cysteine 
sites within 10 proteins were positively and negatively correlated with HW/BW changes, 
respectively (Figure 2.5.B). Pathway enrichment of proteins with a positive correlation to 
phenotype unveiled 4 secretory proteins in the extracellular space that regulate Insulin-like 
Growth Factor (IGF) transport, a key regulatory mechanism of cardiac hypertrophy (Hua, Zhang, 
and Ren 2012; Troncoso et al. 2014). In addition, a BCAA pathway protein, MCCC2, was 
identified in both correlation groups, demonstrating a diverse regulation of MCCC2 cysteine O-
PTM. Notably, reversible O-PTM of an additional two key BCAA proteins, BCAT2 and DBT were 
observed in Cluster 1C, featured by continually decreased oxidation and total cysteine 
abundance. As a BCAA catabolic defect is a metabolic hallmark of the failing heart (Sun et al. 
2016), diverse oxidative regulation of BCAA proteins can potentially contribute to hypertrophy by 
metabolic reprogramming. Detailed information on featured sites, proteins, and their enriched 
pathways are listed in Tables 2.4 and 2.5, respectively. 
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Figure 2.5. Phenotypic alteration and corresponding cysteine site fingerprints during ISO-induced 
cardiac hypertrophy. (A) The HW/BWs were temporally measured three times per time point during 
ISO-induced cardiac remodeling (time points Day 1, 3, 5, 7, 10, and 14), and subsequently normalized to 
HW/BWs of vehicle. The majority of log2 transformed measurements showed positive values, indicating 
HW/BWs of ISO mice increase relative to that of Vehicle mice, as expected. The difference of HW/BWs 
between ISO and Vehicle mice was continuously broadened and peaked at Day 5, and then decreased 
until Day 10, stabilizing thereafter. (B) Twenty-nine cysteine sites which are highly correlated with HW/BW 
changes were identified through Pearson correlation coefficient (p-value <0.01); their abundance ratios 
were displayed over time. The left panel shows eighteen cysteine sites within seventeen proteins that are 
positively correlated with HW/BW, while the right panel shows eleven cysteine sites within ten proteins 
that are negatively correlated with HWBW. The red line indicates each cysteine site and the thick blue line 
shows the average trend of the group. The two thin blue lines indicate upper bound and lower bound that 
cover 95% of the data. Detailed information regarding proteins of each cluster and their enriched 
pathways are listed in the Tables 2.4 and 2.5, respectively. Abbreviations: isoproterenol (ISO); heart 
weight-body weight ratio (HW/BW); control (CTRL).  
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Pathway	Name	
#	Entities	
Found	
#	Entities	Total	 Entities	FDR	
Submitted	Entities	
Found	
Association	
N-glycan	trimming	in	the	ER	
and	Calnexin/Calreticulin	cycle	
2	 40	 0.063407806	 Q01853;P14211	 Positive	Correlation	
Post-translational	protein	
phosphorylation	
3	 165	 0.063407806	
Q61554;P07724;P01
027	
Positive	Correlation	
Binding	and	Uptake	of	Ligands	
by	Scavenger	Receptors	
2	 108	 0.090262572	 P14211;P07724	 Positive	Correlation	
Regulation	of	Complement	
cascade	
2	 129	 0.090262572	 P19221;P01027	 Positive	Correlation	
Complement	cascade	 2	 140	 0.090262572	 P19221;P01027	 Positive	Correlation	
Peptide	ligand-binding	
receptors	
2	 196	 0.090262572	 P19221;P01027	 Positive	Correlation	
 
Table 2.5. Enriched biological pathways of proteins associated with cysteine sites significantly correlated 
with the hypertrophy phenotype. 
 
2.IV.E. Signature pathways and proteins that contribute to cardiac hypertrophy. 
Combining molecular signatures from differential analysis, cubic spline-based temporal 
clustering, and phenotypic correlation, we highlighted 7 biological processes that are 
reproducibly identified as signature pathways during cardiac hypertrophy, including TCA, FABO, 
BCAA, glucose metabolism, protein phosphorylation, creatine metabolism, and response to 
elevated Ca2+. Specifically, among pathways enriched in proteins with significantly increased 
reversible modification, protein phosphorylation, creatine metabolism, and response to elevated 
Ca2+ pathways exhibited an increase in cysteine modification in early stages of hypertrophy, 
whereas glucose metabolism pathways were modified in the later stages (Figure 2.6.A). 
Comparatively, the cysteine oxidative profiles of TCA, FABO, and BCAA were more 
complicated, as metabolic reprogramming is a highly integrative process with complex 
compensatory mechanisms. We mapped all identified BCAA pathway proteins and their 
corresponding temporal dynamics. As expected, temporal trends of cysteine modification differ 
across pathways and even among cysteine sites within one protein. Interestingly, cysteine 
temporal profiles of valine catabolism sub-pathways exhibit a trend towards increase, whereas 
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that of leucine and isoleucine catabolism uniformly illustrates a decreased trend at early stage of 
hypertrophy. These observations demonstrate that cysteine O-PTM profiles are highly 
correlated with key biological processes during cardiac hypertrophy. Furthermore, these 
integrated molecular signatures of hypertrophy are novel and can be used to define phenotypes 
of metabolic reprogramming in new and informative ways. 
 
 
Figure 2.6. Signature pathways and proteins that contribute to cardiac hypertrophy. (A) The 
temporal changes of modified cysteine sites on pathways enriched in proteins with significantly increased 
modification abundance. Pathways and the temporal changes of their corresponding enriched temporal 
clusters are illustrated. Temporal clusters displaying increased trends of modification changes at 
indicated durations are boxed and color-coded as green. Protein phosphorylation, creatine metabolism, 
and response to elevated Ca2+ pathways are increased at early stages of hypertrophy whereas glucose 
metabolism has a trend of increased modification during later stages of hypertrophy. Cysteine sites with 
significantly increased modification in glucose metabolism pathways are labeled with accession number, 
protein name, and modified cysteine site. These cysteine sites with significantly increased modification 
are color-coded as green. (B) The temporal changes of modified cysteine sites on BCAA pathway 
proteins are labeled and illustrated. Each molecular player is labeled with accession number, protein 
name, modified cysteine site, and temporal cluster. Temporal clusters with increased or decreased trends 
at indicated durations are boxed and color-coded as green or red, respectively. Most sites in the shared 
pathways among BCAA pathways exhibit diverse temporal trends. Notably, the valine catabolism 
pathway exhibits an increased trend of cysteine modification whereas the temporal trend of leucine and 
isoleucine is decreased during early stages of hypertrophy. These observations suggest that oxidative 
cysteine regulation of BCAA pathways is highly compartmentalized, based on biological functions. 
Abbreviations: branched-chain amino acid catabolism (BCAA). 
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2.IV.F. Role of cysteine O-PTM in cardiovascular biology. 
ISO induced beta-adrenoceptor stimulation has been shown to evoke cardiac oxidative stress 
(G.-X. Zhang et al. 2005, 2007). Specifically, this process is mediated through increased 
mitochondrial ROS production, as mitochondrial targeted antioxidants diminish oxidative stress 
and its downstream biological events (Andersson et al. 2011). Meanwhile, the capacity of nitric 
oxide synthesis is also increased in response ISO, likely from enhanced expression of 
endothelial and inducible nitric oxide synthases (Krenek et al. 2009). During heart failure 
development, elevated RO/NS production in turn leads to modification of reactive cysteine thiol 
groups. The highly reactive thiol group of cysteine residues has made it difficult to isolate native 
versus non-biological oxidized peptides in the cardiovascular system, and subsequently, to 
elucidate their biological role. Pioneering studies on both technological and biological fronts 
have overcome this barrier and broken new ground in cardiovascular medicine. Recent work 
from Jennifer van Eyk’s laboratory identified distinct subpopulations of nitrosylated cysteines 
through a dual-labeling of nitrosylation that reduces labeling bias (Chung et al. 2015). This 
advanced methodology was then utilized to explore glycogen synthase kinase 3β (GSK3β) 
regulation by nitrosylation and it was discovered that nitrosylation reduces GSK3β kinase 
activity and promotes its nuclear translocation (S.-B. Wang et al. 2018).  
 
The biological and physiological roles of cysteine O-PTM in both vascular systems and cardiac 
muscle have been pioneered and carried into clinical translation by the work of Jonathan 
Stamler and Elizabeth Murphy, respectively. A seminal paper in 2004 by the Stamler laboratory 
was the first demonstration of a role of nitrosylation in innate immunity and vascular function (L. 
Liu et al. 2004). Mice devoid of S-nitrosoglutathione reductase showed marked increased in 
nitrosylation, vascular damage, and mortality following endotoxic challenge. More recent work 
unveiled a role for the hemoglobin β Cys93 residue in nitrosylation-based vasoactivity, 
demonstrating that S-nitrosohemoglobin plays a role in cardioprotection  (R. Zhang et al. 2016). 
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This and other notable contributions (Stomberski, Hess, and Stamler 2019; Seth and Stamler 
2015; Gonzalez et al. 2009) have revolutionized our understanding of cysteine O-PTM in 
vascular signaling. Studies from Elizabeth Murphy’s lab have advanced knowledge of cysteine 
O-PTM in cardiac muscle biology. This group pioneered novel labeling approaches for 
measuring nitrosylation occupancy, the fraction of a given protein that is nitrosylation modified in 
the myocardium, and demonstrated that nitrosylation occupancy levels following ischemic 
preconditioning protect against cysteine O-PTM (Kohr et al. 2012). More recent, formative work 
by this lab demonstrated increased nitrosylation abundance at Cys144 of the cardioprotective 
protein, TRIM72, is a molecular switch preventing TRIM72 degradation following an oxidative 
insult, which increases cardiomyocyte survival (Kohr et al. 2014). Other work unveiled complex 
profiles of nitroso-redox signaling and nitrosylation of cardiac proteins in failing versus non-
failing human cardiac tissue. Sex-specific differences in S-glutathionylation of endothelial nitric 
oxide synthase were discovered, adding to the overall complexity of these pathways in cardiac 
muscle (Menazza et al. 2015). 
   
Our measurements represent the sum of all types of cysteine O-PTM events, including disulfide 
bonds, nitrosylation, glutathionylation, and irreversible cysteine O-PTMs. Among these, different 
modifications result from diverse regulatory mechanisms (Murray and Van Eyk 2012) and can 
be interconvertible. For example, glutathionylation of Cys63 on the ER stress protein BiP is 
mediated by sulfenylation (J. Wang and Sevier 2016). Meanwhile, both sulfenylation and 
glutathionylation of BiP have been shown to enhance BiP’s activity in preventing aggregation. 
Meanwhile, different modifications can also lead to distinct biological consequences. For 
example, two types of oxidative posttranslational modifications have been shown to occur on 
Cys674 of SERCA2: reversible S-glutathiolation increases SERCA activity, whereas irreversible 
oxidative CysSO3H is associated with decreased activity (Qin et al. 2013). Conventionally, 
irreversible modifications were considered to be markers of cellular damage. Yet recent 
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advances suggest that these modifications have regulatory capacities. For example, the unique 
active cysteine sites of nitrile hydratase and thiocyanate hydrolase are responsible for metal 
coordination and can be modified by CysSO2H. The fully reduced forms of these two enzymes 
appear inactive, suggesting that CysSO2H is critical in maintaining their catalytic activity 
(Murakami et al. 2000; Arakawa et al. 2009). Our study provides key signatures modified by 
reversible and irreversible cysteine O-PTMs, facilitating the target prioritization for studying 
hierarchical regulation among different types of cysteine O-PTMs. 
 
2.V. Discussion.  
 
2.V.A. Technical Considerations. 
Capitalizing on several advancements and variations of the biotin switch method (García-
Santamarina et al. 2014; R. Li, Huang, and Kast 2015), we developed a quantitative approach 
for in-depth characterization of the cysteine oxidized cardiac proteome. Firstly, NEM alkylates 
free cysteines via a faster, more specific Michael addition reaction than the nucleophilic 
substitution reaction with IAM (Kramer et al. 2015; Reisz et al. 2013). Efficient labeling with less 
pH dependence makes NEM a great choice to preserve the labile reversible cysteine O-PTM 
and minimize artificial chemical alteration and non-specific labeling during sample processing 
over IAM. Secondly, biotin maleimide labeling offers the efficiency and specificity accompanying 
the Michael addition reaction. In addition, as the avidin-biotin interaction is strong and rapid 
(Haugland and You 2008), enrichment with high-capacity NeutrAvidin agarose enables a large-
scale pull-down with high efficiency. Thirdly, stable-isotope dimethyl labeling using reductive 
amination is a reliable widely-used approach in MS-based quantitative proteomics (Boersema et 
al. 2009; Hsu et al. 2003). Specifically, dimethylation enhances fragmentation efficiency of 
collision-induced dissociation (CID) by increasing the number of positive charges on a peptide 
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(Fu and Li 2005). In addition, high cost-effectiveness makes dimethylation applicable for studies 
with any sample size. 
 
Nevertheless, there are a few limitations to consider. The multi-stage process, including biotin 
maleimide labeling, dimethyl labeling, and avidin enrichment requires milligrams of starting 
material. The development of biotin maleimide-based isotope reagents would be a great tool to 
combine this two-stage labeling. While DTT is a potent and efficient reducing reagent for all 
types of reversible cysteine O-PTM, proteins with a large number of stable disulfide bonds will 
be prevalently enriched in this assay. On the other hand, this method can facilitate discovery of 
functional and catalytic disulfide bonds and less reactive cysteine O-PTMs that require a more 
potent reductant. Despite the limitations mentioned above, our biotin switch-based reversible 
cysteine discovery platform provides a reliable workflow allowing robust detection of reversible 
cysteine sites at multiple time points during cardiac hypertrophy development. 
  
2.V.B. Future Directions. 
To comprehensively understand the impact of ISO-induced hypertrophy on cysteine O-PTM 
sites and proteins identified from this robust biotin switch based quantitative proteomic 
approach, we used a bioinformatics approach that dissects the temporal pattern of the cysteine 
O-PTM proteome using a cubic spline-based K-mean clustering (Bhasi, Forrest, and 
Ramanathan 2005; Straube et al. 2015). The cubic spline method generates a fitted curve for all 
the cysteine O-PTM abundance values across time points for each oxidation site. This de-
noising method extracts the most fitted temporal pattern from a group of highly variable values 
with cross-validation. The smoothed temporal curve facilitates the subsequent unsupervised 
clustering to accurately identify temporal clusters of interests. However, the assumption of this 
method is that alteration across time points is gradual and smooth; this will potentially have a 
tradeoff with a sudden alteration between time points that is biologically significant. Thus, more 
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time points are required or multiple temporal analysis methods widely used in the genomics 
field, including advanced pattern extraction (Tchagang et al. 2009), can be adapted and applied 
to reveal the true biological signal from the technical bias. 
   
2.VI. Conclusions. 
Utilizing a novel cysteine O-PTM discovery platform comprised of customized redox proteomics 
and advanced computational analysis, we present the first proteome-wide study of multi-type 
cysteine O-PTM on the well-known mouse model of ISO-induced cardiac hypertrophy. The 
novelty and strength of our study lie in our ability to cluster the temporal behavioral profiles of 
cysteine residues and visualize distinct patterns of change, as well as how they correlate to the 
hypertrophic phenotype. The advanced computational and statistical platform enabled us to 
create a dynamic and integrated picture of the entire cysteine oxidative proteome, a molecular 
signature that can be used for in-depth profiling and defining of various health and diseased 
states.  
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CHAPTER 3: COMPUTATIONAL APPROACHES TO IDENTIFY 
METABOLOME FINGERPRINTS OF PATHOLOGICAL STAGES 
FOLLOWING HEART FAILURE TREATMENT. 
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3.I. Abstract. 
Pathologic cardiac remodeling from a healthy to diseased state is characterized by an intricate 
and coordinated multitude of alterations among various biomolecules over time. Conversely, 
mechanical circulatory support devices (MCSD) are a promising strategy for unloading the heart 
and reversing this process. Understanding the molecular drivers of remodeling and reverse 
remodeling would inform new mechanistic insights and more nuanced diagnostics, prognostics, 
and therapeutics for hypertrophy and/or heart failure (HF).  Plasma metabolomics holds great 
promise for the temporal profiling and characterization of healthy and diseased phenotypes, but 
large-scale technological platforms with machine learning (ML) pipelines for clinical temporal 
metabolomics profiling are still lacking. In this study, we established a Multiple Reaction 
Monitoring (MRM)-based MS quantitative platform and a corresponding ML-based 
computational workflow to unravel the metabolomics fingerprints of healthy humans, HF 
patients, and a mouse model. Accordingly, we quantified the plasma levels of 610 metabolites, 
and identified those exhibiting high correlation to phenotypic changes. In summary, a total of 30 
metabolites were significantly altered during the cardiac remodeling: 12 metabolites were 
continuously upregulated during ISO-treatment, belonging to the biological categories of amino 
acids and sphingomyelin (SM). In parallel, 18 metabolites were downregulated, consisting of 10 
free fatty acids (FFA), 6 ceramides, and 2 phosphatidylcholine (PC). Among these FFAs, we 
identified 3 saturated FFAs, 6 monounsaturated FFAs (with 1 double bond) and 5 
polyunsaturated fatty acids (PUFA). Importantly, we have identified 4 driver metabolites that are 
significantly associated with changes in HW/BW ratio, all of which are FFAs: C14:0 (Myristic 
acid), cis-C16:1w7 (Palmitoleic acid), cis-C18:1w9 (Oleic acid), and cis-C18:3w3 (α-Linolenic 
acid, ALA). Our study highlights a novel ML workflow that, in conjunction with benchmark 
datasets, will facilitate future biomarker discovery. 
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3.II. Introduction. 
Maladaptive cardiac remodeling and heart failure (HF) are common stages of many heart 
diseases and pose major public health problems in the United States (McMurray 2010). To date, 
advanced HF patients are clinically treated as a homogenous group with similar standard 
therapies (WRITING COMMITTEE MEMBERS et al. 2013). However, HF is a multifactorial 
disease and results not only from cardiac overload or injury, but also from a complex interplay 
among genetic, neurohormonal, inflammatory, and biochemical alterations, requiring refined 
diagnostic means to stratify patient groups for divergent therapies (S. J. Shah et al. 2015; Taylor 
et al. 2004). Many factors including cultural, environmental, and comorbidities (e.g., 
hypertension, obesity, kidney disease, and diabetes) can predict the severity and outcome of 
HF (East et al. 2004; Mensah et al. 2005; Husaini et al. 2011). However, rigorous, quantifiable 
methods that reliably characterize the complexity of changes associated with pathological 
remodeling and hold clinical predictive value are lacking. 
 
Cardiac metabolism is a likely target for pathologic cardiac remodeling (Neubauer 2007), in that 
the mechanical nature of cardiomyocytes makes them substantial energy consumers and even 
more so during remodeling when workloads are heightened. Under healthy conditions, the 
catabolism of fatty acids through β-oxidation provides approximately 70-90% of the total ATP 
used by the heart (Doenst, Nguyen, and Abel 2013). In addition to fatty acids, other metabolites 
are supplemented into the oxidative phosphorylation pathway, including carbohydrates, amino 
acids, and ketone bodies (Kolwicz, Purohit, and Tian 2013). Complex metabolic pathways 
including lipolysis, glycolysis, fatty acid oxidation, tricarboxylic acid cycle, oxidative 
phosphorylation, and regulatory signaling cascades work in concert to maintain functional 
stability of the heart. Both basic research and clinical studies have reported a shift toward 
glucose metabolism from fatty acid β-oxidation in hypertrophied and failing hearts. 
Consequently, ATP synthesis in failing hearts is compromised, leading to cardiac energy deficits 
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(Kolwicz, Purohit, and Tian 2013). Furthermore, inadequate cardiac output leads to insufficient 
hemodynamic circulation and end-organ perfusion, which subsequently alters global 
metabolism. Hence, maladaptive remodeling and advanced HF are associated with disrupted 
levels of multiple metabolites both in the heart and the body (Neubauer 2007). Comprehensive 
quantitation of metabolite abundance in blood plasma, also known as plasma metabolomics 
profiling, can provide mechanistic insights into the molecular alterations underlying maladaptive 
remodeling and HF (Cheng et al. 2015). The large-scale quantitation of circulating metabolites 
may also identify metabolic changes for clinical classification, which may predict the outcomes 
of HF patients before and after optimal medical therapy and surgical interventions (Lloyd-Jones 
2010). These methods can be established as important avenues for biomarker and drug-target 
development, as well as the validation of treatments. 
  
With the advances in high-throughput quantification by MS and Nuclear Magnetic Resonance, 
components of metabolic pathways have been identified as potential biomarkers in complex 
diseases (Emwas 2015; Soininen et al. 2015; A. Zhang, Sun, Wang, et al. 2012; A. Zhang et al. 
2016). Biomarkers are quantifiable small molecules that can be utilized as internal indicators 
(Chen et al. 2011; Graham et al. 2013; J. Kang et al. 2015) or therapeutic targets of disease 
(Arakaki, Skolnick, and McDonald 2008; Ganti et al. 2012; Tolstikov et al. 2014). Metabolic 
survey may offer novel mechanistic insights on disease origin and progression beyond 
traditional approaches (Roux et al. 2011; A. Zhang, Sun, Wu, et al. 2012). A few studies have 
identified metabolites as cardiometabolic risk factors (Sansbury et al. 2014; Soininen et al. 
2015; Würtz et al. 2015). In these investigations, several biological classes of metabolites or 
metabolic pathways were targeted based on previous knowledge of cardiac pathology 
(Armenian et al. 2014). Thus far, a platform for unbiased, discovery-based temporal 
metabolomics profiling empowered by advanced machine learning-based approaches is still 
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missing, which has largely hindered our capabilities for identifying metabolites relevant to 
maladaptive remodeling and HF. 
  
Table 3.1. Biological Classes of 610 Targeted Metabolites in Mouse and Human Plasma. An MRM-
based mass spectrometry approach detected and quantified the absolute abundances of a total 610 
metabolites belonging to 20 biological classes in mouse and human plasma samples. The number of 
metabolites in each biological class is also shown.  
 
In this study, we utilized an MRM-based MS quantitative platform to conduct large-scale plasma 
metabolomics profiling with the intent to capture the temporal dynamics of metabolites in 
plasma. We first applied this to chronic isoproterenol (ISO)-treated mouse strains with diverse 
susceptibilities towards β-adrenergic overstimulation, temporally characterizing 610 plasma 
metabolites that encompass 20 categories of biomolecules based on their chemical structure 
and biological function (Table 3.1). The experimental mouse dataset was used to develop a 
computational workflow, which elucidates the connection between metabolic dynamics and 
phenotypic alterations. We then applied our technical platform and corresponding computational 
Biological Class Metabolites Biological Class Metabolites 
Ceramides 136 Biogenic Amines 18 
Phosphatidylcholines 85 Phosphatidylglycerols 18 
Free Fatty Acids 63 Eicosanoids & Other PUFAs 17 
Phosphatidylethanolami
nes 54 Lysophosphatidylcholines 15 
Acylcarnitines 42 Energy Metabolism Intermediates 9 
Sphingomyelins 40 Lysophosphatidylethanolamines  9 
Phosphatidylserines 27 Neurotransmitter 8 
Bile Acids 22 Oxidative Status 6 
Amino Acids 20 Hexoses 1 
Steroids 19 Lysophosphatidylglycerols 1 
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workflow to human datasets. Blood samples and clinical assessments were acquired from 26 
HF patients receiving Mechanical Circulatory Support Device (MCSD) therapy. Temporal 
metabolomics profiling characterized the metabolic fingerprints following MCSD implantation 
and identified metabolites relevant to phenotypic alterations. Our study illustrates that a 
computational workflow, in conjunction with a benchmark dataset of healthy and diseased 
human plasma metabolomes, may pave the groundwork for future metabolomics studies with 
clinical translation. 
 
 
3.III. Methods and Materials. 
 
3.III.A. Experimental Procedures 
 
Study Approvals. 
Mouse experiments were performed in accordance with the National Research Council’s 
guidelines for the care and use of laboratory animals and were approved by the Animal 
Research Committee (ARC) of UCLA under ARC Protocol #2002-172.  Human procedures were 
performed according to protocols approved by the Institutional Review Board (IRB) of UCLA 
under IRB protocols #12-000351 and #12-000899. All participating human subjects received a 
detailed explanation of the study and provided written informed consent. 
 
Mouse Model of Maladaptive Cardiac Remodeling and Sample Collection. 
Cardiac maladaptive remodeling was induced in mice of six genetic strains (Figure 3.1.) with 
chronic isoproterenol infusion, using a previously reported protocol (Drews et al. 2010). 
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Human Cohort and Sample Collection. 
A pilot human cohort was assembled with 26 advanced HF Patients undergoing MCSD 
implantation and 12 Healthy Human Subjects. The venous blood samples were obtained and 
clinical assessments were concomitantly documented one day before the surgery (T0), and 
subsequently within time windows from one day post-surgery up to 14 weeks depending on the 
availability of patients (Figure 3.4.). 
 
Metabolic Profiling of Blood Plasma. 
Utilizing a Multiple-Reaction-Monitoring (MRM) based MS quantitative approach, we surveyed 9 
quantification panels of plasma metabolites (P180, Energy Metabolism, Free Fatty Acids, 
Eicosanoids and other oxidation products of PUFAs, Lipids, Steroids, Neurotransmitters, Bile 
acids, Oxidative status assays) using service offered by Biocrates Life Science AG (Innsbruck, 
Austria). We targeted a total of 610 plasma metabolites (Table 3.1); the absolute abundance 
levels of plasma metabolites were quantified for subsequent computational analyses. 
 
Healthy Human Subjects 
No
. 
Age 
(y/o) 
Gender Ethnicity BMI  No. 
Age  
(y/o) 
Gender Ethnicity BMI 
H1 61 F Caucasian 25.6  H7 38 M Asian 25.0 
H2 43 F Caucasian 25.0  H8 40 M Asian 25.8 
H3 58 M Asiana 23.3  H9 51 F Asian 22.7 
H4 39 M Hispanic 25.6  H10 36 M Asian 30.5 
H5 45 F Asian 22.5  H11 34 M Asian 24.9 
H6 46 M Asian 25.3  H12 27 M Asian 24.7 
 
Heart Failure Patients 
No. 
Age 
(y/o) 
Gender Ethnicity BMI Etiology SOFA1 SOFA2 SOFA3 
INTER
MACS 
P1 59 F Asian 23.3 Non-ischemic 6 3 2 2 
P2 65 M Caucasian 27.6 Non-ischemic 8 15 18 2 
P3 55 M Caucasian 21.0 Non-ischemic 5 5 2 
Mediu
mc 
P4 38 F Hispanic 29.7 Non-ischemic 5 4 2 3 
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No.	 Age 
(y/o)	 Gender	 Ethnicity	 BMI	 Etiology	 SOFA1	 SOFA2	 SOFA3	 INTERMACS	
P5 24 F Hispanic 32.4 Non-ischemic 4 1 N/A 3 
P6 43 M Hispanic 28.3 Non-ischemic 12 2 N/A 3 
P7 57 M Caucasian 24.1 Non-ischemic 7 3 1 3 
P8 74 M Caucasian 28.0 Ischemic 14 4 3 2 
P9 62 M Asian 28.0 Ischemic 16 8 N/A 1 
P10 64 M Caucasian 27.3 Non-ischemic 8 6 3 2 
P11 43 M 
African 
American 
24.1 Non-ischemic 3 4 1 
Mediu
m 
P12 30 F Caucasian 20.1 Non-ischemic 4 1 N/A 3 
P13 65 M Hispanic 26.3 Ischemic 7 13 4 2 
P14 68 M Hispanic 25.6 Non-ischemic 10 9 2 2 
P15 61 M Hispanic 24.7 Non-ischemic 6 8 3 2 
P16 71 M Caucasian 19.7 Ischemic 5 4 2 4 
P17 66 M Hispanic 22.0 Non-ischemic 6 4 1 3 
P18 62 M Caucasian 23.4 Ischemic 10 15 N/A 2 
P19 37 F Caucasian 29.2 Non-ischemic 5 6 10 2 
P20 61 M Caucasian 21.0 Non-ischemic 13 7 4 2 
P21 63 M Otherb 20.3 Ischemic 12 17 N/A 1 
P22 36 M 
African 
American 
27.0 Non-ischemic 8 N/A 1 2 
P23 46 M 
African 
American 
22.4 Non-ischemic 13 3 4 2 
P24 80 M Caucasian 16.3 Ischemic 8 7 21 3 
P25 59 F Hispanic 47.9 Non-ischemic 15 19 N/A 2 
P26 65 M Hispanic 22.5 Non-ischemic 4 5 3 2 
 
Table 3.2 Demographics of the Human Cohorts. A sample cohort was assembled with 12 healthy 
human subjects and 26 advanced heart failure patients undergoing Mechanical Circulatory Support 
Device (MCSD) implantation. BMI represents Body Mass Index; SOFA1 represents SOFA score of 
patient on 1 day pre-surgery; SOFA2 represents SOFA score of patient 5-6 days post-surgery; and SOFA 
3 represents SOFA score of patient 1 month (or closest date to 1 month) post-surgery. a. Asian 
represents Asian and Pacific Islander; b. Other indicates no available ethnicity record; c. Medium 
presents all profiles above profile 4.  
 
 
3.III.B. Computational Analyses and Annotation Workflow. 
Data Pre-processing. 
To construct a reliable temporal dataset of metabolomics profiling for subsequent computational 
analyses, the original dataset was pre-processed to remove redundancy and to replace missing 
values. 
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Differential Expression Analysis with t-Tests. 
To characterize the temporal dynamics of plasma metabolites in response to maladaptive 
cardiac remodeling in mice, a Differential Expression Analysis was performed. We applied a 
Multiple Testing Correction to the p-values calculated by the t-tests, using the Benjamini-
Hochberg method to reduce the false positives (Benjamini and Hochberg 1995).  
In parallel, t-tests were applied to 12 Healthy Human Subjects and 26 advanced HF Patients 
undergoing MCSD implantation. For both mice and humans, a threshold of adjusted p-value < 
0.001 and ±1.5 fold change was applied to detect metabolites with significant changes. Volcano 
plots, Heatmaps, and PCAs were generated to depict the results of Differential Expression 
Analyses. 
 
Identification of Housekeeping Metabolites. 
A certain set of metabolites are regularly produced and maintained by the basic processes of 
metabolism. This set of metabolites can serve as internal controls to adjust for experimental 
batch effects, and individual differences prior to an experiment. Leveraging the concept of 
housekeeping proteins, we defined the housekeeping metabolites as constitutively expressed 
components to maintain the basic cellular function. Accordingly, they sustain a constant plasma 
concentration over time. As oppose to metabolites that were significantly altered over time, 
housekeeping metabolites are selected with an adjusted p-value > 0.1 in the comparison 
between Untreated mice and ISO-treated mice for the mouse population. For the human 
datasets, housekeeping metabolites were selected using the same criteria. 
  
Adjustment for Sample Relatedness Using a Linear Mixed Model. 
In the effort of identifying plasma metabolites that are highly associated with the phenotypic 
characteristics of ISO treatment or MCSD implantation (i.e., HW/BW or SOFA Score), we 
applied the following Linear Mixed Model to account for any population relatedness represented 
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by the metabolite expression profiles (Furlotte and Eskin 2015). In this model, y represents the 
measurable phenotypic characteristics, µ is the phenotypic mean of a population, β represents 
the strength of metabolite effects, x is the metabolite expression profiles, u represents the 
effects of population stratification with Var(u) = σ2gK, and ε represents the measurement errors 
which follows a normal distribution with mean of zero and variance of σ2e. In a genome-wide 
association study, the population structure is mainly defined by the genetic relatedness among 
strains or individuals, and thus the relatedness matrix (K) is constructed using all genotypes. 
However, the concentrations of plasma metabolites can be influenced by multidimensional 
factors including genetic variances, behavior patterns, and environmental impacts. Accordingly, 
it is more adequate to use the basal expression levels of the “housekeeping” metabolites to 
construct the relatedness matrix. The variances σ2g and σ2e are estimated using a restricted 
maximum likelihood (REML) approach, and the phenotype association is performed through 
computing the F-statistic to test whether β = 0. The relatedness matrix construction, restricted 
maximum likelihood estimation, and the F-statistic computation are carried out using “Pylmm”. 
Since each metabolite is tested independently, the Benjamini-Hochberg procedure is applied to 
correct for multiple testing. A metabolite is identified as highly associated with the phenotypic 
characteristics if its associated weight (β) is significantly greater or smaller than zero with an 
adjusted p-value < 0.01. 
 
3.IV. Results. 
 
3.IV.A. Characterization of Plasma Metabolome Dynamics in Mice following ISO-Treatment. 
 
Temporal Dynamics of Mouse Plasma Metabolome During Maladaptive Remodeling. 
We conducted ISO treatment of six genetic mouse strains that previously displayed variable 
susceptibilities towards hypertrophy caused by chronic β-adrenergic stimulation (Figure 3.1.) 
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(Rau et al. 2015). Using plasma metabolomics profiling, we obtained a temporal dataset 
containing 6 mouse strains, 6 time points, and 610 metabolites (Table 3.1) for computational 
analyses (see details in Experimental Procedures). Accordingly, an integrated computational 
workflow was conceptualized to facilitate data interpretation. To identify metabolites sensitive to 
the progression of ISO-induced cardiac remodeling, the differential expression patterns of all 
610 metabolites were investigated over time using paired Wilcoxon Signed-Rank tests followed 
by the multiple testing corrections (FDR < 0.05 as the threshold). 
 
 
Figure 3.1. Schematic Overview of Experimental Protocol for Global Plasma Metabolomics 
Profiling in ISO-stimulated Mice, Healthy Humans, and HF Patients. (A) Six genetic mouse strains 
with varying susceptibilities towards maladaptive cardiac remodeling by isoproterenol (ISO) stimulation 
were continuously treated with 15mg/kg/day ISO for 14 days using surgically implanted mini-osmotic 
pumps. At baseline (time point D0) and during ISO treatment (time points D1, D3, D5, D7, and D14), 
blood samples and whole hearts were collected for plasma metabolomics profiling (3 technical replicates), 
cardiac phenotypic assessments, and annotation analyses of metabolic pathways. (B) A total of 26 
advanced heart failure (HF) patients undergoing mechanical circulatory support device (MCSD) 
implantation were analyzed for their plasma metabolomics profiles while their clinical data were obtained. 
Venous blood samples were collected one day prior to surgery (-1d, labeled as T0) and subsequently at 
12 time periods up to 14 weeks post-surgery (14 weeks, T12). The post-surgery period was subdivided 
into Stage I (surgical recovery, T0-T3), Stage II (short-term post-MCSD, T4 up to T7), and Stage III (long-
term post-MCSD, T8-T12). A cohort of 12 healthy human subjects was also analyzed for their plasma 
metabolomics profiles at 5 time periods as control (T0-T4). 
 
 
70 
 
A total of 30 metabolites were significantly altered across all time points (Figure 3.2.C). Among 
these altered metabolites, 12 metabolites (Proline, Sphingomyelins C18:0, C20:1, C26:1, etc.) 
belonging to the biological categories of amino acids and sphingomyelin (SM) were continuously 
upregulated during ISO treatment. In parallel, 18 metabolites consisting of 10 free fatty acids 
(FFA), 6 ceramides, and 2 phosphatidylcholine (PC). Among these FFAs, we identified 3 
saturated FFAs, 6 monounsaturated FFAs (with 1 double bond) and 5 polyunsaturated fatty 
acids (PUFA) were downregulated (Figure 3.2.A). A temporal trend in fold change among the 25 
differentially expressed metabolites was visualized using a Heatmap (Figure 3.2.B). Each 
individual metabolite displays a unique pattern across the 14 days of treatment, with some 
metabolites (e.g., Proline and Sphingomyelin) continually increasing, and others (e.g. FFAs) 
reaching a sustained decrease. Using the 25 significantly altered metabolites, Principal 
Component Analysis (PCA) was able to stratify the untreated (D0) mice from the ISO-treated 
mice (D1, D3, D5, D7, D14), indicating that the screening process is sufficient to recognize 
metabolic distinctions between pathological stages (Figure 3.2.B and 3.2.C). At each time point, 
Unsupervised Hierarchal Clustering was applied to stratify the 6 genetic strains (Figure 3.2.D). 
Notably, each heatmap displays unique relationships between expression patterns, suggesting 
that the metabolic alterations are sensitive to both genetic predispositions and temporal 
development. 
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Figure 3.2. Metabolomics Dynamics in Mouse Plasma During ISO-induced Cardiac Remodeling.  
The absolute abundances of 610 plasma metabolites were quantified in six genetic mouse strains during 
ISO stimulation and subjected to statistical analyses to identify differentially expressed metabolites. Over 
time, these metabolites underlie the metabolic responses associated with the progression of ISO-induced 
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maladaptive remodeling of the heart. The results indicate that the global metabolomics profiling is a 
sensitive approach to identify metabolic markers with pathophysiological relevance. (A) A paired t-test 
was performed to identify metabolites significantly altered following ISO treatment (D0 vs. D1, 3, 5, 7 and 
14). One volcano plot depicted as Log2 (Fold-Change expressed as ISO-treated/Untreated) (X-axis) 
against –Log10 (adjusted p-value) (Y-axis) was generated accordingly. A threshold (p < 0.001 and ±1.5 
Fold-Change, dotted lines) was applied to identify metabolites with significant changes. During ISO-
induced maladaptive cardiac remodeling, 21 metabolites were downregulated (Yellow dots) and 4 were 
upregulated (Blue dots). The other metabolites did not display significant changes (Grey dots). (B) A 
temporal Fold-Change profile was generated for the 25 differentially expressed metabolites identified in 
panel 2A. The heatmap shows the metabolite levels expressed as Fold-Change between ISO-treated 
mice on consecutive time points (D1, D3, D5, D7 and D14) and Untreated mice (D0). For all metabolites, 
the Fold-Change value at each time point is indicated in each tile. The color keys (green, upregulation; 
red, downregulation) and histograms (blue line, distribution of metabolites in each color range) are 
displayed at the bottom of heatmap. Both Proline (Pro) and Sphingomyelin (SM) showed an increasing 
Fold-Change over time while multiple species of Ceramides (Cer) and Free Fat Acids (FFA) showed 
consistent downregulation. (C) Principal Component Analyses (PCAs) were performed on the 25 
significantly altered metabolites (Panel 2A) to compare ISO-treated mice during multiple time points (D1, 
D3, D5, D7, and D14) to Untreated mice (D0). The X-axis is depicted as the first principal component 
(PC1) representing the space with the largest variance in data. And the Y-axis is depicted as the second 
principal component (PC2) representing the space with the second largest variance. In each scatterplot, 
ISO-treated mouse strains are colored in red and untreated mouse strains are colored in blue. Ovals are 
95% inertia ellipses. Of the 25 metabolites, a clear separation between the ISO-treated mice and 
untreated mice can be observed starting on D1. The more profound separation on D3, D5, D7 and D14 
reflects prolonged and more severe stress by ISO treatment. In contrast, a PCA of all 610 metabolites did 
not show a separation during all time points, which demonstrates the identified metabolites in panel 6A-C 
reflecting pathophysiological changes over time. (D) A Hierarchical Clustering was generated using 
Spearman correlation coefficients of the metabolites Fold-Change profiles. Accordingly, the heatmaps 
display the metabolite levels expressed as a Fold-Changes between Untreated mice (D0) and ISO-
treated mice at multiple time points (D1, D3, D5, D7, and D14) of the 25 differentially expressed 
metabolites (Panel 2A). The color keys (green, upregulation; red, downregulation) and histograms (blue 
line, distribution of metabolites in each color range) are displayed at the bottom of heatmap. The 
dendrograms on the top of the heat maps represent the distance among the mouse strains. 
Metabolomics Fingerprints of Six Unique Genetic Mouse Strains with Differing Susceptibilities to 
ISO Stimulation. 
To identify metabolomics fingerprints that closely associate with phenotypic characteristics, the 
heart weight-body weight (HW/BW) ratios were documented concomitantly with the plasma 
sample collection to provide temporal phenotypic profiles in parallel with metabolic alterations.  
During ISO treatment, mouse strains C57BL/6J, CE/J and FVB/NJ exhibited relatively lower 
severity of cardiac hypertrophy; the HW/BW ratios ended at ~120% of baseline after 14 days. 
The result agrees with previous observations that these three mouse strains are more resilient 
to cardiac stress following ISO treatment (Rau et al. 2015). In contrast, strains DBA/2J, A/J and 
BALB/cJ showed more substantial hypertrophy, with HW/BW ratios ~140% after 14 days, 
demonstrating a greater degree of susceptibility to ISO-induced cardiac stress (Figure 3.3.A).   
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In our computational workflow, a Linear Mixed Model (LMM) was employed to correlate 
temporal metabolome dynamics with HW/BW ratios. To account for individual relatedness and 
thereby improve statistical accuracy, we incorporated a Relatedness Matrix Correction into the 
LMM. To generate the matrix, we selected the metabolites with an adjusted p-value > 0.1 in the 
aforementioned paired t-test and a total of 309 metabolites, termed “housekeeping metabolites”, 
were identified. These “housekeeping” metabolites maintain consistent levels in plasma over 
time, whereas their similarities among mouse strains indicate individual relatedness. We also 
performed a Multiple Testing Correction to control the false discovery rate. Applying a threshold 
of < 0.01 on adjusted p-values, 4 metabolites were identified as significantly associated with 
changes in HW/BW ratio, all of which are FFAs: C14:0 (Myristic acid), cis-C16:1w7 (Palmitoleic 
acid), cis-C18:1w9 (Oleic acid), and cis-C18:3w3 (α-Linolenic acid, ALA). Their temporal 
changes in plasma levels are displayed in parallel with HW/BW ratios (Fig 3B). In mouse strains 
sharing similar susceptibility to ISO treatment, the 4 metabolites displayed similar temporal 
behaviors during maladaptive remodeling. 
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Figure 3.3. Phenotypic Alteration and Corresponding Metabolic Fingerprints During ISO-induced 
Cardiac Remodeling in Mice. 
(A) The heart weight–body weight ratios (HW/BWs) were temporally measured for the six mouse strains 
during ISO-induced cardiac remodeling (time points D1, D2, D3, D5, and D14), and subsequently 
normalized to HW/BW of untreated mice (D0). The BALB/cJ, A/J, and DBA/2J mouse strains showed an 
elevation up to 40% at an earlier stage, indicating a more severe response to ISO treatment; the 
C57BL/6J, CE/J, and FVB/NJ mouse strains displayed a stabilized increase of 20% at D14, suggesting a 
more resilient response. (B) Four metabolites (C14:0, cis-C16:1w7, cis-C18:1w9, cis-C18:3w3) were 
identified through paired t-test and LMM analyses; their absolute abundances were displayed over time, 
in line with the mice’s susceptibilities towards ISO treatment. Within each mouse strain, the four 
metabolites presented consistent temporal dynamics, indicating shared or synchronized metabolic 
pathways. In mouse strains sharing similar susceptibility towards ISO treatment, the four metabolites 
displayed comparable behavior during the progression of maladaptive remodeling. For example, Balb/c, 
A/J, and DBA/2J mouse strains (ISO-susceptible) showed relatively less basal abundance of α-linolenic 
acid (cis-C18:3w3) than the C57, CE/J, and FVB mouse strains (ISO-resilient). During 14days’ ISO-
treatment, ISO-resilient mouse strains displayed better capability to immediately restore the plasma level 
of α-linolenic acid than ISO-susceptible strains 
 
3.IV.B. Characterization of Plasma Metabolomics Dynamics in HF Patients Receiving MCSD 
Implants.  
 
Enrollment and Demographics of Human Cohort. 
To translate our computational workflow from mouse dataset analyses to human data 
interpretation, we first assembled a test cohort over a 2-year period from Aug 2012 to Nov 2014, 
including 12 healthy human volunteers (H1, H2, … H12) and 26 advanced HF patients (NYHA 
III-IV) who had received MCSD implants (P1, P2, … P26) (Table 3.2). The healthy human group 
contains 9 Asians, 2 Caucasians, and 1 Hispanic with an average age of 43 ± 10 (range: 27-61) 
years. The healthy humans include 4 females and 8 males with an average Body Mass Index 
(BMI) of 25.1 ± 2.0 (range: 20.1-32.4), presenting a normal distribution of body type. The HF 
patients include 11 Caucasians, 9 Hispanics, 3 African-Americans, 2 Asians, and 1 without an 
ethnic record. This group includes 6 females and 23 males with an average age of 56 ± 14 
(range: 24-80) years. The average of BMI was 25.5 ± 5.9 (range: 16.3-47.9). The etiological 
categories of HF patients were classified as ischemic cardiomyopathy (ICM) or non-ischemic 
cardiomyopathy (NICM). The Sequential Organ Failure Assessment (SOFA) score of each 
individual patient was assessed 1 day before MCSD implantation and continuously monitored 
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post-surgery. Within the 5-day period after MCSD implantation, all patients showed a significant 
increase in SOFA score that is most likely induced by post-surgical inflammatory response and 
recovery. We exhibited this period as Stage I (T1-T3, up to 6 days post-surgery, Fig 5). A short-
term clinical assessment Stage II (T4-T7, 7 days to 28 days post-surgery) was chosen to 
evaluate the direct results of MCSD implants and their metabolic imprint due to improved 
systemic hemodynamics and vital signs. A long-term phase was indicated as Stage III (T8-T12, 
29 days up to 120 days post-surgery) to determine the metabolic imprints of the patients with 
respect to their recovery and outcome. Before surgery, the INTERMACS score for each patient 
was assessed to classify the HF patients before MCSD implantation (7.79% in profile 1; 53.85% 
in profile 2; 26.92% in profile 3; 3.85% in profile 4, and 7.69% in profile 5-7).  
 
Plasma Metabolomics Stability in Healthy Human Subjects. 
To validate the practicality and reliability of our technical platform and corresponding 
computational workflow, blood samples were collected from 12 Healthy Human Subjects at 5 
consecutive time points (T0, T1, …T4). A total of 610 metabolites were absolutely quantified for 
the time series of samples. A paired t-test showed that only one metabolite, Cortisol, was 
significantly altered over time (Figure 3.5.A). Cortisol is a human steroid hormone released in 
response to stress and also sensitive to the Circadian rhythm. In addition, cortisol is only slightly 
above the threshold to be considered significant, suggesting general metabolome stability over 
time in Health Human Subjects. In addition, almost all metabolites were identified without 
statistical significance from these biological replicates, in which no pathological difference 
should exist. The results suggest that our technical platform and computational workflow only 
address metabolites in response to pathological alterations and clinical interventions. 
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Figure 3.4. Healthy Human Subjects Plasma Metabolomics Stability and Their Distinction from HF 
Patients. The absolute abundances of plasma metabolites were quantified in 12 Healthy Human Subjects 
at 5 consecutive time points (T0-T4) and in 26 HF Patients before receiving MCSD implantation (T0). 
Resulting datasets were subjected to statistical analyses to identify differentially expressed metabolites. 
(A) A paired t-test was performed to generate a volcano plot depicted as Log2 (Fold-Change expressed 
as T1-T4/T0) (X-axis) against –Log10 (adjusted p-value) (Y-axis) to highlight the differential expression 
patterns of 610 plasma metabolites quantified in 12 Healthy Human Subjects over 5 consecutive time 
points (T0-T4). A threshold (p < 0.001 and ±1.5 Fold-Change, dotted lines) was applied to identify 
metabolites with significant changes. Over T0-T4 only one metabolite was upregulated (Blue dot) and no 
metabolites were downregulated (Yellow dots) in healthy humans. The other metabolites did not display 
significant changes (Grey dots), indicating a notable stability of the plasma metabolome under basal 
conditions. (B) With the same threshold as in Panel (A), a t-test was performed to compare the differential 
expression patterns of 610 metabolites in Healthy Human Subjects and HF Patients before MCSD 
implantation. The volcano plot illustrates 76 metabolites that were differentially expressed, of which 21 
metabolites were downregulated (Yellow dots) and 55 were upregulated (Blue dots) in HF patients, 
respectively. (C) Using the 76 metabolites identified in Panel (B), the Principal Component Analysis 
(PCA) reveals that Healthy Human Subjects and HF Patients are evidently separated, indicating distinct 
metabolomics fingerprints that differentiate healthy and compromised plasma metabolomes. (D) The 76 
metabolites identified in Panel (B) were further subjected to unsupervised hierarchal clustering; this 
method validates that the HF Patients are well-clustered and separate from the Healthy Human Subjects, 
corroborating that the two cohorts have distinct metabolomic fingerprints.  
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Figure 3.5. Metabolomics Dynamics in Plasma from HF Patients Before and After MCSD 
Implantation. The absolute abundances of plasma metabolites were quantified in HF patients receiving 
MCSD implantation and subjected to statistical analyses to identify differentially expressed metabolites. 
The significantly altered metabolites over time underlie the metabolic responses associated with 
mechanical unloading of the heart during advanced HF.  
A paired t-test was performed to generate volcano plots depicted as Log2 (Fold-Change expressed as 
post-surgery/pre-surgery) (X-axis) against –Log10 adjusted p-value (Y-axis) to highlight the differential 
expression patterns of 610 plasma metabolites before (T0) and after the MCSD implantation at Stage I 
(surgical recovery, T1 - T3), Stage II (Short term post-MCDS, T3 - T7), and Stage III (Long term post-
MCDS, T7 - T12). A threshold (p < 0.001 and ±1.5-fold change, dotted lines) was applied to identify 
metabolites with significant changes In Stage I (A), a total of 7 metabolites were significantly altered, of 
which 7 were upregulated (Blue dots) while none were downregulated (Yellow dots) compared with T0. In 
Stage II (B), a total of 22 metabolites were significantly altered, of which 8 were downregulated (Yellow 
dots) while 14 were upregulated (Blue dots) compared with T0. In Stage III (C), a total of 8 metabolites 
were significantly altered, of which 7 were downregulated (Yellow dots) while 1 was upregulated (Blue 
dots) compared with T0. The other metabolites did not display significant changes (Grey dots). (D) A 
temporal Fold-Change profile was generated for the sum of 36 differentially expressed metabolites found 
in Stage I-III. The color keys (green, upregulation; red, downregulation) and histograms (blue line, 
distribution of metabolites in each color range) are displayed at the bottom of each heatmap. 
Dopamine_P180 showed an decreasing Fold-Change over time, while PC aa C32:2_Lipd showed an 
increasing fold-change over time; The other metabolites were consistently upregulated, or downregulated 
over time. (E) Three PCAs were performed for post-surgery Stages I, II and III against the metabolic 
conditions before MCSD implantation (T0). In each scatterplot, post-surgical status of MCSD recipients 
are colored in red and their pre-surgical status (T0) are colored in blue. Ovals are 95% inertia ellipses. Of 
the 36 metabolites, no separation can be observed between Stage I and T0. However, Stage II exhibited 
a moderate separation and Stage III displayed an increased separation, reflecting the metabolic impacts 
of prolonged MCSD unloading for advanced HF patients.  
 
Differences of Human Plasma Metabolomes between Healthy and HF Conditions. 
To assess the scale of metabolic distinction between Healthy Human Subjects and HF Patients, 
a t-test was applied to data points of Healthy Human Subjects versus HF Patients before their 
MCSD implantation (Figure 3.5.B). A total of 21 metabolites were upregulated in HF Patients 
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while 55 metabolites were downregulated. Performing PCA with these 76 significantly 
differentiated metabolites, the first two principal components clearly separated healthy humans 
from HF Patients before MCSD implants (Figure 3.5.C). In parallel, an Unsupervised 
Hierarchical Clustering analysis was applied and the resulting heatmap and dendrograms 
revealed that patients are well clustered away from healthy humans. Furthermore, the 
upregulated metabolites and downregulated metabolites are clustered separately with unique 
relationships (Figure 3.5.D). Through the Differential Expression Analysis, we identified 
metabolites that are potentially related to disease-induced metabolic abnormality. However, 
end-stage HF patients displayed notable pathological conditions dissimilar to those of healthy 
humans; thus, it is not surprising to observe that these severe physical dysfunctions underlie 
drastic metabolic differences. 
 
Temporal Metabolic Alterations Induced by MCSD Implantation in HF Patients. 
Beyond the characterization of readily-discernable metabolomics distinctions between healthy 
humans and HF patients, we aimed to pinpoint the metabolic alterations before and after MCSD 
implantation. Paired t-tests were performed to characterize the differential expression patterns 
of 610 plasma metabolites at the following time points: post-surgery Stage I (surgical recovery, 
up to 6 day post-surgery, see details in Experimental Procedures), Stage II (short-term post-
MCSD, up to 4 weeks post-surgery), and Stage III (long-term post-MCSD, up to 14 weeks post-
surgery). In Stage I, only 7 metabolites were significantly downregulated (Figure 3.6.A). 
Subsequent analysis revealed 14 downregulated and 8 upregulated metabolites in Stage II. 
Notably, all 8 upregulated metabolites are Glycerophospholipids, while the majority of 
downregulated metabolites belong to biological classes of Acylcarnitines and Ceramides (Figure 
3.6.B). Finally, we found that 1 Acylcarnitine was downregulated and 7 Glycerophospholipids 
were significantly upregulated within Stage III (Figure 3.6.C). Accordingly, a temporal trend of 
fold change among the 36 differentially expressed metabolites was visualized using a heatmap 
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(Figure 3.6.D). Plasma metabolites such as Dopamine, Testosterone and several phospholipids 
exhibited a steady fold change after MCSD implantation reflecting the temporal effects of 
mechanical unloading of the heart. Three PCAs were performed for post-surgery Stages I, II 
and III against the metabolic conditions before MCSD implantation (T0). Of the 36 metabolites 
that were cumulatively found to be differentially expressed in either Stages I, II or III, no 
separation could be observed between Stage I and T0. However, Stage II exhibited a moderate 
separation and Stage III displayed an increased separation, reflecting the metabolic impacts of 
prolonged MCSD unloading for advanced HF patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Temporal Changes of Clinical Manifestation and Corresponding Metabolomic 
Dynamics in HF Patients Following MCSD Implantation. In conjunction with Differential Expression 
Analysis, a Linear Mixed Model (LMM) was applied to the temporal metabolomics dataset of 26 HF 
Patients and identified 11 metabolites that were both significantly altered over time and highly associated 
to the clinical manifestations after MCSD implantation. Among these metabolites, 4 acylcarnitines, 4 
phosphotidylethanolamines, 1 phosphotidylcholine, 1 sphingomyelin, and 1 hormone were identified, 
which we consider as potential novel biomarkers with respect to clinical diagnosis, prognosis and 
gradation of disease severity. Particularly, the temporal patterns of testosterone were utilized to stratify 
the patients into 3 risk groups. In Group I, 8 deceased patients (P2, P3, P9, P16, P18, P21, P24, and 
P25) were mostly males (n=7) who constantly maintained a very low Testosterone level. In Group II, 13 
patients (P6, P7, P8, P10, P11, P13, P14, P15, P17, P20, P22, P23, P26) were all males with good 
clinical manifestation. Notably, these patients stayed at low Testosterone levels shortly after implantation 
but exhibited a steady increase of Testosterone after Stage II. In Group III, 5 female patients (P1, P4, P5, 
P12, P19) shared similar low Testosterone levels while showing a promising clinical recovery.  
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Potential Biomarker Candidates Identified by Temporal Metabolomics Profiling and 
Computational Workflows. 
When we applied our integrated computational workflow, including both Differential Expression 
Analysis and LMM, to the MCSD recipient cohort, a total of 11 metabolites were found 
significantly altered over time as well as highly associated with clinical manifestations (SOFA 
Scores). When applied to human datasets, LMM with Relatedness Matrix Correction provides 
notable different results compared to Simple Linear Regression Model. Therefore, QQ-plots 
were used to evaluate the performance of these two computational models. The LMM analyses 
using matrix correction generated more precise p-values than Simple Linear Regression Model 
without matrix correction. Among these metabolites, 4 Acylcarnitine, 4 
Phosphotidylethanolamine, 1 Phosphotidylcholine, 1 Sphingomyelin, and 1 hormone were 
identified. These metabolites may offer significant predictive value to the patient’s clinical 
manifestation and outcome. In particular, Testosterone level could classify patients into three 
groups (Figure 3.7). In Group I, 8 deceased patients (P2, P3, P9, P16, P18, P21, P24, and P25) 
were mostly males (n=7) who constantly maintained a very low Testosterone level throughout 
the entire study period post-MCSD. In Group II, 13 patients (P6, P7, P8, P10, P11, P13, P14, 
P15, P17, P20, P22, P23, P26) were all males who presented with good clinical manifestation 
according to their SOFA scores. Notably, these patients stayed at low Testosterone levels 
shortly after implantation but exhibited a steady increase of Testosterone after Stage I, while 
further increasing in Stage II & III. In Group III, 5 patients (P1, P4, P5, P12, P19) shared similar 
low Testosterone levels as patients in Group I while their SOFA scores showed a promising 
clinical recovery. Interestingly, these were all female patients. It appears that Testosterone 
plasma levels may have more accurate predication of clinical outcomes in male patients, 
potentially as a biomarker candidate in clinical classification. 
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3.V. Discussion. 
Advanced HF is a multifactorial disease in which a patient’s hemodynamics are severely 
compromised. MCSD has been proven to promptly restore blood circulation and end-organ 
perfusion, thus enhancing global metabolism. To fully comprehend the failing heart and 
cardiovascular systemic responses towards MCSD implantation, it is essential to characterize 
the dynamics of metabolic networks. Several successful clinical investigations identified plasma 
biomarkers for diagnosis of cancers and neurodegenerative Diseases (Duarte, Rocha, and Gil 
2013; Jové et al. 2014; G. Wang et al. 2014; Xu et al. 2013). In the cardiovascular research 
field, the metabolic networks in the heart and their perturbations during cardiac disease 
progression have become an emerging research focus (Cheng et al. 2015; Hoefer et al. 2015; 
Stegemann et al. 2014). However, the lack of an effective workflow to systematically screen 
disease-relevant metabolites has limited the clinical application of metabolomics profiling. Within 
this pilot study, we first sought to develop a technical platform with computational tools that can 
adequately handle the volume and analysis of the mouse plasma metabolome in a temporal 
manner. Our established workflow was subsequently refined to characterize complex clinical 
datasets of human HF. Finally, we translated our findings to clinical diagnosis, therapeutic 
validation, and risk stratification. 
 
3.V.A. Methodological Considerations of Animal Models and Human Studies. 
Advanced HF is characterized by prolonged stress and inflammation caused by elevated levels 
of neurohormonal stimuli, including cortisol and catecholamines. Previous studies demonstrated 
that implantation of MCSDs may improve patient quality of life by decreasing clinical symptoms 
and reducing neurohormonal stimulation in patients, which is recognized as reverse remodeling 
in HF (Liem et al. 2014). Technically, it is challenging to simulate a reverse remodeling model in 
mice. Thus, we decided to utilize an ISO-induced hypertrophy model, in which cardiac function 
is compromised by constant neurohormonal overstimulation (opposite to reverse remodeling). In 
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addition, the pathological phenotypes of ISO treatment (e.g., HW/BW ratio) have been well-
documented and can be used as guidance for experimental quality control.  
Six genetically distinct mouse strains were selected for their variable susceptibilities towards 
ISO treatment, which offers a spectrum of molecular responses to ISO-induced stress that 
mimics genetic variances among humans.  
 
We explored the scope of our large-scale metabolic survey to determine the dynamic range and 
sensitivity for data acquisition over time. Theoretically, any plasma metabolite could be 
accurately quantified if we apply extra isolation/enrichment procedures. However, temporal 
metabolomics profiling needs to be balanced between the quantity of identifiable metabolites 
and the technical practicality. Accordingly, we applied 9 quantitative panels of plasma 
metabolites and eventually obtained the absolute abundances of 610 metabolites. They 
encompass 20 categories of biomolecules based on their similarities in chemical structure and 
biological functions. We considered this set of metabolites as the most accessible pool for 
human and mouse plasma profiling without additional enrichment procedures.  
 
In contrast to animal models, in which sample collections follow a well-planned schedule, clinical 
human studies often face challenges that may prevent blood sampling at consistent intervals. 
This necessitates a certain degree of flexibility in the construction of datasets. Accordingly, we 
defined intervals to which a time window is assigned. In brief, smaller intervals of sample 
collection were conducted right after surgery, and larger intervals were used as the patient 
stabilized and continuously recovered. This enabled data-series from multiple patients to be 
compared in a temporal manner, while maintaining a high level of accuracy to reflect clinical 
manifestations. 
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Before committing to extensive temporal profiling studies, it was important to gain confidence in 
our technical design by confirming the plasma metabolomics stability under basal conditions. 
Thus, 12 Healthy Human Subjects were recruited and blood samples were collected individually 
at 5 consecutive time points. A differential expression analysis validated that our computational 
workflow is tolerant of the insignificant changes among 610 metabolites that may occur due to 
varying factors such as sample collection, diet, physical activity, etc (Figure 3.5.). This result 
provided the confidence for conducting the two-year enrollment of MCSD recipients for blood 
sample collections up to 14 weeks. Furthermore, this dataset of healthy humans could be used 
as a benchmark reference for plasma metabolomic homeostasis. 
 
3.V.B. Conceptualization of Computational Workflow Modules. 
Unlike animal models, human studies present major challenges due to human biochemical 
individuality. Variability in genetic assembly and metabolic homeostasis may prevent deduction 
of mechanistic insights, especially in the presence of comorbidities. Large, longitudinal clinical 
studies take years to conduct, and the scope of metabolite profiling is usually limited by financial 
costs. Studies with smaller cohorts provide enhanced possibility for “data-driven” biomarker 
discoveries. However, small numbers of human subjects restrains the statistic power for in-
depth characterization using standard computational methods. We demonstrate in our study 
that temporal metabolomics profiling datasets with smaller cohorts, in conjunction with 
customized computational approaches, may offer the benefit of sensitivity in response to 
pathological stress or therapeutic regimens, enabling in-depth analysis of biomarker candidates. 
To date, the most widely-used computational analyses in metabolomics studies are Univariate 
Analysis (e.g., t-test or ANOVA), Multivariate Analysis (e.g., PCA or PLS-DA) and Cluster 
Analysis (e.g., hierarchical clustering or partitional clustering) (Xia et al. 2012, 2009, 2015), 
offering snapshot comparisons of static conditions (e.g., healthy vs. diseased). However, these 
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methods have not been integrated to characterize temporal datasets extracted from large-scale 
metabolomics profiling.  
The plasma metabolome is a summation of global metabolism, containing metabolites whose 
plasma levels range from stable to vastly dynamic. In this study, paired t-tests were first utilized 
to process temporal data series and differentiate metabolites’ responses towards stress or 
therapies over time. A pilot subset of 12 healthy humans was initiated to establish a preferable 
threshold. With an adjusted p-value less than 0.001, we only identified one metabolite, Cortisol 
(stress hormone), which was slightly above the significance threshold. The stringent threshold 
reduces false positive rates potentially caused by systematic error (e.g., lack of biological 
replicates). Using the same criteria, this approach enabled us to identify significantly altered 
metabolites from HF patients following MCSD implantation. Our benchmark dataset of Healthy 
Humans and HF Patients revealed not only the stability but also the dynamics of plasma 
metabolome under varying pathological conditions. Such references may serve as guidance for 
future clinical investigations. 
 
Following the identification of significantly altered metabolites over time, we sought to recognize 
a strong association between metabolic dynamics and pathophysiological alterations. The 
Regression Analysis has been widely used to correlate metabolite concentration and clinical 
characteristics (Riesmeyer et al. 2012; Weinstock-Guttman et al. 2011; Adibi et al. 2009). 
However, few metabolomics studies have considered Random Effects in their statistical 
equation, in which each element of one given variable presents different (weighted) impact on 
the final result (Bonate 2013). In clinical studies, Random Effects need to be taken into account 
because factors such as age, gender, or comorbidities contribute unevenly to disease 
phenotypes. To address these Random Effects in our regression model, a Relatedness Matrix 
Correction was applied. Although common in genomics studies (H. M. Kang et al. 2010; Orozco 
et al. 2015; H. M. Kang et al. 2008), such matrix correction has not been employed in 
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metabolomics investigations. The immediate challenge is that SNPs are routinely used in 
genomics to generate the relatedness matrix, whereas such genetic background is not available 
for human subjects in our study. In addition, genetic relatedness may not completely translate 
into metabolic similarities. It is more logical to generate the matrix using original plasma 
metabolite concentrations, which reflects the intrinsic metabolic differences among individuals 
and should remain consistent throughout the entire temporal profiling study.  
Given that a fraction of metabolites are more dynamic, and a Relatedness Matrix will be 
universally applied to correct all data points for the entire time series, we decided to select 
metabolites with stable plasma levels to generate the matrix. Similar to the concept in 
proteomics, we term those metabolites as “housekeeping metabolites”. Thus, we computed a 
pairwise Relatedness Matrix among patients according to their housekeeping metabolite 
abundances, and performed the Linear Mixed Model (LMM) with the Matrix Correction using a 
software package pyLMM (https://github.com/nickFurlotte/pylmm) (Orozco et al. 2015). 
In this study, a metabolite must fulfill the criteria for both the differential expression analyses and 
LMM to be considered as a biomarker candidate. However, those extremely stable metabolites 
also bear biological importance. The pool-size differences of metabolite plasma reservoirs may 
also indicate the individual’s capability to handle stress and perturbation, offering new directions 
for further investigations. 
 
3.V.C. Gradation of Cardiac Remodeling and HF Using Identified Metabolites as Biomarker 
Candidates. 
In the ISO treatment mouse model, we identified four metabolites that are both differentially 
altered over time and highly associated with ISO-induced phenotypic alteration (i.e., HW/BW 
ratio). They belong to the biological class of Free Fatty Acids (FFAs), including C14:0 (Myristic 
acid), cis-C16:1w7 (Palmitoleic acid), cis-C18:1w9 (Oleic acid) and cis-C18:3w3 (α-Linolenic 
acid). Following the initiation of maladaptive remodeling, their plasma levels significantly 
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dropped to below 30% of baseline levels within 3 days, suggesting that elevated cardiac energy 
demand directly led to plasma FFA deficiency (Figure 3.4). The stratification of mouse strains 
with these 4 FFAs is in line with their susceptibility towards ISO. In particular, the plasma α-
linolenic acid (ALA) levels in ISO-resilient strains were promptly restored after the first wave of 
ISO-induced stress, which maintained in a level as much ~2-fold as that of ISO-susceptible 
strains. In a recent study using a rat model with β-adrenergic overstimulation, ALA was found to 
prevent ISO-induced myocardial fibrosis and hypertrophy by preserving the Src-PI3K protective 
pathway also known as the β2AR pro-survival pathway (Folino et al. 2015). Similar studies 
confirmed that an ALA-enriched diet prevents myocardial damages in an independent animal 
model (Fiaccavento et al. 2006) and might be associates with cardioprotective effects in human 
(Djoussé et al. 2005; Singh et al. 1997). According to our results, the temporal profiles of 
plasma ALA can be used as a potential biomarker to differentiate ISO-resilient mouse strains 
from ISO-susceptible ones.  
 
In this human HF study, our integrated computational workflow identified a total of 11 
metabolites that were significantly altered over time and highly associated with the patient’s 
clinical manifestation (i.e., SOFA Score). Among these metabolites, 4 acylcarnitines, 4 
phosphotidylethanolamines, 1 phosphotidylcholine, 1 sphingomyelin, and 1 hormone were 
identified, which we consider as potential novel biomarkers with respect to clinical diagnosis, 
prognosis and gradation of disease severity. In addition to static differences in plasma levels, 
we have considered the temporal fold change (Figure 3.6.D) of potential metabolomics 
biomarkers as a predictive clinical parameter. For clinically established biomarkers such as B-
type natriuretic peptide (BNP) and Troponin-I, their fold changes over time (in parallel to their 
absolute plasma levels) provide valuable clinical insights on the pathological state of the heart 
(Twerenbold et al. 2012). Hence, a 10 fold change of plasma Troponin-I over time indicates 
more severe cardiac ischemic damage compared to a 2-fold change. Similarly, our results 
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indicate that plasma metabolites such as Dopamine, Testosterone and several phospholipids 
exhibit a steady fold change after MCSD implantation, reflecting the temporal impacts of 
mechanical unloading of the heart. 
 
Remarkably, the human plasma levels of the hormone Testosterone appear to have strong 
clinical predictive values. In 8 HF patients deceased after MCSD implantation, their plasma 
testosterone values remained consistently low over phase I, II and III (Group I in 3.7); 
concomitantly, their SOFA scores remained in high-risk ranges. In contrast, 13 HF patients who 
showed favorable clinical recoveries after MCSD implantation (illustrated by a consistently 
improving SOFA score over time) displayed a steady increase of Testosterone plasma levels 
starting in Phase II, and further increasing over Phase III (Group II in 3.7). Lastly, 5 HF patients 
who showed good clinical recoveries with improving SOFA scores post-MCSD demonstrated 
low plasma testosterone levels (Group III in Figure 3.7.). Interestingly, these 5 patients were all 
females, which explains the lower hormone values despite the good clinical manifestation. 
Accordingly, our findings on plasma testosterone levels suggest that monitoring plasma 
testosterone in male HF patients before and after therapeutic intervention may furnish accurate 
predictive value to the patient’s clinical outcome. Low testosterone levels post-MCSD may 
predict complications and a poor clinical performance, whereas an increasing plasma value may 
indicate that the HF patient is responding well to MCSD. Notably, 3 patients (P3, P9, P16 in 
Group I) displayed good SOFA scores but still expired post-MCSD. However, these 3 patients 
exhibited consistently low Testosterone levels, suggesting that plasma Testosterone levels may 
remain predictive even when the SOFA score is ambiguous. Correspondingly, previous 
observations in patients who were critically ill with trauma, shock or sepsis in the intensive care 
unit indicated that hypotestosteronemia was correlated with a poorer clinical outcome (Almoosa 
et al. 2014; Nierman and Mechanick 1999). To our knowledge, by applying our technical 
platform and novel computational workflow, we are the first group to identify a correlation 
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between hypotestosteronemia in advanced HF patients before and after MCSD implantation 
and their clinical outcome, in parallel to other plasma metabolomics fingerprints that may be 
utilized as potential biomarkers.  
 
3.V.D. Future Perspectives and Directions. 
In the current pilot study, we developed a technical platform and computational workflow to 
characterize the temporal dynamics of the plasma metabolome. A mouse model of maladaptive 
remodeling was applied as well as a human model of advanced HF and reverse remodeling. 
Our results suggest that this novel workflow is adequate for identifying significant metabolic 
changes that are correlated to the cardiac phenotypes and clinical outcomes. To further validate 
and optimize our technological platform and computational workflow (i.e. defining it’s sensitivity, 
specificity, and positive & negative predictive values), it is critical to expand the current study to 
large HF patient cohorts. Moreover, advanced HF is a complex heterogeneous disease with a 
multitude of underlying molecular mechanisms and different etiologies, which must be taken into 
account within our computational workflow when being applied to large patient cohorts. For 
instance, many comorbidities and clinical characteristics relevant to cardiovascular disease 
(e.g., lipid status, blood chemistry, organ (dys)function, medication panel), and etiological 
subgroups (e.g., ischemic- vs. non-ischemic heart disease) most likely impact the plasma 
metabolome fingerprints (Stegemann et al. 2014; S. H. Shah, Kraus, and Newgard 2012; T. J. 
Wang 2011). Thus, their interferences should be assessed in greater detail using large patient 
cohorts. 
 
In contrast to the mouse model consisting of 6 homogeneous genetic strains, each patient in our 
study exhibits unique demographics and individual variability in lifestyle. Consequently, different 
ethnic backgrounds, environmental stimuli, personality types, dietary preferences and physical 
activities most likely impact their metabolomes in advanced HF pre- and post-therapy. To meet 
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the challenge of taking these individual variability’s into account, it is a mandatory endeavor to 
extract information from multi-dimensional data sets; this includes combining conventional 
clinical data from electronic health records with “omics” data from high-throughput technologies 
and computational workflows (Collins and Varmus 2015). It is the combination of diverse 
datasets from large patient cohorts that will enable a better understanding of disease risks, 
complex disease mechanisms, and optimal therapies as well as suitable intervention points in 
advanced heart failure. 
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CHAPTER 4: CLOUD-BASED COMPUTATIONAL KNOWLEDGEBASE TO 
ANALYZE, ANNOTATE, AND INTEGRATE METABOLOMICS AND 
PROTEOMICS DATASETS. 
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4.I. Abstract. 
The integrated cardiovascular proteomics and metabolomics knowledgebase project entails a 
computational pipeline to fully characterize the plasma metabolome amid the development of 
heart failure (HF), and to establish a cloud-based bioinformatics platform that enables analysis, 
annotation, and integration of proteomics and metabolomics datasets. This project aims to 
unravel the interplay of the cardiovascular proteome and metabolome, ultimately to deliver novel 
knowledge in cardiovascular medicine. 
The progression of HF on the molecular level is determined by the complex interplay among a 
broad spectrum of biomolecules and cellular pathways, where both proteins and metabolites are 
key players. Identifying how various biomolecules contribute to the pathological progression of 
HF is a major goal in cardiovascular research for informing pathological mechanisms, indicating 
disease phenotypes, and identifying new therapeutic targets. However, one current bottleneck 
for realizing this goal is the lack of computational tools and algorithms that can effectively 
integrate large-scale multi-omics data, including clinical datasets.  
Accordingly, in this Chapter, we will discuss the outcome of three specific projects:  
● Project 1: Development of a simplified computational pipeline to characterize the plasma 
metabolome and application to two specific cardiovascular scenarios: first, metabolome 
datasets from a mouse model of HF (isoproterenol [ISO]-treated mice); and second, 
metabolome datasets from HF patients. 
● Project 2: Development of bioinformatics strategies to integrate proteome datasets with 
metabolome datasets and application to datasets obtained from six genetic mouse strains. 
● Project 3: Establishment of a cloud-based platform, MetProt, to streamline and empower the 
above bioinformatics strategies, as well as disseminate the pipeline to the cardiovascular 
community at-large. 
 
 
 
 
94 
4.II. Intorduction. 
4.II.A. Omics Phenotyping of HF. 
HF causes >300,000 deaths a year in the US, with 5.8 million Americans currently afflicted 
(Mancini and Colombo 2015; Braunwald 2015; Roger 2013; Goldberg et al. 2007). A major 
reason why this common disease is so intractable is its complex, multifactorial nature, where 
overall phenotypic traits and disease outcomes are the effect of multiple biological and 
environmental factors. Technologies and approaches used to characterize HF and develop 
therapeutics must be able to embrace the complexity of the data. 
 
4.II.A.a. Systematic characterization of the cardiac proteome.  
As molecules that perform most mechanical and biochemical functions in the heart, proteins 
provide critical information to systems biology studies that aim to uncover the mechanisms of 
disease susceptibility. Technologies now exist that can easily identify and quantify large 
numbers of proteins in a single experiment (Lotz et al. 2014; Mann 2006). These studies have 
advanced our understanding of the components constructing protein interaction networks 
(Orchard et al. 2014), the role of post-translational modifications (PTMs) in modulating cellular 
signals (Streng et al. 2013), the dynamics of individual protein half-life in response to 
perturbation (Lam et al. 2014), and the totality of proteins contributing to a given cellular process 
or organelle (Kim et al. 2014). One of the principal lessons from the proteomics revolution is that 
gene expression does not necessarily mirror protein expression; one example of this is following 
ISO challenge on the heart we see protein abundance change independently of mRNA (Lam et 
al. 2014). 
 
4.II.A.b. Temporal profiling of the cardiac metabolome.  
The continuous contraction of cardiomyocytes demands tremendous amounts of energy; thus, 
maintaining metabolic homeostasis is essential for heart function. Accumulating evidence 
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suggests that perturbation of cardiac metabolism plays an important role in the pathological 
progression of HF (Neubauer 2007). Comprehensive quantification of metabolite abundance in 
blood plasma, also known as plasma metabolomics profiling, provides mechanistic insights into 
the molecular alterations underlying HF (Cheng et al. 2015). The large-scale quantification of 
circulating metabolites is useful for clinical applications, which can help classify HF patients 
before and after optimal medical therapy and surgical interventions (Lloyd-Jones 2010). These 
metabolomic approaches can be established as important avenues for biomarker and drug-
target development, as well as validation of therapeutic efficacy. 
 
4.II.A.c. Multi-omics phenotyping of HF. 
Along with advances in high-throughput technologies, current studies have successfully 
integrated gene expression profiling with proteomics, and have facilitated our understanding of 
the pathophysiology and the molecular mechanisms of HF (Hou et al. 2015; Dos Remedios et 
al. 2003). However, there are no systematic approaches for the integration of large proteomic 
datasets with metabolome datasets due to the lack of strategies to connect proteins to 
metabolites and elucidate their relationships. 
 
4.II.B. Computational Approaches to Identify Driver Molecules. 
The availability of metabolomics data analysis tools is currently limited; for example, the Aztec 
discovery index lists 778 proteomics tools, but only 147 metabolomics tools. To our knowledge, 
there is no application that comprehensively analyzes and integrates proteomic and 
metabolomic datasets, and a simplified computational pipeline to analyze and annotate large-
scale proteomics datasets with metabolomics datasets currently does not exist. This limitation 
hinders our capability to identify biomolecules relevant to HF. 
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4.II.B.a. Differential Expression Analysis with Paired t-Test.  
Differential Expression Analysis is a univariate method widely used in omics studies for 
targeting molecules that are altered in a statistically significant manner (i.e., up-regulated or 
down-regulated) after a treatment or physical exercise (Xia et al. 2015, 2012, 2009). We employ 
a paired sample t-test, which is a statistical technique that is used to compare two population 
means in ‘before-after’ studies. Following the paired t-test, multiple testing correction to the p-
values is applied using the Benjamini-Hochberg method to reduce false positives. 
 
4.II.B.b. Principal Component Analysis.  
Principal Component Analysis (PCA) is a well-established method for dimensional reduction of 
large datasets with many variables. This facilitates visualization, clustering, pattern recognition, 
and identification of the key variables that vary most significantly across a population. PCA can 
aid investigators in understanding complex, higher-dimensional datasets by projecting them into 
a 2- or 3-dimensional space, where they can be more easily visualized without sacrificing fidelity 
(Xia et al. 2015, 2012, 2009).  
 
4.II.B.c. Unsupervised Hierarchical Clustering Analysis.  
Unsupervised Hierarchical Clustering is a widely used data analysis method to build a binary 
tree from data by merging similar groups of points based on the calculated distances across 
samples or molecules. Usually, the distances are displayed as dendrograms (Xia et al. 2015, 
2012; Xia and Wishart 2011b, [a] 2011; Xia et al. 2009). 
 
4.II.B.d. Linear Mixed Model with Sample Relatedness Correction.  
Linear Mixed Model (LMM) with Sample Relatedness Correction analyzes time-series omics 
data generated from heterogeneous samples to identify driver molecules that are highly 
associated with phenotypic characteristics. LMM correlates two variables and incorporates the 
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samples’ relatedness, represented by omics expression or demographic factors, to improve 
statistical accuracy. We have applied LMM with Sample Relatedness Correction in our 
preliminary metabolomics study to find fingerprints of pathological stages during HF progression 
(Kirby et al. 2010; H. M. Kang et al. 2008). 
                          
4.II.B.c. Pathway Enrichment Analysis.  
Significantly altered metabolites may be searched against several metabolomics databases, 
including Chemical Entities of Biological Interest (ChEBI, UK) (Hastings et al. 2013), Human 
Metabolome Database (HMDB, Canada) (Wishart et al. 2013, 2009, 2007), and LIPID 
Metabolites And Pathways Strategy (LIPID MAPS) (Fahy et al. 2009, 2007) to cross-reference 
identifiers that are commonly used by pathway enrichment search engines and databases. The 
pathways enriched with identified metabolites may be further annotated with resources including 
MetaboLights (Haug et al. 2013) and Reactome (EMBL-EBI, UK) (Fabregat et al. 2018, 2016; 
Milacic et al. 2012). 
 
4.II.C. Cloud-based Computational Knowledgebase. 
To extract biological meaning from multi-omics datasets, researchers rely heavily on 
computational resources that analyze and annotate the molecules of interest with known 
information. Currently, access to tools/annotations is not straightforward because they reside in 
fragmented and incomplete repositories. To address this challenge, we are creating a novel 
distributed query system and cloud-based infrastructure, MetProt, that is capable of providing 
unified access to protein and metabolite datasets, allowing users to submit a single query to 
access multiple resources including Reactome (Fabregat et al. 2018, 2016; Milacic et al. 2012), 
UniProt (UniProt Consortium 2015), MetaboLights (Haug et al. 2013), BioGPS (Wu et al. 2016; 
Wu, Macleod, and Su 2013), Gene Wiki (Tsueng et al. 2016), and COPaKB (N. C. Zong et al. 
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2013; H. Li et al. 2013). We will also engineer customized application programming interfaces 
(APIs) to provide direct access for information in MetProt. 
 
4.II.C.a. COPaKB.  
COPaKB (N. Zong et al. 2014; N. C. Zong et al. 2013; H. Li et al. 2013) 
(http://heartproteome.org) is an omics analysis platform with two key components: (1) a peptide 
spectral search engine; and (2) spectral library modules for knowledge annotation.  
 
4.II.C.b. Reactome. 
The Reactome (Croft et al. 2014; Milacic et al. 2012) (http://reactome.org) platform is a suite of 
network analysis tools for performing topology analysis and over-representation analysis of 
gene/protein networks. It comprises a manually curated database of human pathways with 
views of protein and metabolite structures overlaid with expression data. We will interface with 
Reactome to identify key pathways of interest in our omics data. 
 
4.II.C.c. MetaboLights. 
MetaboLights (http://ebi.ac.uk/metabolights/) is a public database dedicated to the submission 
and sharing of metabolomics data, mass spectra, annotated biological roles, and other derived 
information (Haug et al. 2013). Based on spectral similarities and chemical structures, we will 
employ its search services to analyze and interpret metabolite data we collect from the studies. 
 
4.II.C.d. BioGPS/Gene Wiki:  
BioGPS (http://biogps.org) is an interface for omics research (Wu et al. 2016). It provides a 
user-customizable portal with aggregated information on protein annotations and target list 
analyses. Gene Wiki translates molecular information into structured knowledge; relevant pages 
representing molecular transducers will be aggregated and recruited into MetProt. 
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4.III. Results. 
4.III.A. Multi-Omic Data Acquisition from Public Repositories.  
We have at hand large human and mouse plasma metabolomics datasets that are clinically 
relevant to advanced HF. The datasets include multiple reaction monitoring (MRM) mass 
spectromertry (MS)-based absolute quantification measurements of 610 distinct plasma 
metabolites (including lipids, steroids, amino acids, and energy metabolism metabolites) from 26 
advanced HF patients and 12 healthy controls recruited at UCLA. In parallel, we established a 
systems genetics model of cardiac hypertrophy in which the metabolomics of six genetic mouse 
strains were measured. In total, the datasets comprise 21,960 measurements of absolute 
concentrations in mouse plasma, and 147,620 measurements of absolute concentrations in 
human plasma. In addition, a large dataset of protein dynamics data, including the abundance 
of 8,064 cardiac proteins and turnover rates of 3,228 cardiac proteins in the normal and 
hypertrophic hearts of six mouse strains, was acquired from ProteomeXchange (PXD002870) 
and Sage Synapse (syn2289125). This dataset contains over 120,000 protein quantification 
data points and covers over 200 cellular pathways, and used to support development of a 
strategy to integrate protein and metabolite data as detailed in Project 2. 
 
4.III.B.  Simplified computational pipeline for triaging and prioritizing molecular markers. 
We have established a computational pipeline to identify biomarker candidates that are 
associated with both phenotypic alterations and temporal dynamics following medical therapy 
and surgical intervention. In our pipeline, we explored the analytical power of two major 
components, a Differential Expression Analysis and a Linear Mixed Model. To account for the 
individual relatedness, we incorporated the Relatedness Matrix Correction into the Linear Mixed 
Model by exploiting the “housekeeping metabolites”, which remain at constant plasma levels 
after mechanical circulatory support device (MCSD) implantation. With these preliminary 
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analyses, we successfully identified a number of plasma metabolites that are altered in cardiac 
remodeling. 
 
Figure 4.1. MetProt Integrated Workflow. This workflow diagram depicts the individual elements and 
logical connections in the proposed bioinformatics platform for prioritizing and analyzing data, finding 
connections between proteins and metabolites, and annotating molecular functions. User data will be 
submitted in two major categories: 1) lists of protein and/or metabolite identifiers from hypothesis-driven 
research with biological information enriched by Gene Wiki, COPaKB, and/or BioGPS, or 2) large-scale 
molecular data from data-driven investigations with their quantitative values and phenotypic information. 
For the latter category, MetProt will review and analyze the data to identify driver molecules that are 
significantly altered over time and highly associated with phenotype (Project 1). The molecules of interest 
are then annotated using information fetched from Reactome/KEGG (biological pathways), Uniprot/HMDB 
(chemical reactions), dbPTM/PhosphoSitePlus (PTM data), and KEGG LIGAND/DrugBank (ligand & drug 
information). The extracted information are now integrated to construct interaction graphs among proteins 
and metabolites, with additional annotations from COPaKB/Gene Wiki and MetaboLights/CheBI (Project 
2). Collectively, we will engineer a cloud-based platform to enable these analyses on the cloud and to 
generate integrated reports, including table views of protein-metabolite interactions, functional 
annotations, and graphical views as output (Project 3). Detailed platform system architecture is shown in 
Figure 4.3. 
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4.III.B.a. Develop a simplified computational pipeline to characterize plasma metabolomics data. 
Plasma metabolomics profiling has great potential to identify biomarker candidates as internal 
indicators of diseases or as novel therapeutic targets. However, its clinical applications are 
challenged by the complex nature of patient cohorts, hospital protocols, and policy. Subject 
individuality, affected genetic variability, diverse metabolic homeostasis, and interference of 
comorbidities can further complicate accurate quantification of metabolites. To overcome these 
challenges, large-scale clinical cohorts have been assembled to provide sufficient statistical 
power, though the studies were limited to a “hypothesis-driven” metabolomics approach. 
Alternatively, temporal datasets using small clinical cohorts can be established as a profiling 
approach to pursue “data-driven” metabolomics studies. However, an integrated computational 
workflow simplified for clinical metabolomics datasets has never been fully explored. 
We first implement a data pre-processing component, which replaces the Limit of Detection 
(LOD) values with half of the minimum value in the original data and remove any metabolites 
missing more than 50% of the quantification values. Second, Differential Expression Analysis 
will be performed on the filtered dataset with a stringent threshold of adjusted p-value < 0.001 
and ±1.5-fold change to detect metabolites with significant changes. To depict the results of 
Differential Expression Analysis, volcano plots and heatmaps will be automatically generated. 
Next, to identify metabolites that are highly associated with the phenotypic characteristics (e.g., 
HW/BW or SOFA Score), we first account for the individual relatedness by incorporating the 
relatedness matrix into a linear mixed model (LMM). The relatedness matrix will be generated 
using “housekeeping metabolites”, which are metabolites that maintain a consistent level of 
plasma concentration over time. Differences in plasma concentration exist among individuals, 
which can indicate individual relatedness. Housekeeping metabolites will be defined using a 
threshold of adjusted p-value > 0.1 and subsequently used to create the relatedness matrix. The 
LMM employs time series metabolite concentrations along with phenotypic values, and it adjusts 
the regression based on their relatedness matrix. We perform the multiple testing correction, 
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using the Benjamini-Hochberg method, and apply a threshold of FDR < 0.01 to identify 
metabolites highly correlated with phenotypic alterations. The metabolites that are detected by 
both Differential Expression Analysis and Linear Mixed Model with relatedness correction are 
considered driver molecules. We also use Principal Component Analysis (PCA) to verify that the 
driver molecule expression pattern has sufficient power to stratify patients with distinct 
outcomes (Figure 4.1.). Users upload metabolite identification and quantification datasets with 
phenotypic information and matching time points in .tsv or .csv file formats, using file transfer 
and management protocols we have previously established in our knowledgebase, COPaKB. 
Output contains: (i) a list of metabolites that are significantly altered over time; (ii) a list of 
metabolites that are highly associated with the phenotypic characteristics; (iii) a list of 
metabolites commonly detected in both (i) and (ii); and (iv) p-values, FDRs, and metabolite 
annotations for each detected metabolite (Figure 4.1.). 
We utilize a mouse model of maladaptive cardiac remodeling via β-adrenergic overstimulation to 
validate the computational pipeline with stringent thresholds. To investigate whether the pipeline 
is applicable to different organisms, we subsequently apply our integrated computational 
pipeline to a clinical temporal dataset of HF patients undergoing MCSD implantation. 
 
4.III.B.b. Develop bioinformatics strategies to integrate proteome datasets with metabolome 
datasets.  
The proteome and the metabolome are both intermediate phenotypes that are tightly connected 
to the biochemical functional output of a system. Both proteomics and metabolomics methods 
are now being increasingly deployed to identify disease markers and mechanisms. There are 
intrinsic connections between proteins and metabolites: (i) proteins in major metabolic pathways 
function to synthesize and degrade metabolites, (ii) metabolites in turn can modulate protein 
activities via allosteric interactions, and (iii) metabolomics and proteomics experiments share 
mass spectrometry (MS) techniques. Unfortunately, current efforts to integrate these two types 
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of molecules are limited. Our goal is two-fold: (i) first, to identify the biological interface of 
proteins and metabolites; and (ii) second, to develop a bioinformatics strategy to integrate 
proteome and metabolome datasets. Therefore, we enable users with either hypothesis-driven 
or data-driven approaches to annotate and enrich their data, and to gain biomedical insights 
with metabolite-level information (Figure 4.3.). We start by enumerating various direct linkages 
via which metabolite information may be relevant to data interpretation and hypothesis 
generation from proteomics data. We then lay out a computational strategy and software tool to 
integrate multiple data types, drawing broadly from existing databases on protein and metabolite 
information. The utility, applicability, and scalability of our approach are rigorously validated 
using large-scale proteomics and metabolomics data on six distinct genetic mouse strains and 
perturbations that we have already acquired. 
 
 
Figure 4.2. Intersections where metabolome meets proteome. meet proteins. Protein	 PTMs	 are	
critically	modulated	by	the	presence	and	concentration	of	particular	metabolites.	With	Histone	Acetyltransferase	
(HAT),	e.g.,	enzyme	PCAF	(lysine)	acetyltransferase,	an	Acetyl	group	from	metabolite,	Acetyl-CoA,	is	transferred	to	
histone	protein,	forming	the	Acetylated	protein.	The	Acetylation	is	considered	as	a	PTM. 
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We identify five important relationships between proteins and metabolites essential to the 
annotation of a dataset in biomedical investigations: (i) given a list of quantified proteins, we find 
the enriched biological and cellular pathways from Reactome and KEGG, and we retrieve a list 
of metabolites that participate in these pathways; (ii) given a protein that catalyzes an enzymatic 
reaction, we retrieve its natural biochemical substrates and products from UniProt, HMDB, 
Reactome, and KEGG; (iii) given a protein known to participate in a particular type of PTM, we 
retrieve metabolites known to critically induce, suppress, or otherwise participate in these 
modifications (e.g., NAD+ to acetylation and ADP-ribosylation) from dbPTM; (iv) given a protein 
that is a receptor or is allosterically regulated by a known metabolite, we retrieve its natural 
agonist and/or allosteric regulator (e.g., from KEGG LIGAND database); and (v) given a protein 
with known transcriptional regulation, we retrieve metabolites that are known to induce or 
suppress its transcription (e.g., oxysterols and liver X receptor downstream targets) (Figure 4.2 
and 4.3). 
 
To enable these functionalities, we begin by building broad interfaces with large-scale 
databases of proteomics and metabolomics data. Currently, we are at pace to complete a 
dedicated web API to retrieve protein cardiovascular disease relevance information from 
COPaKB. Data from Reactome, MetaboLights, and UniProt will be retrieved through existing 
and to-be-developed high-performance APIs. We develop a scoring schema to weigh retrieved 
protein-metabolite connections from each category based on the strength of existing evidence. 
As the data retrieval and integration strategies mature, we demonstrate the strategy’s utility in 
the analysis of a large protein and metabolite dataset of cardiac hypertrophy that we have 
already acquired (see Preliminary Data). We construct protein-metabolite graphs based on the 
retrieved connections, followed by visualization of the integrated protein-metabolite networks on 
the browser. 
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In addition, biological and chemical functional annotations for proteins and metabolites are 
retrieved from COPaKB/Gene Wiki and MetaboLights/ChEBI. MetProt will be hosted on Amazon 
Web Services (AWS), enabling users to perform these analyses on the cloud and generate 
integrated reports, including a table view of protein-metabolite interactions, and functional 
annotations as well as graphical views of networks and pathways. 
 
Users input a list of proteins with Uniprot accession numbers and columns of numerical qualities 
in text formats. Output will be annotations for each Uniprot accession in each of the 
aforementioned classes of protein-metabolite linkage (Figure 4.3.). We use the proteomics and 
metabolomics data from the mouse hypertrophy model as a test case to determine whether the 
knowledge integration approach between protein and metabolite data in a common disease 
model can be used to discover new pathways and generate new hypotheses (Project 3). 
 
4.III.C. Build a cloud-based platform, MetProt, to enable the computational/bioinformatics 
strategies.  
Cloud-based platforms have become an increasingly popular mode of large-scale high-
dimensional omics datasets (big data) analysis and dissemination of biomedical 
knowledgebases. The many operational advantages of cloud-based knowledgebases include 
minimal requirements of end-user investment in computational infrastructure, strong software 
compatibility, lack of installation hassle, and high visibility on the web, all working to ensure 
maximal use and access of the tools. Successful examples include UniProt and Reactome; both 
currently support broad user engagement in global biomedical research. Accordingly, we have 
chosen to establish a cloud-based platform, tentatively named MetProt, as an approach 
enabling the above computational and bioinformatics strategies (Projects 1 & 2). This cloud-
based platform connects to collaborating partners and knowledgebases to promote 
interoperability, utilization, and dissemination.  
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Figure 4.3. MetProt Distributed System Architecture. MetProt is designed to run on a modern system 
architecture that will make it robust, versatile, and extensible. An Amazon Web Service (AWS) EC2 
server will host the MetProt Core. Users will programmatically access and retrieve search results via 
REST APIs or the web interface on www.metprot.org. MetProt Database Updater will integrate various 
types of biomolecular interaction information extracted from REACTOME, KEGG PATHWAY, UniProt, 
HMDB, dbPTM, PhosphoSitePlus, KEGG LIGAND, and DrugBank, and will store the comprehensive 
interaction information among proteins and metabolites in MetProt Databases. In addition, MetProt will 
provide biological and chemical functional annotation for biomolecules by utilizing APIs provided by Gene 
Wiki, BioGPS, MetaboLights, HMDB, ChEBI, and COPaKB. 
 
Our team previously developed COPaKB, a cardiovascular knowledgebase for cloud-based 
proteomics analysis. COPaKB enables users to upload and analyze MS data files remotely on a 
highly scalable cloud server (N. C. Zong et al. 2013; H. Li et al. 2013) and has received over 
177,604 page views from ~125 countries as of June 2016. The spectral library search engine on 
COPaKB is an emerging alternative to sequence database search, and allows fast identification 
of peptides with low error rates. In addition, API integration has enabled COPaKB to feature a 
pathway enrichment analysis tool, a Gene Wiki embedding widget, and a protein-protein 
interaction and visualization tool. These efforts demonstrate our credentials in developing and 
deploying widely-utilized, community-centric data science platforms. 
MetProt system architecture includes: (i) a Wiki interface, which serves as evolving 
documentation and a canvas for users to document protein and metabolite annotations; (ii) a 
MetProt Core, which receive and process user queries and connect to Gene Wiki, BioGPS, 
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MetaboLights, COPaKB, HMDB, and ChEBI via APIs provided by these knowledgebases; (iii) a 
Database Access Object (DAO), which interfaces with MetProt Database Updater, retrieving 
and integrating information from collaborating knowledgebases (i.e., Reactome, KEGG, UniProt, 
etc.); and (iv) MetProt will build upon two complimentary database systems (MySQL and 
MongoDB) and ensure efficient search/query operations (Figure 4.3.). 
 
 
Figure 4.4. MetProt User Interface. Technologies used in MetProt user interface include HTML/CSS, 
JavaScript, and Bootstrap. Back-end/server is written in Java and R programming languages. The 
MetProt can be accessed at http://metaprot-env.us-west-2.elasticbeanstalk.com/. 
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We anticipate users upload protein identification and quantification datasets, using file transfer 
and management protocols we have established from our experience with COPaKB. Output 
contains the list of proteins that are linked to known metabolites and metabolite annotations, 
and the manner in which such conceptual or molecular connections are established. For 
example, users are able to identify the number of proteins from the uploaded list that participate 
in major metabolic pathways and visualize the proteins that are driving chemical and 
biochemical reactions, as well as proteins whose protein PTMs may be critically modulated by 
the presence and concentration of particular metabolites. These connections serve to identify 
the potential involvement of various metabolite species in the biological model being studied, 
and will be systematically organized and presented to facilitate data interpretation, knowledge 
integration, and hypothesis generation. Additional features will be developed (which will extend 
beyond my dissertation), where we will support metabolite datasets as input and allow reverse 
queries of protein-level regulation of metabolite levels. 
 
MetProt is evaluated by the number of installed servers and the volume of depositions in the 
MetProt database at the end of the project. In addition, the user access statistics of MetProt, 
including number of unique users, pageviews, and pageviews per visit, are measured by Google 
Analytics (Figure 4.4.). We will also continuously monitor the usage of our MetProt API through 
Google Analytics. 
 
4.IV. Discussion. 
 
4.IV.A. Significance and Innovation of Completed MetPro Projects. 
The proposed three projects have two major aspects of significance. First, our studies will 
establish a computational pipeline, applying it to two benchmark plasma metabolomic datasets 
of ISO-treated mouse strains and HF patients, to pave the groundwork for future metabolomics 
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studies with clinical translation. Protein and metabolite identities/quantities are tightly regulated 
parameters reflecting cardiac function. 
●      Conceptual innovation: We took advantage of a novel systems genetics model, in which 
natural mouse genetic strains span a wide spectrum of HF susceptibility, to discover disease 
mechanisms. 
●      Technological innovation: Proteomics and metabolomics investigations are rarely integrated, 
despite the obvious connections between proteins and metabolites that are critical for fully 
understanding biological mechanisms. Our studies innovate approaches that enable multi-omics 
investigations and empower the broad user base of cardiovascular investigators. 
●      Translational innovation: The proposed studies directly support experiments aimed at 
understanding in vivo protein and metabolite dynamics of HF patients. 
 
4.IV.B. Feasibility of Integrating MetPro with Other Existing Resources. 
 
4.IV.B.a. Aztec search results for other available resources that conduct multi-omics analysis 
and integration (http://aztec.bio/). 
 The availability of multi-omics data analysis tools is currently limited; for example, the Aztec 
discovery index lists 778 proteomics tools and 147 metabolomics tools. However, Aztec resulted 
in only one multi-omics visualization tool, and to the best of our knowledge, there is no 
application that comprehensively analyzes and integrates proteomic and metabolomic datasets. 
A simplified computational pipeline to analyze and annotate large-scale proteomics datasets 
with metabolomics datasets currently does not exist. This limitation hinders our capability to 
identify integrated biomolecular profiles relevant to HF. 
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 4.V.B.b. Function, application and accuracy of the existing/alternative methods. 
Previous studies have systematically examined the interplay between proteomes and 
metabolomes and reported that approximately 20% of proteins bind to at least one hydrophobic 
metabolite (X. Li et al. 2010; X. Li and Snyder 2011), suggesting that a large portion of the 
proteome physically interfaces with metabolites. However, the resources for the true integration 
of proteins and metabolites remain limited. One notable effort that successfully tackled this topic 
is the development of “Search Tool for Interacting Chemicals” (STITCH), which is a database 
integrating the disparate data sources into a singular resource (Szklarczyk et al. 2016; Kuhn et 
al. 2014, 2008). 
 
STITCH facilitates access to the information of protein-metabolite interactions that can be 
extracted from the databases of metabolic pathways, crystal structures, binding experiments, 
and drug-target relationships. Further, this database provides a comprehensive list as well as 
visualization of protein-metabolite interactions. Specifically, STITCH enables users to query the 
interacting partners of the list of proteins or metabolites of interest. A full-text search is available 
for identifiers (e.g., STRING identifier) and common names of chemicals and proteins. The 
chemical structures and protein sequences can also be submitted for a database search. In 
addition, STITCH contains a visualization tool that displays the search results in a network view, 
providing an overview of the complex networks among proteins and metabolites and possibly 
biological insights. Further, STITCH allows users to filter out the molecules in the results that 
are believed not to be present in a specified tissue. This filtering capability reduces the false 
positives in the protein-metabolite network. STITCH aggregates information from multiple 
sources into a unified global network of protein–metabolite interactions. It is widely applicable to 
targeted small-scale analyses via web interface to large-scale analyses via their API access.  
 
Due to its powerful capacity for bridging metabolic pathways, protein 3D structures, protein-
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metabolite binding data, and drug-target relations, STITCH enables synergistic data sharing 
with MetProt. This resource offers granular details for biological and cellular pathways, 
describing chemical and biochemical reactions at each step. Moreover, it provides critical 
information for metabolites when they function either as ligands for protein-based receptors or 
cofactors for translational and post-translational regulations. This effort affords opportunities for 
comprehensive knowledge pertaining to interfaces between the proteome and metabolome; 
furthermore, it facilitates an in-depth understanding of molecular and cellular function underlying 
disease initiation and progression. 
 
4.V.B.c. Potential limitations and alternative strategies. 
The proposed platform will incorporate information from multiple resources. Some resources 
provide APIs allowing us to programmatically retrieve information; some provide only 
spreadsheets without structured data. Our approach is to retrieve programmatically where 
possible and manually where APIs are not available. Hence, a potential pitfall is the 
heterogeneity and incompatibility of vocabularies from these different data sources; for example, 
KEGG and Reactome may have different terminologies for some identical pathways. We will 
apply community standards to particular resources and either request the resources, adopt a 
consistent community standard, or alternatively, host the converted information on our local 
server, with periodical updates. 
 
4.V.C. Future Direction of MetProt Development. 
 
4.V.C.a. Differentiate physiological relevant protein-metabolite relations from “enzymatic 
promiscuity” (“Comprehensive Natural Products II” 2010).  
For an enzyme, its “native function” is physiologically relevant to the organism hosting this 
enzyme. Many enzymes have more than one physiological function, or exhibit a broad 
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specificity towards a whole range of similar substrates, which still belong to the category of 
naturally evolved “native function”. However, purely accidental protein-metabolite interactions 
occur, which comprise the idea of enzymatic promiscuity. When a high-throughput, unbiased 
proteomics dataset has been established, we need to differentiate the physiologically relevant 
associations from non-specific ones. The traditional binding assay-based method is labor-
intensive and not practical for validating hundreds of thousands of relations within a global 
proteome-metabolome network. Therefore, computational approaches, in particular, machine 
learning (ML)-based strategies may be incorporated into the current infrastructure of MetPro. 
 
4.V.C.b. Analysis of protein-metabolite regulatory events that are relevant to a particular 
phenotype.  
 
Large-scale characterization of metabolomes has gained traction over the last decade, and as 
with proteomics, advanced MS techniques can now be used to detect and quantify thousands of 
chemical compounds in a single run. Data analysis pipelines are not quite as well developed for 
metabolomics as for standard proteomics data, and since the structures of many metabolites 
cannot be readily distinguished above a certain mass tolerance, rigorous validation criteria are 
required for confident identification. While the main bottleneck in computational analysis 
remains the lack of annotation for many uncharacterized metabolites, serendipitously the global 
study of metabolite–protein interactions will likely provide an elegant solution to address this 
(Guo, Peng, and Emili 2017). To this end, a major goal of MetProt moving forward is to 
systematically address the metabolite annotation conundrum. 
 
It is estimated that there are >1 million metabolites in a biological cell, and the number of 
metabolites is approximately 100-fold larger than proteins (Milo 2013; Bennett et al. 2009). 
However, the interaction between the proteome and metabolome has been difficult to 
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systematically define on a large-scale. While bioinformatics analysis of proteomes and 
metabolomes has traditionally been performed separately, integrative data analysis strategies 
are urgently needed to obtain a deeper mechanistic understanding of biological processes and 
complex protein-metabolite networks. From a technical standpoint, the allosteric, or noncovalent 
nature of the binding between proteins and metabolites has hampered the development of 
methods for systematically mapping protein-metabolite interactions. MS-based approaches are 
largely restricted to metabolite classes (e.g., lipids), and while NMR spectroscopy shows 
promise for defining sophisticated interaction mechanisms (Nikolaev et al. 2016), it has lower 
throughput than MS. It has also become clear in recent work that some PTMs, such as 
acetylation and succinylation, can occur non-enzymatically in vitro through inherently reactive 
metabolites (Weinert et al. 2013; Wagner and Payne 2013). The identification of PTM sites or 
allosteric interactions which are highly conserved across species can help to select regulatory 
events which are more likely to be functionally relevant. The next step is to identify those 
regulatory events that are actually relevant to a particular phenotype (Kochanowski, Sauer, and 
Noor 2015), including efforts to address how post-translational regulatory events relate to other 
physiological measures, such as fluxes or metabolite concentrations. 
 
A study in 2010 conducted in eukaryotic yeast cells which looked at purified proteins and their 
association with metabolites revealed that approximately 70% of ergosterol biosynthetic proteins 
and 20% of the protein kinases studied bound hydrophobic metabolites (X. Li et al. 2010). 
Extrapolating from this results, the authors speculated that >1200 soluble yeast proteins bind 
hydrophobic molecules in vivo. A recent study in 2018 achieved a comprehensive, systematic 
analysis of the bacterial proteome-metabolite interactome via the Limited Proteolysis-small 
molecule mapping (LiP-SMap) technique (Piazza et al. 2018). They looked at the binding of 
over 2,500 proteins with 20 common metabolites and demonstrated that ~25% of the proteome 
interacted with at least one of the evaluated metabolites, with preference exhibited for the “core 
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proteome” (Yang et al. 2015). Moreover, the fraction of the proteome that underwent structural 
variations upon metabolite binding was approximately one-third of the total proteome (620 
proteins out of 2,565). This study indicates that the size and complexity of the metabolite-protein 
interactome is substantially larger than previously anticipated. Currently, MetProt contains xxx 
number of protein-metabolite interactions from xxx protein and xxx metabolites for xxx 
organisms. Despite the sizable nature of our database, this likely represents only a portion of 
biologically relevant interactions.  
 
4.V.C.c. Using advance ML-based methods to predict protein-metabolite regulatory events that 
are relevant to disease phenotypes.  
 
The increasingly complex protein-metabolite datasets that have been generated, such as those 
listed above, have spurred the development of powerful new computational capabilities for 
integrating proteomic and metabolomic datasets. An example of this is deep learning, which 
allows for deeper mechanistic inferences of biomedical significance, as well as better 
diagnostics and drugs (Guo, Peng, and Emili 2017). Several computational tools have been 
developed to predict the protein targets of small molecules (Koutsoukas et al. 2011), such as 
GUSAR, PASS INet, PharmMapper, and TarFisDock. However, these approaches and others 
used in recent studies are univariate and don’t fully take an advantage of using big data. 
Advanced ML approaches to tackle this topic may be suitable, and we have plans to employ 
ML-based prediction methods to predict highly possible interactions between proteins and 
metabolites. In this project a cloud-based platform is developed to aggregate knowledge of 
protein-metabolite interfaces from multiple sources. We can leverage the massive datasets in 
MetProt as training data to predict other interactions, and use existing text-mining tools 
developed by Dr. Jiawei Han and Dr. Peipei Ping to validate the predicted interactions reported 
in both current and future biomedical literature. Moreover, rapid progress in the drug discovery 
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field is expected in the next few years, resulting in much needed new opportunities for improving 
sparse drug discovery pipelines. Our future plans for MetProt include using deep learning to find 
the associations between the protein-small molecule interactions and disease phenotypes, 
among others. 
 
4.V. Conclusion.  
We are establishing a cloud-based platform, MetProt (http://metaprot-env.us-west-2. 
elasticbeanstalk.com/), for quantifying, triaging and analyzing omics datasets. MetProt will 
enable us to find existing as well as novel connections between proteins and metabolites, 
annotate molecular functions, and provide biomedical insights. 
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